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Pre-exposure prophylaxis (PrEP) is a biomedical intervention to prevent HIV infections 
among HIV-negative individuals. PrEP has been found to be effective in reducing HIV infec-
tions among several populations who are at high risk for HIV, such as serodiscordant couples 
and men who have sex with men (MSM) (Baeten et al., 2012; Grant et al., 2010). Despite the 
high effectiveness of PrEP, the uptake of PrEP has been limited in the past years, because PrEP 
has not directly been implemented in all healthcare systems around the world. The Europe-
an Medicines Agency (EMA) approved PrEP in August 2016 (European Medicines Agency, 
2016), and three years later, PrEP became implemented in the healthcare system in the Neth-
erlands (Ministry of Health Welfare and Sport, 2019). Because of the limited accessibility and 
availability of PrEP during these years, some MSM obtained PrEP via informal channels such 
as (online) pharmacies abroad, clinics in other countries, and through pill sharing of people 
living with HIV who take antiretroviral therapy (Charpentier et al., 2014; Kurtz & Buttram, 
2016; Rosenthal et al., 2014; Zablotska et al., 2013). Because informal PrEP users are usually 
not medically supervised, concerns were raised about misinformation and incorrect use of 
PrEP (Buttram, 2018; Dimitrov et al., 2013; Kurtz & Buttram, 2016). The combination of in-
correct PrEP use and increased sexual risk-taking may put informal PrEP users at increased 
risk of HIV (Buttram & Kurtz, 2017). This thesis aims to assess whether informal PrEP use 
also occurs in the Netherlands, and what risks are related to informal PrEP use. Therefore, we 
investigated the interest in PrEP and the experiences of PrEP users in the years prior to formal 
PrEP implementation in the Netherlands. 
This general introduction provides background information on the context of PrEP use in 
the Netherlands. First, it describes the HIV epidemic, worldwide and in the Netherlands, to 
emphasize the need for PrEP. Second, it presents the introduction of PrEP. Third, it describes 
the fragmented implementation of PrEP around the world, and its impact on the availability 
and use of PrEP. Fourth, it discusses challenges that emerged after the introduction of PrEP, 
that form the basis of the research questions that this thesis aims to answer. Finally, an outline 
of the chapters is provided, illustrating how the research aims are related to the studies that 
were conducted for this thesis. 
Epidemiology and prevention of HIV in the age of antiretroviral treatment advances
It is estimated that 38 million people worldwide are living with HIV (World Health Organiza-
tion, 2020). In 2019, 1.7 million people got newly infected with HIV, and 700.000 people died 
due to AIDS. Globally, the yearly number of new infections and deaths have been decreasing 




HIV prevention and education. However, despite these global improvements in HIV inci-
dence and mortality, there are regions where the number of new infections have been in-
creasing in the past decade, such as Eastern Europe and Central Asia (+29%), Latin America 
(+7%), and Middle East and North Africa (+10%) (UNAIDS, 2019). In a global world, these 
regional increases make clear that continuous efforts are needed to control the HIV epidemic 
also in regions with stable or decreasing incidence. 
There are 23.300 people living with HIV in the Netherlands (Van Sighem et al., 2019). Since 
2008, the number of yearly new infections is decreasing, down to 664 new HIV diagnoses in 
2018. The Netherlands reached the UNAIDS 90-90-90 HIV treatment targets (90% of people 
living with HIV know their HIV status, of whom 90% are on antiretroviral treatment and of 
whom 90% are virally suppressed) with a continuum of care of 92-93-96 in 2018 (Van Sighem 
et al., 2019). 
MSM have an increased risk for HIV (Beyrer et al., 2012). In the Netherlands, 66% of HIV 
infections are among MSM, and in the European Union sex between men is the predominant 
mode of HIV transmission (European Centre for Disease Prevention and Control, 2019b). It 
is preferable that multiple HIV prevention strategies are implemented for MSM, as available 
prevention tools are insufficient as single interventions (Beyrer et al., 2013). Existing effective 
prevention tools included frequent HIV testing (Wainberg et al., 2016), condom use (Smith, 
Herbst, et al., 2015) and post-exposure prophylaxis (PEP, the administration of antiretroviral 
treatment within 72 hours after exposure for 28 days) (Almeda et al., 2004). Recent develop-
ments in biomedical HIV prevention methods, such as treatment as prevention (TasP) and 
PrEP, provide opportunities to further reduce new HIV infections. 
Effectiveness and safety of PrEP
Clinical trials demonstrated that the daily use of the combination of tenofovir and emtricit-
abine (marketed as Truvada® by Gilead Sciences, and by now also available as a generic formu-
lation in many countries) for PrEP is highly effective in reducing HIV infections among MSM 
and other populations, especially when adherence is high (Fonner et al., 2016). Initially, a re-
duction in HIV incidence of 44% was found in the iPrEx study (Grant et al., 2010). Later, the 
IPERGAY and PROUD studies found reductions in HIV incidence up to 86% (McCormack 
et al., 2016; Molina et al., 2015). In the IPERGAY study, it was found that PrEP is also effective 
for MSM when taken in an on demand regimen, with reductions in HIV incidence up to 97% 
(Molina et al., 2015; Molina et al., 2017). In an on demand, or event-driven, regimen, PrEP 
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users only use PrEP at times when they expect a high risk of HIV. This regimen consists of two 
pills two to 24 hours in advance and one pill per day in the following two days.
Next to the effectiveness of PrEP, the clinical trials also assessed the safety of PrEP. A me-
ta-analysis summarizing the results of 13 randomized clinical trials, including 15,678 partic-
ipants, found no increase in severe renal or bone damage when using Truvada compared to 
a placebo (Pilkington et al., 2018). Even though side effects in renal function (such as creati-
nine elevations) were found to be limited and fully reversible (Pilkington et al., 2018), clin-
ical guidelines recommend to frequently monitor renal function among PrEP users (World 
Health Organization, 2015).
The strong evidence for the effectiveness of PrEP in reducing HIV infections, together with 
the high safety, led to the development of guidelines to recommend PrEP for people at high 
risk of HIV, such as MSM (World Health Organization, 2014). According to the guidelines, 
MSM are eligible for PrEP if, for example, they have had a sexual transmitted infection (STI) 
in the past, or if they have condomless anal sex. Furthermore, the World Health Organiza-
tion (WHO) indicated that “All men who have sex with men should have the opportunity to 
choose PrEP if they feel that it meets their HIV prevention needs” (World Health Organiza-
tion, 2014). Despite these recommendations, PrEP was not immediately implemented on a 
large scale. An important barrier for PrEP implementation is the high price of PrEP. The price 
of Truvada is currently around €500 per month in Europe and $1600 per month in the U.S. 
However, mathematical modeling studies show that PrEP is cost-effective, especially when 
MSM with high-risk behavior are targeted (Juusola et al., 2012; Kessler et al., 2014; Schneider 
et al., 2014). Also a modeling study on the situation in the Netherlands showed that PrEP 
is cost-effective, and even cost-saving when the price reduces and the effectiveness is high 
(Nichols et al., 2016). 
With the high effectiveness of PrEP, the encouragement in WHO guidelines, and the prom-
ising results regarding cost-effectiveness, a rapid rollout of PrEP seems desirable. However, 
PrEP is not universally available, and the implementation of PrEP varies from country to 
country.
Implementation of PrEP around the world
The WHO formulated guidelines for the implementation of PrEP (World Health Organiza-
tion, 2015), which were adopted by 40 countries (Hodges-Mameletzis et al., 2018), including 




tional guidelines on PrEP implementation, most of the countries do not provide formal access 
to PrEP services. The global advocacy organization AVAC maintains the website PrEPWatch.
org including a ‘global PrEP tracker’ to provide information on the availability and accessibil-
ity of PrEP nation-by-nation (AVAC, 2020). A brief chronological overview of the introduc-
tion of PrEP in several regions is provided below, to highlight how PrEP was implemented 
in early adopting countries, and to outline the context that is relevant to the interpretation of 
findings of studies from different countries.
United States
The United States was the first country to take efforts in making PrEP available. The Food 
and Drug Administration (FDA) in the United States approved Truvada ® for PrEP for the 
prevention of HIV infections in 2012 (Gilead, 2012; Roehr, 2012), taking the first step in 
making PrEP available outside of clinical trials. The Centers for Disease Control and Preven-
tion (CDC) developed clinical guidelines for providing PrEP and PrEP became available via 
(free or co-payed) medication assistance programs and is covered by most national insurance 
plans (CDC, 2020; Kay & Pinto, 2020). Initially, the uptake of PrEP was slow (Kirby & Thorn-
ber-Dunwell, 2014), even among MSM who met the eligibility criteria for PrEP, (Parsons et 
al., 2017). Recently, PrEP uptake has been increasing, mostly among MSM in urban settings, 
for example in New York (Myers et al., 2018), San Francisco (Volk et al., 2020), and Chicago 
(Morgan et al., 2018). It is estimated that 200.000 people are using PrEP in the United States 
in 2020 (AVAC, 2020). Still, PrEP uptake should increase further, as the CDC estimated that 
there are 1.2 million eligible candidates for PrEP in the United States (Smith, Van Handel, et 
al., 2015).
Australia
Australia had a relatively rapid trajectory of implementing PrEP at a large scale. After small 
demonstration projects in 2014-2015 (Lal et al., 2017; Vaccher et al., 2017), PrEP became 
available via large-scale implementation projects in 2016 (Zablotska et al., 2018). As a result, 
PrEP use among eligible MSM increased between 2013 and 2017 from 2% to 24% (Holt, Lea, 
et al., 2018). In 2018, PrEP was approved for public subsidy in the Pharmaceutical Benefits 
Scheme (NPS MedicineWise, 2018), enabling further uptake of PrEP.
Europe
Four years after the approval of PrEP by the FDA in the United States, the European Medi-
cines Agency (EMA) approved Truvada for PrEP (European Medicines Agency, 2016), there-
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by making PrEP legally accessible in the European Union (EU). In 2016, prior to the approval 
of PrEP, the attitudes towards PrEP were examined among 15,000 MSM in the Flash! PrEP in 
Europe study. About half of the MSM participants were interested in using PrEP and about 
5% had already used PrEP (AIDES, 2016). A year later, the EMIS-2017 study among 113,000 
MSM in Europe found similar levels of interest in PrEP (44.4%) and PrEP use (3%) (European 
Centre for Disease Prevention and Control, 2019a). PrEP use was low, because PrEP was not 
formally available yet in most countries.
Across Europe, every country has to decide itself on the implementation of PrEP in the na-
tional health system. France was the first country in Europe to make PrEP available in January 
2016, even before the approval of PrEP by EMA. This rapid PrEP implementation was driven 
by the successful results of the French IPERGAY trial (Molina et al., 2015) and the influence 
of strong community organization (Rojas Castro, Delabre, Morel, et al., 2019). England fol-
lowed suit at the end of 2016 by making PrEP available in a National Health Service (NHS) 
trial for 10,000 individuals (Mayor, 2016). This temporary implementation of PrEP was crit-
icized because it brought uncertainty about the long-term accessibility of PrEP for a larger 
group of people (Nagington & Sandset, 2020). At the moment, most countries in Europe have 
not yet implemented PrEP in their healthcare system. According to data from the European 
Centre for Disease Prevention and Control (ECDC) from 2019, formal access to PrEP is only 
available in 16 of 53 reporting countries in Europe and neighboring countries (European 
Centre for Disease Prevention and Control, 2019b). In countries where PrEP is formally im-
plemented and (partially) reimbursed, PrEP use increases rapidly, as studies in Belgium and 
Germany have shown (Mysior et al., 2020; Vuylsteke et al., 2019). 
The Netherlands
The implementation of PrEP in the Netherlands started with the AMPrEP demonstration 
trial in 2015 (Public Health Service Amsterdam, 2015), providing initial access to PrEP to 
376 MSM and transgender individuals. After the approval of Truvada for PrEP by the EMA in 
2016, Truvada became available on prescription at Dutch pharmacies for approximately € 500 
per 30 pills. MSM in the Netherlands became aware of PrEP (Bil et al., 2015), but due to the 
limited capacity of AMPrEP and the high price of PrEP in pharmacies, PrEP was inaccessible 
for most MSM. The Dutch PrEP advocacy group PrEPnu lobbied for improving accessibility 
and affordability of PrEP. In 2017, the patent for Truvada for PrEP in the EU expired, and 
generic versions of PrEP became available. PrEP became more affordable for MSM in the 




the Minister for Medical Care and Sport announced that PrEP would be included in the re-
imbursement scheme of the health insurance for 6500 people for the next five years, requiring 
a co-payment of the PrEP user of 25% of the costs (Ministry of Health, Welfare and Sport, 
2018). In August 2019, PrEP provision started via the public health centers, and the costs of 
PrEP are (partially) reimbursed, making PrEP accessible to a larger group of MSM (Ministry 
of Health, Welfare and Sport, 2019). 
Informal PrEP use
The timeline of the introduction of PrEP in the Netherlands shows that many years passed 
between the approval of PrEP and the introduction of national guidelines (in 2016) and the 
formal provision of PrEP in a reimbursement scheme (in 2019). During these years, the avail-
ability of PrEP was low and the price of PrEP was high, limiting the accessibility of PrEP for 
people who are at risk of HIV. Consequently, people tried to obtain PrEP via channels that are 
more affordable or readily available to them. Obtaining PrEP via unofficial channels has been 
labelled ‘informal PrEP’, and these channels mostly include clinics and (online) pharmacies 
in other countries where PrEP is available for a lower price, (Charpentier et al., 2014; Kurtz 
& Buttram, 2016; Rosenthal et al., 2014; Zablotska et al., 2013). Also in their home coun-
try, MSM can obtain PrEP informally, by taking antiretrovirals (ARVs) that were prescribed 
as post-exposure prophylaxis (PEP) or as HIV treatment for HIV-positive individuals (“pill 
sharing”) (Zablotska et al., 2013).
It was expected that informal PrEP use would be equivalent to incorrect use of PrEP, because 
informal PrEP users may have misunderstandings of PrEP and do not receive PrEP coun-
seling (Buttram, 2018; Dimitrov et al., 2013; Kurtz & Buttram, 2016). The incorrect use of 
PrEP could then lead to drug resistance (Dimitrov et al., 2013). In practice, drug resistance is 
rare, especially when PrEP adherence is high (Parikh & Mellors, 2016). In a qualitative study 
in England, informal PrEP users were found to be highly motivated early adopters who were 
well informed through community engagement (Paparini et al., 2018). Test results from an 
sexual health clinic in London showed that most informal PrEP users had similar drug plas-
ma concentrations as formal PrEP users in clinical trials, indicating that PrEP adherence was 
high among informal PrEP users (X. Wang et al., 2018). 
Informal PrEP use is mainly an issue in Europe, as most countries in Europe lack formal PrEP 
implementation. In Europe, varying by country, up to 67% of PrEP users obtain PrEP via 
informal channels (European Centre for Disease Prevention and Control, 2019b). Given this 
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prevalence of informal PrEP use, it is important to investigate what the experiences of these 
informal PrEP users are, as they may differ from PrEP users in clinical trials.
Challenges and opportunities related to PrEP access and uptake
Given the improved availability of PrEP and the slow but steady increasing uptake of PrEP, 
questions arise regarding how PrEP should be implemented and how PrEP use can increase 
further to reach the maximum potential of PrEP in reducing new HIV infections. Determin-
ing who is interested in PrEP can help to identify under whom PrEP should be promoted. 
Furthermore, in the Netherlands, in a context where PrEP was not formally available, it is 
important to investigate what issues potential PrEP users face when trying to obtain PrEP. 
Interest in PrEP and PrEP uptake
To reach the maximum potential of PrEP in reducing HIV infections at population level, it 
is important that the right persons start taking PrEP. On the one hand, MSM with high risk 
behavior who are eligible for PrEP should start using PrEP to reduce new HIV infections. On 
the other hand, MSM with low risk behavior who do not meet eligibility criteria, should not 
start using PrEP, in order to reach maximum cost-effectiveness. National guidelines provide 
eligibility criteria for PrEP use, but how does this translate into practice? 
Studies in the United States have shown that there are disparities in the uptake of PrEP. Firstly, 
there is a gap between PrEP eligibility and PrEP uptake. It was found that while many MSM 
met the eligibility criteria for PrEP, only about 10% of them were using PrEP (Parsons et al., 
2017). In the Netherlands, it is estimated that there are currently 3,500 individuals on PrEP 
(AVAC, 2020), of which 95% are MSM (Staritsky et al., 2020), while it is estimated that 10,000 
MSM are eligible candidates for PrEP (Hoornenborg, Krakower, et al., 2017; Reitsema et al., 
2020).  MSM may underestimate their own risk of HIV and may therefore not see themselves 
as eligible candidates for PrEP, inhibiting their intention to use PrEP (King et al., 2014; Rendi-
na et al., 2017). Secondly, there are disparities in PrEP uptake between population subgroups. 
While Black and Latino MSM have an increased risk of HIV compared to white MSM (Hess 
et al., 2017), they are less likely to use PrEP (Bush et al., 2016; Kelley et al., 2015; Rolle et al., 
2017). These findings are from a United States context and may not generalize to the situation 
of PrEP in the Netherlands.  
To increase PrEP uptake among MSM, it is important to understand who is interested in 
PrEP. Determining what factors are related to interest in PrEP, may help to identify under 




lands, a study among 448 MSM in the Amsterdam Cohort Study found that high-risk MSM 
(i.e. MSM who had condomless anal sex or had more than five casual sex partners in the 
past six months) and MSM with no steady partner were more interested in PrEP (Bil et al., 
2015). This implies that PrEP interest was higher among MSM who could benefit most from 
PrEP. Since this study was conducted before the introduction of PrEP in the Netherlands, it 
is important to investigate current interest in PrEP, as the attitudes towards PrEP may have 
changed due to increased awareness. 
Accessing PrEP and PrEP-related healthcare
After having identified who is interested in PrEP and who is willing to use PrEP, it is impor-
tant to address how potential PrEP users access PrEP and PrEP-related healthcare. Especial-
ly when PrEP is limited available, or unaffordable, it is difficult to get hold of PrEP. In the 
Netherlands, PrEP can be obtained on prescription from the general practitioner.  However, 
some general practitioners have a moralistic opinion about PrEP and refuse to prescribe PrEP 
(Leusink, 2020; Plomer et al., 2020). Furthermore, the high price of PrEP (€ 500 per 30 pills 
in 2016 and 2017) was a hurdle for PrEP use in the Netherlands. Consequently, some MSM 
searched for PrEP through informal channels. A possible risk is that these informal PrEP 
users cannot maintain a constant supply of PrEP, because they do not have continuous access 
to PrEP points of sale (Rivierez et al., 2018). Having limited access to PrEP can lead to subop-
timal use of PrEP and to increased risk of HIV (Buttram & Kurtz, 2017). 
In addition to access to PrEP, access to PrEP related healthcare is also relevant. Clinical guide-
lines recommend regular counseling, renal function testing, and HIV and STI testing for PrEP 
users (World Health Organization, 2015). When formal PrEP services are not implemented 
yet, or when MSM obtain PrEP informally, PrEP users may not receive regular counseling 
and testing: A study among 300 informal PrEP users in the United States in 2016 found that 
27% of them were not making use of any medical care (Galea et al., 2016). Because of a lack of 
counseling, PrEP users may have misunderstandings of PrEP or may have increased risk-tak-
ing behaviors (Buttram, 2018; Dimitrov et al., 2013; Kurtz & Buttram, 2016). Since the limited 
access to PrEP and the possible lack of counseling and testing may put informal PrEP users at 
risk for incorrect use of PrEP (and increased risk for HIV), it is relevant to investigate to what 
extent informal PrEP use occurs in the Netherlands and what the experiences of MSM in the 
Netherlands are regarding accessing PrEP related healthcare. 
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Behavioral changes following PrEP uptake
While early research on PrEP focused on the effectiveness of PrEP and the implementation of 
PrEP, there is a need for psychosocial studies that can help to translate clinical findings into 
PrEP uptake (Auerbach & Hoppe, 2015). PrEP may not only have an impact on sexual behav-
ior, but also on attitudes towards sex and HIV. Promoting the psychosocial benefits of PrEP, 
such as increased feelings of empowerment and decreased stigma, may help to improve PrEP 
uptake (Grant & Koester, 2016).
Sexual risk behavior
A much-debated topic around PrEP is the sexual risk behavior of PrEP users. Healthcare 
providers assumed that MSM who start using PrEP would use less condoms because they feel 
sufficiently protected against HIV by PrEP (Karris et al., 2014; Tellalian et al., 2013). During 
the first trials of PrEP, it seemed that condom use was increasing among PrEP users (Grant et 
al., 2010). An explanation for this increased condom use was that PrEP users received coun-
selling in the setting of a clinical trial and were therefore more aware of the risks of HIV and 
STI and the usefulness of condoms. Later open-label and cohort studies showed that condom 
use decreased after PrEP initiation, as described in a meta-analysis and systematic review 
(Freeborn & Portillo, 2018; Traeger et al., 2018). Condom use particularly declined among 
MSM who already used condoms inconsistently prior to PrEP use (Traeger et al., 2018).
A consequence of decreased condom use is that PrEP users may have an increased risk of 
getting other STIs. The Dutch demonstration trial AMPrEP found no increase in the number 
of STIs, but these participants already had a high prevalence of STIs prior to PrEP use (Hoor-
nenborg et al., 2018). However, an increased risk of Hepatitis C was found among PrEP users 
in this trial, mainly because there was an increasing overlap between the sexual networks of 
PrEP users and men living with HIV (Hoornenborg, Achterbergh, et al., 2017). A meta-anal-
ysis of open-label studies showed that more recent studies and studies with a longer follow-up 
time did show an increase in STIs among PrEP users (Traeger et al., 2018). Given the variety 
in findings of long-term studies, and the fact that these studies were conducted in clinical 
settings, it is important to investigate how PrEP users’ sexual behavior develops in practice. 
Particularly in the case of informal PrEP use, when PrEP users may not receive counselling, 
there may be an effect of risk compensating behavior.
The concept of risk compensating behavior should not stand in the way of implementing 




risk compensating behaviors occur because people perceive less threat of HIV (Eaton & Kali-
chman, 2007; Stolte et al., 2004).  To mitigate increases in STIs as a result of risk compensating 
behaviors, the importance of behavioral counselling for PrEP users is stressed (Oldenburg et 
al., 2018; D. K. Owens et al., 2019). Instead of focusing on risk compensation that would hin-
der PrEP implementation, researchers have argued that the positive effects of PrEP on sexual 
health should be considered (Rojas Castro, Delabre, & Molina, 2019).
Psychosocial benefits of PrEP
In addition to the potential HIV-preventive effect of PrEP, there may be other benefits of PrEP, 
such as psychosocial benefits. By identifying and promoting these psychosocial benefits, PrEP 
uptake may increase further. In a study among visitors of a sexual health clinic in Toronto it 
was found that decreasing fear of getting HIV was the second most common reason for will-
ingness to use PrEP, after the reason of decreasing HIV risk (Rana et al., 2018). The reason of 
decreasing fear of getting HIV was not only mentioned by MSM with a high objective risk of 
getting HIV, but even more by MSM with a low objective risk of getting HIV. This indicates 
that PrEP can have psychosocial benefits even for MSM who are not necessarily eligible can-
didates for PrEP. 
Many MSM experience fear of HIV infection (Koester et al., 2017; Prestage et al., 2012; Whit-
field et al., 2019) and PrEP has the potential to reduce this HIV-related fear (Collins et al., 
2017; Hojilla et al., 2016; Koester et al., 2017). By reducing fear of HIV, PrEP users may have 
more pleasurable sex, and consequently an increased quality of sex life (Mabire et al., 2019). 
Moreover, PrEP may empower PrEP users in their sexual decision making (UNAIDS, 2016), 
increasing their control over their sex life. For example, PrEP users can experiment with new 
sex practices that they previously did not dare because of fear of HIV, such as taking the re-
ceptive role in anal intercourse. A qualitative study in France found that PrEP users indeed 
express greater feelings of sexual freedom and increased sexual pleasure (Mabire et al., 2019). 
However, the amount of research into psychosocial benefits of PrEP is limited, and it remains 
to be investigated to what extent PrEP contributes to these effects. In addition, it is not inves-
tigated yet to what extent these improvements change over time, similar to changes in risk 
behavior over time.
Another dimension of increased sexual freedom is that PrEP users may feel more comfortable 
using recreational drugs. Drug use in a sexual context is also known as chemsex, and main-
ly includes the use of mephedrone, γ-hydroxybutyrate (GHB), γ-butyrolactone (GBL), and 
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crystallized methamphetamine (Crystal Meth/Tina) (McCall et al., 2015). A study among 
4925 MSM visitors of the sexual health clinic in Amsterdam in 2016 found that 17.6% of 
MSM practiced chemsex in the past 6 months (Drückler et al., 2018). MSM who practiced 
chemsex were more often on PrEP (25.5%) than MSM who did not practice chemsex (5.7%) 
(Drückler et al., 2018). Chemsex is associated with an increased risk of HIV and STIs, because 
drug use can prolong sex sessions in which one has sex with multiple sex partners (Bourne 
et al., 2015). PrEP is a useful tool to reduce this risk of HIV, as condoms are not always used 
consistently during chemsex sessions (Roux et al., 2018). However, while PrEP might be ben-
eficial in the context of chemsex, PrEP uptake is still limited among MSM who practice chem-
sex (Maxwell et al., 2019). The exact relationship between chemsex and PrEP should be more 
closely examined to encourage PrEP uptake among MSM who practice chemsex.
Social stigma
In the early years of PrEP the media readily spoke of ‘Truvada whores’ (Calabrese & Under-
hill, 2015; Schwartz & Grimm, 2017; Spieldenner, 2016).PrEP stigma is based on judgements 
about the sexual behavior of PrEP users (Dubov, Galbo, et al., 2018). For example, MSM as-
sociated PrEP use with condomless sex (“barebacking”) (Pawson & Grov, 2018). As a result, 
MSM held PrEP users responsible for spreading STIs within the gay community. Moreover, 
if PrEP was seen as an alternative to condoms, PrEP was evaluated as ‘irresponsible’, because 
condoms have been associated with responsible sexual behavior (Haire, 2015). PrEP stigma 
has two possible consequences. Firstly, it creates a barrier for PrEP uptake. It was found that 
MSM who believed that PrEP is for promiscuous people are less interested in PrEP, despite 
the fact that they showed high-risk sexual behavior themselves (Eaton et al., 2017). Secondly, 
it may create a divide between PrEP users and MSM who are not using PrEP. PrEP users 
reported that they were sometimes rejected for sex because of their PrEP use (Franks et al., 
2018). Data on PrEP stigma is not yet available in the Netherlands. Especially in a context of 
limited, but emerging PrEP availability, it is important to investigate whether PrEP-related 
stigma provides a hurdle for PrEP use.
In contrast to stigmatizing reactions and rejections for sex, PrEP can also have positive effects 
on sex partner selection. It was found that  PrEP users can be seen as preferred sex partners, 
because of the HIV-preventive effect of PrEP, and consequently a lower transmission risk of 
HIV (Martinez & Jonas, 2019). A study among 5,000 MSM in the United States found evi-
dence for serosorting and ‘PrEP sorting’: MSM were more likely to have sex partners with 




more likely to have sex with PrEP users than with HIV-negative men not on PrEP (Grov et 
al., 2018). This indicates that PrEP can play a role in bridging the serodivide between sero-
discordant MSM. It was found that PrEP improves sexual experiences for both HIV-positive 
men and PrEP users, because of diminishing HIV stigma (Tester & Hoxmeier, 2020). 
HIV stigma is very common among MSM. In a study among 513 gay men living with HIV in 
the Netherlands, 70.2% reported experiencing stigma within the gay community (Stutterheim 
et al., 2008). HIV stigma has a negative impact on the wellbeing of gay men living with HIV 
as well as HIV-negative gay men (Courtenay-Quirk et al., 2006; Smit et al., 2012; Starks et 
al., 2013; Stutterheim et al., 2009). PrEP holds the potential of reducing HIV stigma, as PrEP 
may enable MSM to feel more comfortable having sex with people living with HIV (Brisson 
& Nguyen, 2017; Grant & Koester, 2016; Haas et al., 2017; Jaspal & Daramilas, 2016; Malone 
et al., 2018; Persson, 2016). It must be examined to what extent PrEP can play a role in over-
coming HIV stigma and improve sexual interactions between serodiscordant sex partners.
Research questions
This thesis aims to investigate the use of PrEP and the experiences of PrEP users in the Neth-
erlands. This thesis addresses the following research questions:
1. What are the attitudes and usage intentions of MSM for PrEP in the Netherlands?
2. How do high-risk MSM in the Netherlands obtain PrEP and access PrEP-related 
healthcare?
3. What are the hurdles for PrEP use in the Netherlands?
4. What is the sexual behavior of PrEP users after PrEP initiation?
 
We investigate these questions in a context of limited, but emerging PrEP availability in the 
Netherlands. While PrEP use and sexual risk behavior have been investigated in the demon-
stration trial AMPrEP (Public Health Service Amsterdam, 2015), no studies have been con-
ducted yet on (informal) PrEP use outside a clinical setting. The behavior of informal PrEP 
users may differ from the behavior of PrEP users in demonstration trials, as informal users do 
not always receive counseling. We examine sexual risk taking behavior, as well as the positive 
consequences of PrEP on sexual health. By investigating these aspects of PrEP use, we can 
inform community organizations and health care providers about optimal PrEP implementa-
tion. Tailored interventions can be derived to increase PrEP uptake among eligible MSM, to 
increase the maximum potential of PrEP to reduce new HIV infections.
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Outline of the thesis
In chapter 2 we first examine interest in PrEP. In the study in this chapter, we use data from 
the European research project ‘Flash! PrEP in Europe’. This project was an initiative of the 
French community-based organizations AIDES and Coalition PLUS and was carried out 
jointly by 17 non-governmental organizations (NGOs) and two universities in twelve Euro-
pean countries. The aim was to assess PrEP usage and interest in PrEP among MSM on the 
eve of the introduction of PrEP in Europe in 2016. Various recruitment methods were used 
for the Dutch sample. This allowed us to investigate differences in PrEP interest among MSM 
who were recruited via various strategies. We specifically compared MSM from an LGBT 
research panel (AmsterdamPinkPanel, https://app.uva.nl/) with MSM who were recruited via 
convenience sampling. Furthermore, we investigated which factors were related to interest in 
PrEP and intention to use PrEP.
Chapter 3 describes the results of a qualitative study on the initial experiences of early PrEP 
users in the Netherlands. In 2018, we conducted interviews with informal PrEP users. At the 
time, generic PrEP was available in the Netherlands since a few months, making PrEP more 
affordable. As a result, informal PrEP users were able to switch from procuring PrEP via in-
formal channels, to procuring PrEP at the local pharmacy on prescription. We explored the 
experiences of PrEP users in the context of this transition from informal PrEP use to formal 
PrEP access. We aimed to explore the experiences of these PrEP users as broadly as possible, 
particularly because PrEP use has not been investigated before in the Netherlands outside a 
demonstration trial. Therefore, we addressed three domains in this study. First, we investigat-
ed access to PrEP and PrEP-related healthcare. Second, we explored the responses PrEP users 
faced regarding their PrEP use, to assess possible PrEP stigma. We assessed responses from 
sex partners, as well as from friends and family. Third, we investigated the sexual behavior 
of PrEP users. Because participants in the Dutch demonstration trial AMPrEP were selected 
based on their high-risk behavior, we wanted to investigate the sexual behavior of other PrEP 
users in the Netherlands.
In chapter 4 we investigate predictors of PrEP uptake. We recruited participants via the web-
site of the PrEP advocacy group PrEPnu (https://www.prepnu.nl/) over a period of two years 
(2017-2019). The website of PrEPnu provides information about using and obtaining PrEP 
aimed at potential PrEP users in the Netherlands. Participants received follow-up question-
naires after three and six months. At the first point of assessment, most participants did not 




we analyzed which behavioral and demographic characteristics on the baseline measurement 
predict PrEP uptake after six months. During the two years in which we recruited partic-
ipants, there were changes in the accessibility of PrEP. Halfway through, in January 2018, 
generic versions of PrEP became available, reducing the price from €500 to €50 per 30 pills. 
We examined whether this price drop was related to increased PrEP uptake.
In chapter 5 we use the same dataset as in the previous chapter, and elaborate on the experi-
ences of the participants who used PrEP. To investigate the role of PrEP in improvements in 
sexual health, we investigated the quality of sex life of PrEP users. We addressed several po-
tential psychosocial and behavioral sequelae of PrEP, such as reduced fear for HIV, increased 
sexual freedom, and reduced condom use. In addition, we investigated how these attitudes 
and behaviors were related to quality of sex life.
In chapter 6 we examine the potential role of PrEP in reducing HIV stigma. We in particular 
investigated the attitudes of PrEP users who indicated to have sex with men living with HIV. 
We assessed their experiences of fear, comfort, and safety when having sex with men living 
with HIV. For this analysis the same dataset is used as in the previous chapters. We assessed 
whether the attitudes towards having sex with HIV positive men changes further over time 
after prolonged PrEP use.
Chapter 7 presents the general discussion. In this chapter the findings from the preceding 
studies are summarized, integrated, and connected to existing literature. After describing the 
main findings, the implications of these findings for the societal and scientific debates around 
PrEP are discussed. Subsequently, the strengths and limitations of this thesis are discussed. 
Finally, the directions for future research and the conclusions are discussed.
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Despite increased availability of pre-exposure prophylaxis (PrEP), PrEP uptake has remained 
low. To promote uptake, factors related to PrEP interest among relevant target populations 
warrant investigation. The aim of this study was to provide an analysis of PrEP interest 
among men who have sex with men (MSM) in the Netherlands, while taking study recruit-
ment strategies into account. We recruited 154 MSM from an LGBT research panel (Amster-
damPinkPanel) and 272 MSM from convenience sampling. Both samples were part of the 
Flash! PrEP in Europe survey and were compared on their PrEP interest, usage intentions, 
and sexual behavior. We conducted logistic regression analyses to discover variables associ-
ated with PrEP interest and intentions. Participants from the AmsterdamPinkPanel were less 
likely to use PrEP, had less knowledge of PrEP, and were less interested in PrEP than partic-
ipants from convenience sampling. Significant covariates of PrEP interest were being single, 
more prior PrEP knowledge, sexual risk behaviors, such as not having used a condom during 
last sex and having ever used drugs in a sexual context, and not participating in the Amster-
damPinkPanel. Adding the recruitment strategy to the regression increased explained vari-
ance on top of predictors already described in the literature. Increased sexual risk behavior 
is related to increased PrEP interest and it helps to identify PrEP target groups. Recruitment 
strategies have a substantial impact on findings regarding PrEP interest and usage intentions. 
This study emphasizes the importance of using multiple strategies for recruiting participants 
to obtain a more comprehensive view of MSM’s attitudes toward PrEP.




Pre-exposure prophylaxis (PrEP) is an effective biomedical intervention to prevent HIV in-
fection among HIV-negative individuals (Grant et al., 2010, 2014; Liu et al., 2013; McCor-
mack et al., 2016; Molina et al., 2015). In the past years, the availability and accessibility of 
PrEP have improved. Four years after the approval of the Food and Drug Administration 
(FDA) in the United States in 2012 (Roehr, 2012), PrEP became formally available in Europe 
based on the approval of the European Medicines Agency (EMA) in 2016 (European Medi-
cines Agency, 2016). Moreover, in many countries, PrEP has become more affordable through 
the inclusion of PrEP coverage in health insurance, such as in Belgium and Portugal (NAM 
Aidsmap, 2017), and the introduction of cheaper, generic versions of PrEP in some European 
countries (PrEPnu, 2017). 
Despite the increased accessibility of PrEP, PrEP uptake has remained low, even among men 
who have sex with men (MSM) who are primary candidates for PrEP (Parsons et al., 2017). 
MSM may underestimate their risk of getting HIV, and may therefore see themselves as not 
requiring PrEP (Blumenthal et al., 2019; Parsons et al., 2017). Other barriers for PrEP uptake 
may include medical mistrust and anticipated stigma from sex partners (Biello et al., 2017; 
Cahill et al., 2017; Golub, 2018). To promote PrEP uptake, it is essential to further examine 
factors related to interest in PrEP in populations for whom PrEP implementation should be 
fostered. 
Previous studies have shown substantial variation in PrEP interest. MSM at higher risk of 
getting HIV, because of a history of sexually transmitted infections (STIs) or multiple sex 
partners, were found to be more interested in taking PrEP (Bil et al., 2015; Golub et al., 2010; 
Yang et al., 2013). Further, some studies reported that younger MSM were more interested 
in taking PrEP (Aghaizu et al., 2013; Barash & Golden, 2010), while other studies found that 
older MSM were more interested in taking PrEP (Yang et al., 2013); some studies did not find 
a relation between age and PrEP interest (Bil et al., 2015; Holt et al., 2012).
Variation in PrEP interest between studies can at least in part be explained by variation in 
how the question was formulated. Some studies assessed willingness to use PrEP (Barash & 
Golden, 2010; Golub et al., 2013; Grov et al., 2016), while other studies combined measures of 
willingness to use PrEP and intention to use PrEP into one variable (Bil et al., 2015; Holt et al., 
2012). Importantly, health risk research found that willingness and intention were related, but 
independent constructs. According to the prototype/willingness model, intentions are more 
Chapter 2
28
reflective thoughts in order to achieve a particular goal state, while willingness does not in-
volve goal states, plans, or instrumental actions (Gibbons et al., 1998). Consequently, research 
has also found a clear distinction between willingness to use PrEP and intention to use PrEP 
(Rendina et al., 2017); MSM with a high intention to use PrEP had  a lower education level, a 
lower income, a younger age, higher beliefs in the effectiveness of PrEP, saw themselves more 
often as appropriate candidates for PrEP, and felt greater partner pressure for condom nonuse, 
compared to MSM with a high willingness to use PrEP.  
In addition, different recruitment strategies might also explain part of the variation in PrEP 
interest within MSM samples. For instance, in a cohort study in the Netherlands in 2012, 
13.5% of MSM had a high intention to use PrEP and 60% had a medium intention to use PrEP 
(Bil et al., 2015), while an online study in Scotland in the same period found a much lower 
intention to use PrEP (47.8%; Frankis, Young, Flowers, & McDaid, 2016). Differences in PrEP 
use and PrEP interest were also found in a study that directly compared different recruitment 
strategies: PrEP use and PrEP interest were higher among clients of an HIV/STI testing loca-
tion compared to an online MTurk sample (Beymer et al., 2018). 
The aim of the current study was to provide an in-depth analysis of PrEP interest among 
MSM in the Netherlands, while taking recruitment strategies into account. Our first research 
question was what the PrEP knowledge, PrEP use, PrEP interest, and PrEP usage intentions 
were among MSM in the Netherlands. Next, we investigated covariates of interest in PrEP and 
of intention to use PrEP. Our second research question was whether participants that were 
solicited via different recruitment strategies differed in PrEP interest and usage intentions. 
Specifically, participants in an LGBT research panel were compared to participants who were 
recruited online and at LGBT social venues. Finally, we compared characteristics of partic-
ipants recruited through the LGBT research panel with LGBT research panel members not 
participating in this study to shed further light on underlying differences.
Methods
Participants 
Dutch participants for the Flash PrEP in Europe (FPIE) survey were recruited via two re-
cruitment strategies: (1) via an LGBT research panel (AmsterdamPinkPanel), or (2) via con-
venience sampling, through gay dating apps and websites (Hornet and PlanetRomeo), LGBT 
or MSM-related websites (for example, gay.nl), and 5000 flyers distributed in LGBT-themed 
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bars, cafés, saunas, and STI clinics in June and July 2016. This provided the opportunity to 
compare sampling strategies, as FPIE participants stemming from the AmsterdamPinkPanel 
could be identified.
The AmsterdamPinkPanel is a partnership between COC Amsterdam (Dutch LGBT rights 
organization) and the Psychology Research Institute of the University of Amsterdam. The 
AmsterdamPinkPanel is a psychosocial LGBT research panel with more than 1400 members, 
of which 931 are MSM, with an age-range from 18 to 78 years. The members not only live 
in Amsterdam, but throughout The Netherlands. Sampling for the AmsterdamPinkPanel is 
community-driven and by self-enrollment. 
Participants needed to be 18 years or older and to be HIV-negative or unaware of their 
HIV-status for inclusion in the current survey. Given the focus on MSM, only cisgender males 
were included in the analysis, defined by male gender at birth and current male gender. Par-
ticipants were excluded from participation if they were HIV-positive, as PrEP is indicated 
only for HIV-negative individuals.
Measures
The FPIE survey was designed by the French community-based organizations AIDES and Co-
alition PLUS and adjusted by input from other non-governmental organizations and academ-
ics from 12 European countries. The 82-item questionnaire was the same in all participating 
countries and available in the local language. Translators chose the phrasing that seemed most 
adequate according to the populations targeted. A back-translation in English was conducted 
to ensure translation accuracy. For Dutch participants, the questionnaire was offered in Dutch 
and English. At the start of the survey, the only information provided about PrEP was that it is 
an HIV-prevention tool that is available in some countries around the world. We describe the 
measures relevant to the current research questions below. A full description of all measures 
in the FPIE survey can be found in the online supplementary material . The questionnaire was 
created in Qualtrics and the participants could not click back to previous questions.
Sociodemographic characteristics
In the FPIE survey, participants were asked to indicate their gender, age, relationship status, 
educational level, financial situation, country of birth, and country of residence. Gender was 
determined using two questions: gender at birth and current gender. Educational level was 
indicated by five levels, ranging from no higher education to PhD degree. Financial situation 
was assessed with a 6-point scale ranging from (1) “You can’t make ends meet without bor-
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rowing” to (6) “You are doing really well.”
In the annual intake survey of the AmsterdamPinkPanel, some demographic questions were 
asked with different response options than the questions in the FPIE survey. In the Amster-
damPinkPanel educational level was indicated by seven levels, ranging from elementary 
school to university degree, and also included the options “rather not say” and “other educa-
tion.” Financial situation was indicated by self-reported yearly income in one of five different 
categories (< €30.000, €31.000-€50.000, €51.000-€75.000, > €75.000 and “prefer not to say”).
Knowledge of PrEP
Participants indicated if they were aware of PrEP (yes/no). If they did, they were asked to 
choose the correct definition out of five options to assess their knowledge. Two of the five 
definitions were correct (“PrEP is a pill that greatly reduces the risk of contracting HIV. You 
have to take it every day.” and “PrEP is a pill that greatly reduces the risk of contracting HIV. 
You have to take it when you plan to have sex, before and two days after.”), and a maximum 
of two choices were allowed. We defined knowledge of PrEP as correct if participants chose at 
least one of the correct definitions and none of the incorrect definitions. After these questions, 
all participants were provided with information about PrEP. This stated that PrEP provides 
protection against HIV when the drug is sufficiently present in the blood, but that it does not 
provide protection against other STIs and that it should not be confused with PEP (Post-Ex-
posure Prophylaxis).
PrEP use
We asked participants if they were using PrEP. If so, they were not asked questions about in-
terest in PrEP and intentions to use PrEP. Current PrEP users were asked how they obtained 
PrEP (e.g., via doctor’s prescription, online purchase, or using HIV treatments prescribed as 
PEP).
Interest in PrEP
To investigate willingness to use PrEP, we asked participants who did not use PrEP if they 
were interested in PrEP, using a 5-point scale, ranging from (1) definitely not interested to (5) 
definitely interested. Participants who indicated that they were (maybe) interested in PrEP 
were asked for their reasons why they were interested. They could express their agreement on 
the statements listed in Table 2 by using a 5-point scale, ranging from (1) strongly disagree 
to (5) strongly agree. Participants who indicated that they were not interested in PrEP were 
asked for their reasons why they were not interested. They could express their agreement on 
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the statements listed in Table 3 by using a 5-point scale, ranging from (1) strongly disagree to 
(5) strongly agree. Participants could not add reasons themselves.
Intention to use PrEP
Participants’ intentions to use PrEP were evaluated by asking if they intended to use PrEP 
when it becomes available, and before it becomes officially available within their countries’ 
health care system. Both questions were rated on a 5-point scale, ranging from (1) definitely 
having no intention to (5) definitely having the intention to use.
Sexual behavior
We asked participants about the number of sex partners they had in the past six months and 
the frequency of anal sex, using a 5-point scale ranging from (1) never to (5) daily. Partici-
pants indicated if they used condoms during anal sex in the past six months by using a 5-point 
scale ranging from (1) never to (5) always. 
Subastance use
Participants were asked if they used injectable drugs and if they used other drugs. If they re-
sponded yes to one of those questions, they were asked if they used drugs in a sexual context 
(yes/no).
Data Analysis
We analyzed the data using IBM SPSS Statistics version 24. We controlled for duplicate par-
ticipation by checking IP addresses and response patterns on demographics and key variables.
We used descriptive statistics to describe the sociodemographic characteristics of the sample, 
and undertook difference tests to compare subsamples of participants recruited through the 
AmsterdamPinkPanel and through convenience sampling. To investigate self-selection bias, 
we further assessed differences in the sociodemographic characteristics of the AmsterdamP-
inkPanel members who participated in FPIE with panel members who did not participate in 
the survey, based on intake data of the AmsterdamPinkPanel. We used descriptive statistics to 
describe the sample with respect to PrEP knowledge, use, interest and usage intentions, and 
assessed differences on these variables between AmsterdamPinkPanel participants and par-
ticipants recruited through convenience sampling. For all difference tests we used analysis of 
variance (ANOVA) for continuous variables and chi-square tests for categorical variables. We 
used a multivariate analysis of variance (MANOVA) for comparing the answers on the multi-
ple reasons for interest in PrEP, and reasons for disinterest in PrEP, between the participants 
recruited from the AmsterdamPinkPanel and the participants recruited through convenience 
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sampling. Given the most common type of variables, we conducted logistic regression analy-
ses to assess variables associated with interest in PrEP and intention to use PrEP. 
Results
Participant Characteristics
In total, 426 participants completed the FPIE survey. The mean age of the participants was 42 
years, with age ranging from 18 to 75 years (Table 2.1). The Netherlands was the place of birth 
of 363 (85.2%) participants. A bachelor degree or higher had been obtained by 290 (68.1%) 
participants. The average score regarding perceived financial situation was 4.29 (SD = 1.24), 
indicating that participants perceived their financial situation between “all right” and “rather 
well.” The relationship status of 191 (44.8%) participants was single. We recruited 154 (36.2%) 
males via the AmsterdamPinkPanel and 272 (63.8%) males via convenience sampling. The 
AmsterdamPinkPanel participants and the participants recruited via convenience sampling 
differed on several sociodemographic characteristics. AmsterdamPinkPanel participants 
were on average older, perceived their financial situation as better, had a higher education 
level, and were more likely to be in a relationship (Table 2.1).
Furthermore, we could identify differences between AmsterdamPinkPanel participants and 
AmsterdamPinkPanel members who did not participate in the FPIE study. We invited all 931 
male members of the AmsterdamPinkPanel to participate in the FPIE study, of whom 203 
(21.8%) decided to participate. The survey was completed by 154 participants. To answer our 
question whether there was a self-selection bias in MSM who responded to a survey about 
PrEP among research panel members, we compared AmsterdamPinkPanel members who 
participated in FPIE (n = 203) with AmsterdamPinkPanel members who did not participate 
(n = 728) on demographic variables. We observed differences in age and income, based on 
intake survey data: AmsterdamPinkPanel members participating in FPIE (M age = 52, range: 
18–81) were older than AmsterdamPinkPanel members who did not participate (M age = 46, 
range: 19–90; F (1, 926) = 29.14, p < .001, ƞ2p=.031). Of those who provided information on 
their income (n = 850), AmsterdamPinkPanel members participating in FPIE had a higher 
income than the AmsterdamPinkPanel members who did not participate, with 19.9% of the 
AmsterdamPinkPanel members participating in FPIE having an income below € 31.000 com-
pared to 33.1% of the AmsterdamPinkPanel members who did not participate (χ2(4) =18.74, 
p < .001). AmsterdamPinkPanel members overall are well educated, with a majority (75.5%) 
having a Bachelor degree or higher. There were no differences in education level between the 
PrEP interest among MSM in the Netherlands
33
2













(n = 272, 
63.8%) p ƞ2p
M (range / SD) F (df)





4.29 (1.24) 4.75 (1.09) 4.03 (1.24) 36.62 
(1, 421)
<.001 .08
Number of sex 
partners in past 6 
months





No higher  
education




61 (14.6%) 14 (9.2%) 47 (17.6%)
Bachelor degree 138 (32.9%) 40 (26.3%) 98 (36.7%)
Master degree 118 (28.2%) 55 (36.2%) 63 (23.6%)
PhD degree 34 (8.1%) 26 (17.1%) 8 (3.0%)
Relationship status
Single 209 (49.2%) 56 (36.4%) 153 (56.5%) 26.11 (2) <.001 -
In a relationship 123 (28.9%) 67 (43.5%) 56 (20.7%)
In an open 
relationship
93 (21.9%) 31 (20.1%) 62 (22.9%)
Had an STI in the 
past 12 months
80 (20.3%) 17 (12.1%) 63 (24.8%) 9.12 (1) .003 -
Used a condom the 
last time
201 (51.1%) 69 (49.3%) 132 (52.2%) .30 (1) .58 -
Used drugs in a 
sexual context
136 (33.2%) 38 (25.3%) 98 (37.7%) 6.55 (1) .01 -
AmsterdamPinkPanel members participating in FPIE or not (χ2(6) = 5.00, p = .54). Amster-
damPinkPanel members participating in FPIE were less often single (36.0%) than other Am-
sterdamPinkPanel members (44.8%), but there was no significant difference in relationship 
status between the two groups (χ2(6) = 9.17, p = .16).
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PrEP Knowledge and PrEP Use
Out of the 426 FPIE participants, 383 (89.9%) indicated that they were aware of PrEP. Of 
those who were aware of PrEP, 327 participants (85.4% of those who were aware of PrEP) had 
correct knowledge of PrEP. Thirty-four participants (8.0%) mistook PrEP for Post-Exposure 
Prophylaxis (PEP). AmsterdamPinkPanel participants were less likely to have correct knowl-
edge about PrEP than the participants recruited through convenience sampling (77.1% vs. 
89.7%, χ2(1) = 10.93, p < .001). 
Out of the 426 FPIE participants, 29 (6.6%) used PrEP. AmsterdamPinkPanel participants 
used PrEP less often than the participants recruited through convenience sampling (3.2% vs. 
8.8%, χ2(1) = 4.82, p = .03). One participant received PrEP via a doctor’s prescription. The 
remaining 28 participants received PrEP via a research trial, such as the Dutch AMPrEP trial 
(Hoornenborg et al., 2019). 
Interest in PrEP
Out of 426 FPIE participants, 120 (28.2%) were definitely interested in using PrEP, and 73 
(17.1%) participants were probably interested in using PrEP. There was a substantial differ-
ence in PrEP interest between participants recruited from the AmsterdamPinkPanel and the 
participants from convenience sampling (χ2(4) = 100.33, p < .001). The majority of partici-
pants recruited from the AmsterdamPinkPanel were not interested in using PrEP; 53 (36.1%) 
of these participants were definitely not interested and 36 (24.5%) were probably not interest-
ed. In contrast, the majority of the participants recruited through convenience sampling were 
interested in using PrEP; 106 (42.9%) of these participants were definitely interested and 57 
(23.1%) were probably interested.
For those participants (n = 260) who were interested in using PrEP we assessed the reasons 
for their interest (Table 2.2). In a MANOVA, we found no significant difference in the reasons 
for interest in PrEP between AmsterdamPinkPanel participants and the participants recruited 
through convenience sampling (F (6, 253) = 1.76, p = .11, Wilk’s Λ = .96, ƞ2p = .04).
For those participants (n = 119) who were not interested in using PrEP we assessed the rea-
sons for their lack of interest (Table 2.3).  In a MANOVA, there was no significant difference 
in the reasons for lack of interest in PrEP between AmsterdamPinkPanel participants and the 
participants from convenience sampling (F (10, 108) = 1.64, p = .10, Wilk’s Λ = .87, ƞ2p = .13). 
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Table 2.2. Mean scores on reasons for interest in PrEP for AmsterdamPinkPanel participants and 













I’d rather have condomless sex 3.76 (1.33) 3.46 (1.40) 2.16 .14 .008
I’m at risk of being infected by 
HIV
3.57 (1.19) 3.69 (1.10) .58 .46 .002
I would feel safer 4.33 (1.02) 4.58 (.76) 4.23 .04 .016
I would feel less anxious 4.24 (1.10) 4.44 (0.85) 2.15 .14 .008
I would feel more in control 4.17 (.96) 4.36 (.88) 1.99 .16 .008
I would have a more satisfying 
sex life
3.62 (1.28) 3.93 (1.22) 2.85 .09 .011
Note: The scores are on a 5-point Likert scale, with (1) for strongly disagree and (5) for strongly 
agree. Please note that in a MANOVA, no significant difference was found in the reasons for interest 
in PrEP between AmsterdamPinkPanel participants and the participants recruited through conveni-
ence sampling (F (6, 253) = 1.76, p = .11, Wilk's Λ = .96, ƞ2p = .04).
Intentions to use PrEP
Regarding intention to use PrEP when it becomes officially available within the countries’ 
health care system, we saw the same distribution of scores as for PrEP interest. Out of 426 
FPIE participants, 119 (27.9%) participants definitely had the intention to use PrEP when it 
becomes available and 81 (19.0%) participants probably had the intention to use PrEP when 
it becomes available. The participants recruited through convenience sampling had a higher 
intention than AmsterdamPinkPanel participants (χ2(5) = 100.74, p < .001). Of the partici-
pants recruited through convenience sampling, 39.9% definitely and 28.6% probably had the 
intention to use PrEP when it becomes available, compared to 13.4% and 6.7% of Amster-
damPinkPanel participants.
The intention to use PrEP before it becomes officially available was substantially lower than 
the intention to use PrEP when it becomes available. Only 26 (6.1%) participants definitely 
and 37 (8.7%) participants probably had the intention to use PrEP before it becomes availa-
ble. Again, participants recruited through convenience sampling had a higher intention than 
AmsterdamPinkPanel participants (χ2(5) = 55.69, p < .001). Of participants recruited through 
convenience sampling, 9.3% definitely, and 12.1% probably had the intention to use PrEP be-
fore it becomes available, compared to 2.0% and 4.7% of AmsterdamPinkPanel participants.
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Table 2.3. Mean scores on reasons for non-interest in PrEP for AmsterdamPinkPanel participants 











n = 37 F (1,117) p ƞ2p
I don’t want to take 
medication every day
4.38 (1.22) 3.84 (1.46) 4.39 .04 .036
I don’t want to pay for 
PrEP
2.67 (1.31) 2.65 (1.27) .01 .93 <.001
I’m worried about the 
side-effects
3.93 (1.15) 3.70 (1.27) .91 .34 .008
I’m afraid of being seen 
in a negative light if I 
take PrEP
2.35 (1.26) 2.11 (1.13) 1.03 .31 .009
I don’t believe it works 2.09 (1.19) 2.57 (1.30) 3.95 .05 .033
I’m worried of getting 
other STIs
3.26 (1.52) 3.51 (1.54) .72 .40 .006
I don’t need to change 
how I protect myself
4.39 (.94) 4.27 (1.10) .37 .54 .003
I don’t think I’m at risk 
of being infected by 
HIV
3.77 (1.18) 3.19 (1.41) 5.43 .02 .044
I don’t want to undergo 
regular medical check-
ups
2.91 (1.44) 2.81 (1.39) .14 .71 .001
I’m worried that I might 
use condoms less often
2.56 (1.43) 2.65 (1.47) .09 .76 .001
Note: The scores are on a 5-point Likert scale, with (1) for strongly disagree and (5) for strongly 
agree. Please note that in a MANOVA, no significant difference was found in the reasons for lack of 
interest in PrEP between AmsterdamPinkPanel participants and the participants from convenience 
sampling (F (10, 108) = 1.64, p = .10, Wilk's Λ = .87, ƞ2p = .13).
Factors Associated with PrEP Interest and Intention to Use PrEP
Table 2.4 shows the outcomes of the logistic regression of correlates of interest in PrEP. Sig-
nificant multivariate correlates of PrEP interest were being single (aOR = .31, 95% CI .17–59, 
p < .001), having correct prior PrEP knowledge (aOR = 1.96, 95% CI 1.05–3.69, p = .04), not 
having used a condom for last sex (aOR = 2.00, 95% CI 1.17–3.42, p = .01), having ever used 
drugs in a sexual context (aOR = 2.68, 95% CI 1.52–4.73, p = .001), and not being a member 
of the AmsterdamPinkPanel (aOR =.18, 95% CI .10–.34, p < .0001). Adding the variable “be-
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Table 2.4. Multivariable logistic regression examining correlates of interest in PrEP.
B S.E. p aOR 95% CI
Age .01 .01 .55 1.00 .99–1.03
Education level
No higher education Ref
Professional qualification .59 .45 .19 1.81 .65–4.38
Bachelor .08 .39 .83 1.08 .51–2.31
Master .47 .41 .26 1.60 .71–3.59
PhD -.17 .64 .79 .84 .24–2.94
Financial situation -.15 .11 .18 .86 .69–1.07
Relationship status
Single Ref
In a relationship -1.16 .32 <.001 .31 .17 - .59
In an open relationship .07 .34 .83 1.08 .55–2.10
STI in past 12 months* .42 .36 .24 1.53 .76–3.08
PrEP knowledge* .68 .32 .04 1.96 1.05–3.69
Not used a condom the last time* .69 .27 .01 2.00 1.17–3.42
Used drugs in a sexual context* .99 .29 .001 2.68 1.52–4.73
Participant of AmsterdamPinkPanel* -1.71 .33 <.001 .18 .10–.34
* The reference category for these variables is “no”.
χ2(13, N = 358) = 117.38, p < .001, Nagelkerke R2 = .37
ing a member of the AmsterdamPinkPanel” to the regression model increased the proportion 
of explained variance by eight percent from R2 = .29 (χ2(12, N = 358) = 87.74, p < .001) to R2 
= .37 (χ2(13, N = 358) = 117.38, p < .001).
Similarly, we conducted a logistic regression analysis regarding correlates of intention to use 
PrEP. The same multivariate correlates as for PrEP interest were found for intention to use 
PrEP, except for having correct prior PrEP knowledge (aOR =1.40, 95% CI .75–2.62, p = .29). 
Significant multivariate correlates of intention to use PrEP were being single (aOR = .42, 95% 
CI .23–.79, p = .007), not having used a condom for last sex (aOR = 1.88, 95% CI 1.09–3.23, 
p = .02), having ever used drugs in a sexual context (aOR = 2.90, 95% CI 1.62–5.17, p <.001), 
and not being a member of the AmsterdamPinkPanel (aOR =.13, 95% CI .07–.25, p < .001). 
Adding the variable “being a member of the AmsterdamPinkPanel” to the regression model 
increased the proportion of explained variance by 12 percent from R2 = .27 (χ2(12, N = 356) = 




The aim of this study was to provide an in-depth analysis of PrEP interest of MSM while tak-
ing recruitment strategies into account. It is important to examine factors related to interest in 
PrEP to be able to identify who can be targeted to increase PrEP uptake, because PrEP uptake 
has generally remained low, even among individuals with an elevated risk of an HIV infection 
(Parsons et al., 2017). Moreover, taking recruitment strategies into account is important since 
previous studies making use of different recruitment strategies have shown substantial varia-
tion in PrEP interest (Beymer et al., 2018; Bil et al., 2015; Frankis et al., 2016; Holt et al., 2012; 
Yang et al., 2013). For the current study, we recruited participants in two ways: via an LGBT 
research panel (AmsterdamPinkPanel) and via convenience sampling. 
We found that recruitment strategies had a substantial impact on findings regarding interest 
in PrEP and intention to use PrEP. In particular, in the regression analysis, we found that 
adding recruitment strategy as a covariate substantially increased the proportion of explained 
variance of interest in PrEP and intention to use PrEP. We found that MSM participants re-
cruited through the AmsterdamPinkPanel were less interested in PrEP, and had a lower inten-
tion to use PrEP than MSM participants who were recruited via convenience sampling. Also, 
AmsterdamPinkPanel participants were older, more educated, wealthier, and more often in 
a relationship compared to the participants from convenience sampling. Previous studies 
showed mixed results for the influence of sampling strategies on findings regarding interest in 
PrEP.  Beymer et al. (2018), for example, reported higher interest in PrEP among visitors to an 
STI clinic compared to online participants, while Ferrer et al. (2016) reported lower interest 
among visitors to an STI clinic compared to online participants. Overall, the pattern of results 
across studies is diverse, confirming our notion that recruitment strategies and sample char-
acteristics can play a major role in explaining different findings.
Overall, we found that 89.9% of the participants already knew what PrEP is. This is a large 
proportion compared to earlier studies (Bil et al., 2015; Frankis et al., 2016; Grov et al., 2016), 
suggesting that knowledge of PrEP is increasing over the years. Despite the high level of PrEP 
knowledge, we found low actual use of PrEP (6.6%). This is comparable to findings of other 
studies in Europe (Bourne et al., 2019), and globally (Kamitani et al., 2018), and likely reflects 
the early stages of PrEP implementation. Nevertheless, about half of the participants (45.3%) 
were interested in taking PrEP, and a similar number of participants (46.9%) had the inten-
tion to use PrEP when available. This is in line with the majority of earlier studies, reporting a 
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willingness to use PrEP among about 50% of participants, as described in a review by Young 
and McDaid (2014). Covariates of interest in PrEP were being single, having correct prior 
PrEP knowledge, not having used a condom for last sex, having ever used drugs in a sexual 
context, and not being participant of the AmsterdamPinkPanel. The same covariates were 
found for intention to use PrEP, except for the covariate having correct prior PrEP knowledge. 
In contrast with the notion that there is a clear distinction between willingness to take PrEP 
and intention to take PrEP (Rendina et al., 2017), we did not encounter this distinction in our 
results. Because PrEP had only limited availability in the Netherlands at the time of our study, 
PrEP use was fairly distant for most MSM and, therefore, it may not have been possible to find 
this fine distinction between interest in PrEP and intention to use PrEP, as was found in the 
U.S.-based study of Rendina et al. (2017).
To investigate the possibility of a self-selection bias in MSM who respond to a survey about 
PrEP, we compared AmsterdamPinkPanel members who participated in FPIE with Amster-
damPinkPanel members who did not participate. We found that MSM from the Amster-
damPinkPanel who participated in the FPIE survey were older and more affluent than MSM 
from the AmsterdamPinkPanel who did not participate. This finding is surprising since we 
expected that younger MSM would be more likely to respond to the questionnaire, because 
they are more interested in taking PrEP according to previous studies (Holt et al., 2012). 
However, the majority of the AmsterdamPinkPanel participants (60.6%) were not interested 
in using PrEP, which may have influenced their motivation to take part in the survey and to 
voice their views.
A limitation of our study is that, while we recruited participants via different strategies, in-
clusion was based on convenience sampling. Random population sampling strategies, in 
which each individual in the population has the same probability of being included, seem to 
be less affected by self-selection bias than nonprobability samples (Meyer & Wilson, 2009), 
and LGBT probability samples are found to differ from LGBT participants in nonprobability 
community samples. LGBT nonprobability community participants were younger, had more 
often an exclusive same-sex orientation, and were more open about their sexual orientation 
(Kuyper et al., 2016). They also reported more high-risk sexual behavior (Dodds et al., 2006; 
Evans et al., 2007). However, probability samples for LGBT participants are expensive to es-
tablish, and most studies on PrEP use and PrEP interest are based on nonprobability samples. 
The LGBT population makes up a small fraction of the general population, requiring the 
recruitment or screening for inclusion of many people ineligible for participation to be able to 
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include a sufficient amount of LGBT participants (Meyer & Wilson, 2009). However, a recent 
study, conducted in the United States in 2016, made use of data from a probability sample 
to examine PrEP use and familiarity with PrEP among MSM (Hammack et al., 2018). They 
found that 4.1% of the respondents had used PrEP, and that 59.8% was familiar with PrEP. 
This level of PrEP use is comparable to the online nonprobability samples in the study of Bey-
mer et al. (2018), who conducted the study in roughly the same period (2015-2016).
A further limitation is that we could only compare AmsterdamPinkPanel participants with 
the participants from convenience sampling, but could not make further distinctions within 
the latter group. We could not track the recruitment source of the convenience sampling par-
ticipants, because this was not a primary goal of the FPIE survey. For example, we could not 
compare participants recruited through gay dating apps with participants recruited through 
gay social venues. This is a drawback as it is expected that MSM who use gay dating apps have 
different sexual behaviors than MSM who are not using such apps (Lewnard & Berrang-Ford, 
2014). Another limitation is that the results were based on participants’ self-reports, which 
may be affected by reporting bias, as opposed to clinical data such as measuring intracellular 
PrEP drug levels. However, as participants filled out the questionnaire anonymously, social 
desirability bias is expected to be limited. 
For future research, we recommend that researchers not only focus on obtaining an MSM 
sample per se, but to carefully consider the characteristics of the sample they recruit, and how 
this can influence their findings. Having clear inclusion and exclusion criteria, and drawing 
on different sample sources and recruitment strategies, will help to identify and address po-
tential sampling biases. A strength of our study is that we could compare two samples that 
were recruited at the same time, eliminating the influence of timing. This is important be-
cause PrEP is relatively new and community awareness and accessibility are increasing.
In conclusion, while findings show differences between samples according to recruitment 
strategies, overall findings suggest that PrEP knowledge is high among participating MSM, 
but PrEP use is low. About half of the participants were interested in using PrEP, and findings 
regarding covariates of interest in PrEP and intention to use PrEP provide important direc-
tions for the promotion of PrEP. Promotional activities may in particular target MSM who are 
single, do not always use condoms, and use drugs in a sexual context. Promoting PrEP among 
these MSM may be especially pertinent to increase PrEP uptake.
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The aim of this qualitative study was to explore the experiences of informal PrEP users re-
garding access to PrEP and PrEP-related healthcare, community responses, sexual behav-
ior and well-being. We interviewed 30 men who have sex with men (MSM) in semi-struc-
tured online interviews between March and August 2018. Interviews were analyzed using 
interpretive description. Informal PrEP users were well informed about the use of PrEP, but 
sometimes did not make use of renal testing. Participants reported a lack of PrEP knowledge 
among healthcare providers, which limited their access to PrEP and put them at risk, as they 
received incorrect information. Although some participants reported negative reactions from 
potential sex partners, most received positive reactions and were sometimes seen as more 
desirable sex partners. PrEP healthcare services should not only be accessible to formal PrEP 
users, but also to PrEP users who procure PrEP informally.




Despite improvements in the availability of pre-exposure prophylaxis (PrEP), there is still a 
large gap between PrEP access and expressed need for PrEP in many countries around the 
world (Hayes et al., 2019; Weiss et al., 2018; Zablotska et al., 2016). According to data from 
the European Centre for Disease Prevention and Control (ECDC) from 2019, formal access 
to PrEP is available only in 16 of 53 reporting countries in Europe and neighboring countries 
(European Centre for Disease Prevention and Control, 2019c). Access to PrEP has been lim-
ited due to structural barriers such as the high costs of PrEP, but also by a lack of PrEP im-
plementation in existing healthcare settings (Arnold et al., 2017; Dubov et al., 2019; Golub et 
al., 2013; Hannaford et al., 2018; Rice et al., 2019). As a consequence, some men who have sex 
with men (MSM) obtain PrEP via channels that have been labelled “informal”. These informal 
channels include online pharmacies, pharmacies and clinics in other countries where generic 
PrEP is sold at a cheaper price point, via post-exposure prophylaxis (PEP) treatments, and via 
pill sharing of HIV-positive friends who take antiretroviral therapy (Charpentier et al., 2014; 
Kurtz & Buttram, 2016; Rosenthal et al., 2014; Zablotska et al., 2013). In Europe, varying by 
country, up to 67% of PrEP users obtain PrEP via informal channels (European Centre for 
Disease Prevention and Control, 2019c). Informal PrEP use has been associated with subop-
timal regimens and dosing of PrEP, a lack of knowledge about PrEP, and a lack of uptake of 
the recommended health services, such as regular HIV and renal testing and behavioral coun-
seling (Buttram, 2018; Dimitrov et al., 2013). Inconsistent access to PrEP and PrEP-related 
health services, combined with the potentially suboptimal use of PrEP, puts informal PrEP 
users at risk for HIV infection and other health risks (Buttram, 2018).
Most studies to date have investigated PrEP use in the context of clinical trials or in formal 
healthcare settings (Grant et al., 2010; Hojilla et al., 2016; Holt, Lea, et al., 2018; Hoornenborg 
et al., 2019; Lal et al., 2017; Liu et al., 2013; McCormack et al., 2016; Milam et al., 2019; J. M. 
Molina et al., 2017; Sagaon-Teyssier et al., 2016). However, because the availability of for-
mal PrEP healthcare is limited in many countries (European Centre for Disease Prevention 
and Control, 2019c), there is a need to study PrEP use in such contexts of limited availabil-
ity, reflecting a real world setting that for many imply informal use. Moreover, to optimize 
PrEP implementation, it is needed to understand how MSM comprehend and experience 
PrEP, thereby taking their psychological and social realities into account (Auerbach & Hoppe, 
2015). Informal PrEP use comes with specific challenges that cannot be observed in clinical 
trials, such as how PrEP is obtained and how to communicate with healthcare providers who 
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are less informed about PrEP. So far, only a few studies have been conducted on informal 
PrEP use, mainly focusing on obtaining PrEP, using PrEP, and receiving medical support 
(Buttram, 2018; Paparini et al., 2018; Rivierez et al., 2018; Zablotska et al., 2013). While sexual 
risk behavior, including risk compensation, is often studied in the context of formal PrEP use 
(Hojilla et al., 2016; Holt, Lea, et al., 2018; Hoornenborg et al., 2019; Lal et al., 2017; Liu et al., 
2013; Milam et al., 2019; Sagaon-Teyssier et al., 2016), this is underexplored in the context of 
informal PrEP use. 
While informal PrEP use typically refer to “non-prescribed” or “off-label” PrEP use (Brisson 
et al., 2019), focusing on the procurement of PrEP, it is also important to consider how in-
formal PrEP users access the appropriate medical supervision indicated with respect to PrEP 
use (i.e. CDC-guidelines (CDC, 2017)). A broader definition of informal PrEP use is hence 
the “non-prescribed and non-medically supervised” PrEP use (Buttram, 2018). This broader 
definition is particularly appropriate in the context of the Netherlands, and other countries 
where (generic) PrEP can be obtained before formal access is realized and formal PrEP-re-
lated medical supervision services are made available. The aim of this study was to explore 
the experiences of informal PrEP users in a context of the transition to full formal PrEP ac-
cess. More specifically, we investigated the experiences of informal PrEP users across three 
domains: Access to informal PrEP and PrEP-related healthcare, and perceived community 
responses to PrEP use, and PrEP users’ sexual behavior and well-being.
Access to PrEP and PrEP-related healthcare
Compared to the formal PrEP use, informal PrEP use may be challenging, as PrEP may not 
be easily obtained, and PrEP-related healthcare may often not be accessible. Obtaining PrEP 
and maintaining a consistent supply of PrEP is reported as a common difficulty for informal 
PrEP users (Rivierez et al., 2018), often resulting in the use of a regimen that requires less 
pills, for example an on demand regimen (Koppe et al., 2019). PrEP users may also be forced 
to take less pills than the recommended dosage. Nevertheless, a study among informal PrEP 
users in London found that despite difficulties in obtaining PrEP, most informal PrEP users 
had similar drug plasma concentrations as formal PrEP users in clinical trials (X. Wang et al., 
2018). In addition, informal PrEP users have to arrange the recommended counseling and 
three-monthly HIV, STI and renal function tests themselves, and they may also have to pay 
for these services out-of-pocket. Research has found that most of the informal PrEP users do 
not access PrEP-related healthcare, and do not regularly test for HIV (AIDES, 2016). Those 
who do access PrEP-related healthcare may be confronted with healthcare providers who may 
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reject or stigmatize them for their informal use, or have a lack of knowledge or moralistic 
opinions about PrEP (Brisson, 2018; Leusink, 2020; Schwartz & Grimm, 2019). For exam-
ple, healthcare providers were worried about risk compensating behavior (Karris et al., 2014; 
Tellalian et al., 2013), and medical students were less likely to prescribe PrEP to patients with 
the highest risk behaviors (Calabrese et al., 2018), indicating that personal assessments of the 
healthcare provider play a role in the decision to prescribe PrEP or to offer medical supervi-
sion to PrEP users.
Community responses
PrEP users may face stigmatizing reactions regarding their PrEP use, and have been described 
in the media as “Truvada whores” (Calabrese & Underhill, 2015; Schwartz & Grimm, 2017). 
Among MSM, and even among PrEP users themselves, stigmatizing reactions are also noted 
(Puppo et al., 2020). For example, gay and bisexual men have been found to associate PrEP 
use with “barebacking” (intentional condomless anal intercourse), and to hold PrEP users 
responsible for the spread of STIs in the gay community (Pawson & Grov, 2018). PrEP users 
also report feeling stigmatized as a result of being rejected for sex dates or by being seen as 
HIV positive (Franks et al., 2018). On the other hand, PrEP users can also be preferred as sex 
partners by MSM who are not using PrEP, as they are potentially at lower risk of transmitting 
HIV (Martinez & Jonas, 2019). PrEP users have also been seen as more responsible and trust-
worthy, and their use of PrEP was not itself perceived as a reflection of sexual promiscuity 
(Martinez & Jonas, 2020). Given these mixed findings regarding PrEP-related stigma, it is im-
portant to further explore the responses that informal PrEP users face from other MSM and 
potential sex partners. We did not expect differences in the perceptions of informal and for-
mal PrEP users per se. It could however be that informal PrEP users are evaluated as having a 
poor “PrEP citizenship” (Orne & Gall, 2019) compared to formal PrEP users, as they may not 
have a reliable PrEP supply or are not being continuously monitored on HIV and STI testing. 
Sexual behavior and well-being
Sexual behaviors of PrEP users have mainly been studied in the context of formal PrEP use, 
in particular in the context of clinical trials and demonstration projects, such as ANRS-IPER-
GAY (J.-M. Molina et al., 2015), AMPrEP (Hoornenborg et al., 2018), iPrEx (Grant et al., 
2010), and PROUD (McCormack et al., 2016). However, clinical trials may give a biased view 
of changes in sexual behavior, because of the selection of participants (i.e. selected partic-
ipants are MSM with (extreme) high risk behavior) or because of the included behavioral 
counseling, that may be absent in a real-world situation. Therefore, we also explored the sex-
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ual behavior of informal PrEP users in this study. A commonly reported change in sexual 
behavior after initiation of PrEP use is an increase in condomless anal intercourse (Hoornen-
borg et al., 2018). Studies of formal PrEP use have also highlighted reduced fear of HIV, and 
improved sexual satisfaction and well-being (Collins et al., 2017; Hojilla et al., 2016). Similar 
findings have been obtained in studies of PrEP in non-clinical settings as well as in relation 
to informal PrEP use, including decreased condom use, reduced fear of HIV, and improved 
quality of sex life (Keen et al., 2020; Paparini et al., 2018; Prestage et al., 2019). Informal 
PrEP use has also been associated with other increases in risk behavior, including recreational 
drugs use and group sex (Zablotska et al., 2013). 
The current study
The current study explored the behaviors and experiences of informal MSM PrEP users in the 
Netherlands. In the Netherlands, some MSM started to use PrEP informally before PrEP be-
came formally available through Dutch pharmacies in 2016. Even after PrEP became formally 
available, informal procurement of PrEP continued, because PrEP was initially not affordable 
for many if not most MSM (~€ 500,- per 30 pills). At the time, affordable PrEP in the Neth-
erlands was only formally available through the AMPrEP study, a demonstration project that 
provided PrEP for free to 376 participants (Hoornenborg et al., 2019). In November 2017, the 
price of PrEP in the Netherlands dropped significantly (to ~€ 50,- per 30 pills) when generic 
versions became available in pharmacies in the Netherlands (PrEPnu, 2017). Although formal 
PrEP guidelines have been available in the Netherlands since 2016 (Hoornenborg & Rijnders, 
2016), the practical implementation of PrEP was delayed as healthcare providers waited for an 
implementation policy of the Ministry of Health that addressed the provision of PrEP-related 
medical care. This PrEP implementation policy came into effect only in August 2019 (Minis-
try of Health Welfare and Sport, 2018, 2019). In other words, while PrEP users were able to 
obtain PrEP in the Netherlands as of 2016, it took another three years until arrangements of 
medical supervision of PrEP use were in place. 
Investigating the experiences of informal PrEP users can inform healthcare professionals and 
community support groups about the challenges that informal PrEP users face. This inves-
tigation can provide guidance for necessary actions to provide PrEP related healthcare for 
informal PrEP users, and how to potentially bring them into formal PrEP care. Furthermore, 
our study also aims to corroborate previous findings of effects of formal PrEP use, such as on 
sexual well-being, as the type of procurement and use should not impact on the perceived 
benefit of PrEP.





In a survey that was conducted through the website of the Dutch PrEP advocacy group PrEP-
nu (www.prepnu.nl), 64 MSM indicated using PrEP informally. We invited these MSM for an 
interview, of which 26 (40.6%) agreed. In addition, four participants were recruited via peer 
referral, resulting in a total sample of N = 30. The participants did not receive any compensa-
tion for participation in the interview. The study was approved by the Ethical Review Com-
mittee of the Faculty of Psychology and Neuroscience, Maastricht University (code ERCPN 
188_05_02_2018).
Procedure
Between March and August 2018, 30 semi-structured interviews were conducted using an 
instant messaging program (Skype or WhatsApp, depending on the preference of the partic-
ipant). We used instant messaging, because this allowed us to reach MSM from all over the 
country without being restricted by travel time and costs. In addition, because of the sensitive 
nature of the topics under investigation, we expected that MSM would express themselves 
more freely in an online chat interview compared to a (online) face-to-face interview, as an-
onymity can be ensured. Instant messaging has been suggested to be beneficial and fitting to 
study sensitive research questions, and produces comparable results as face-to-face interviews 
(Ayling & Mewse, 2009; Opdenakker, 2006). Two interviews were carried out in English and 
28 in Dutch. All participants provided informed consent at the start of the interview.
We developed an interview guide with fifteen questions, related to the topics of PrEP use, 
PrEP-related healthcare, PrEP communication, and sexual risk behavior. Every question was 
copied (one by one) into the chat window from the interview guide. Interviews were held in a 
conversational style and additional questions were asked for clarification or elaboration. The 
order of questions was adapted to the flow of the conversation. The interviews took a maxi-
mum of two hours and were conducted uninterruptedly. 
Twenty-six interviews were conducted by a female interviewer (RK, 23 years old, master stu-
dent in health and social psychology) and the remaining four interviews were conducted by a 
male interviewer (MvD, 28 years old, PhD student in applied social psychology). The first two 
interviews were jointly conducted by the interviewers, to align the use of the interview guide, 




The experiences of informal PrEP users were explored using interpretive description (Thorne, 
2016). The data was sorted into categories in line with the topics of the interview guide, and 
we identified and described issues that emerged during the interviews. The interviews were 
coded in a deductive and iterative process, using the qualitative data analysis software ATLAS.
ti version 8.3.0 (ATLAS.ti Scientific Software Development GmbH, 2018). The first five inter-
views were coded by the two researchers independently. The researchers discussed the coding 
to improve reliability of their interpretation. Inconsistencies in coding were resolved through 
discussion. Thereafter, the remaining interviews were coded by only one of two researchers 
(26 by RK and 2 by MvD). After coding, the results were saved in a summarized manner in an 
Excel table for further analysis. Quotes that were originally in Dutch were translated verbatim 
into English, when reported in the results section.
Results
Participant characteristics and PrEP use
The age of the participants ranged from 24 to 66 years; about half of the participants (40.0%) 
were younger than 40 years. The participants resided all over the Netherlands: Most of the 
participants lived in an urban area (12 in Amsterdam, 11 in other cities in the Netherlands), 
and seven participants lived in a rural area of the Netherlands. Eighteen participants (60.0%) 
were single and 12 participants (40.0%) were in an open relationship. Nineteen participants 
(63.3%) used PrEP in a daily regimen and 11 participants (36.7%) used PrEP on demand. The 
average time since commencement of PrEP use was 15 months (range: 3 – 60 months). 
Methods of PrEP procurement 
Most participants obtained PrEP abroad, notably in Thailand, India, and South-Africa, where 
PrEP at the time (2015 – 2017) was available for a lower price than in the Netherlands (ap-
proximately € 30 per 30 pills). They travelled to these countries for their jobs or for holidays, 
or they asked friends to bring PrEP from these countries. A minority also bought PrEP online 
from sources abroad, although some MSM experienced that their shipment was intercepted 
by customs in the Netherlands, or that the shipment took long to arrive. As soon as cheaper 
generic versions of PrEP became available in the Netherlands (November 2017), most par-
ticipants switched to obtaining PrEP via local pharmacies, as it was faster and cheaper than 
buying PrEP abroad. However, some participants continued to obtain PrEP from sources 
abroad, as they reported to be used to the procedure, or found it more convenient since a 
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friend obtained it for them, as illustrated by one participant:
“…because I am used to this way [of obtaining PrEP], and I don’t have to do much 
effort for it, thus simply out of convenience.” (P21)
Challenges in access to PrEP-related healthcare services
In the Netherlands, the healthcare services related to PrEP can be accessed via general practi-
tioners (GP), medical specialists, pharmacies, and the public health centers for HIV/STI test-
ing. Almost all participants received a prescription from their GP, which allowed them to buy 
PrEP in a pharmacy abroad or online, and later also in the Netherlands. Most of them were 
satisfied with their GP regarding PrEP care. Some participants perceived a lack of knowledge 
among their GPs about the use and effectiveness of PrEP, or even a lack of awareness. Nine of 
these participants indicated that their GP took time to learn about PrEP, for example by con-
sulting a specialist in the hospital or a public health center. Moreover, participants themselves 
could be a source of information for their GPs, and provided PrEP information to their GPs: 
“We [my partner and I] have a very open dialogue with our GP. He knows that we 
have an open relationship and he has always supported us in the use of PrEP. In fact, I 
am his informant when it comes to the latest information. He applauded that we take 
responsibility ourselves regarding safe sex.” (P4)
It is noteworthy that some participants had selected their GP based on the gay friendliness 
of the GP, sometimes already before obtaining PrEP, which made it easier to discuss PrEP 
with their GP. At least three participants switched GPs when they wanted to obtain a PrEP 
prescription, as their previous GP did not want to support their needs:
 “I had to switch GPs, as the previous one had very old-fashioned ideas about sex and 
numbers of partners. The one I have now is understanding, thinks along, thinks about 
alternatives, and in case of STIs he asks questions in a professional way.” (P3)
After receiving the prescription from the GP, people can obtain PrEP in their pharmacy (note 
that in the Netherlands, clients are usually registered with a specific pharmacy). Six partici-
pants stated that their pharmacy had sufficient information about PrEP, whereas others stated 
that their pharmacy did not know a lot about PrEP. For example, the pharmacist assumed 
that they were HIV-positive and mistook PrEP for antiretroviral treatment (ART), or mistook 
PrEP for post-exposure prophylaxis (PEP). In one case made known to us, this lack of 
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knowledge amongst pharmacists resulted in putting misinformation and unclear informa-
tion on the PrEP package, including an incorrect dosing scheme, and only mentioning “virus 
infection” without any reference to prevention (Figure 3.1). This puts PrEP users at risk of 
wrong dosage, and may lead to the misperception that the user is HIV positive, which could 
create social barriers to use PrEP:
“[The label on] the jar always states *virus infection*. I do not like that, because I just 
place it at home on the kitchen table. If you have people visiting, they immediately 
think you are sick.” (P31)
This unclear, and sometimes erroneous, information about PrEP use from healthcare provid-
ers puts informal PrEP users at risk for incorrect PrEP use. It places a burden on PrEP users 
to be well informed about PrEP themselves to be able to educate their healthcare provider.
After obtaining PrEP, informal PrEP users can arrange regular HIV and STI testing at the 
public health centers (for free) or via the GP. Renal function testing can be done via the GP, 
but must be paid for by the client up to a maximum of € 385 per year. Almost all participants 
Figure 3.1. Image provided by an interview participant. Label on the package of generic PrEP pills of one 
of the participants, stating the misinformation regarding dosing scheme and the use for the treatment 
of a virus infection. Translated from Dutch: “Date: 07-03-2018. If necessary, 2 times per day 2 pills. Take 
with meals. Store in this package, close well. After opening one month shelf-life. **virus infection**”. 
Please note that the correct PrEP dosing scheme is one pill per day for a daily regimen, and that PrEP is 
meant for the prevention instead of treatment of a virus infection.
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reported that they underwent HIV and STI testing every three months. Renal function test-
ing was done less frequent and by less participants compared to HIV and STI testing. A few 
participants did not do renal function testing at all, because they thought it was not necessary 
as they were using PrEP on demand, or because it was too expensive. This lack of renal test-
ing demonstrates that while informal PrEP users often have a prescription for PrEP, medical 
supervision is not always present. Most participants had found a testing routine that worked 
well for them, with (free) STI testing carried out in public health centers and (paid) renal 
function testing done via their GP, although some participants reported difficulties with find-
ing test locations for renal testing: 
“[I do] not [test my renal function]. But I use [PrEP] sporadically, and your renal 
function should recover when you stop using the medication. I would like to test [renal 
function] more often, but I do not know how. At the STI clinic, where I come twice per 
year, they do not offer that.” (P20)
Some participants also reported difficulties with making an appointment in public health 
centers as they faced waiting lists of more than four months for HIV and STI testing. Par-
ticipants who lived in multiple places also mentioned that PrEP-related healthcare is more 
developed in Amsterdam compared to other places in the Netherlands: 
“In the big cities it works. The rural area and the villages... for that matter the PrEP care 
is dependent on where you live, and that is worrisome.” (P1)
To summarize, themes in challenges of informal users arranging their own access to PrEP-re-
lated healthcare services were gay-friendliness of GPs, lack of information and knowledge 
among GPs and pharmacists, and availability and pricing of testing facilities for HIV and STI 
testing as well as renal function testing. 
Community responses: PrEP related reactions from sex partners and friends
Some participants did not disclose their PrEP use to (potential) sex partners, because they 
did not find it necessary to discuss this with the partner, as they saw PrEP as a preventative 
measure for themselves, independent of the other person. When participants disclosed their 
PrEP use, about half of them experienced negative reactions, especially in online dating apps. 
For example, they got rejected for a sex date, or they were seen as more promiscuous. On the 
other hand, most of the time participants experienced neutral or positive reactions by other 
MSM. For example, they were seen as taking care of their health. Moreover, informal PrEP 
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users received questions on dating apps from other MSM who were interested in PrEP. They 
received questions about how to obtain PrEP and where to buy it. 
Participants mentioned that other MSM assumed that PrEP users only want condomless sex, 
which was seen as both favorably and unfavorably by sex partners: Favorably because the 
other MSM preferred to have condomless sex and believed a PrEP user would agree on this; 
unfavorably because the other MSM associated PrEP use and condomless sex with irrespon-
sibility:
“There are people who did not want to have sex with me, because I used PrEP and thus 
I was seen as irresponsible. This happens mainly with younger guys (16 – 24) and it 
happens approximately once every two months. I try to let these young guys realize 
that they also have a chance to get HIV, and this chance is much higher [when they 
have sex] with someone who does not use PrEP than with someone who uses PrEP.” 
(P12)
When participants encountered negative reactions from other MSM on online dating apps, 
they noticed that this was sometimes a reflection of a lack of knowledge about PrEP. This 
was especially the case for participants from more rural areas or in the “early years” of PrEP 
use (2014-2015). As a result, PrEP users often found themselves educating other MSM about 
PrEP:
“Occasionally [I get] a negative reaction. But that is because they do not understand 
what it is and what it does. Then I explain it properly. […] It arises often from ignorance, 
they think for example that you have HIV. Or they form a notion of that you are a dirty 
slut.” (P14)
Some participants told their gay friends about their PrEP use and received mainly positive 
reactions. One participant mentioned that PrEP helped to raise issues of HIV and STI with 
gay friends. In addition, some participants mentioned that gay friends started PrEP use after 
discussing PrEP and sexual health:
“And also with gay friends, I have had more conversations about STI / HIV in the past 
six months than ever before. It feels really like a kind of smokescreen has disappeared. 
More and more [friends] use it. At least among my friends there is a lot of discussion 
about [PrEP].” (P30)
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The fact that PrEP was obtained informally did not stop others to want starting to use PrEP 
too. It helped informal PrEP users to connect socially, and one participant mentioned that he 
ordered PrEP in Thailand for his friends too. 
Some participants also told their family and heterosexual friends about their PrEP use. Fam-
ily and friends were surprised that something like PrEP existed, and were proud or jealous 
of how participants managed their sex life. The family of one participant was worried about 
his health and if PrEP (without condoms) would be enough protection for him. At least two 
participants did not tell their family about PrEP because they were ashamed to tell or feared 
to be judged.
Changes in sexual behavior and sexual well-being
Despite the informal way that these participants obtain their PrEP, they experienced similar 
responses to using PrEP as those reported by formal PrEP users. Most participants (N = 22) 
reported a decrease in condom use since they started using PrEP. For some it was a deliberate 
decision to stop or decrease condom use when on PrEP, because they had erection problems 
when using condoms or they doubted the effectiveness of condoms. For others, condom use 
decreased because they felt less discipline to use condoms consistently. Some participants 
emphasized that it would not make sense for them to use both condoms and PrEP:
“During a PrEP information meeting two years ago, it was said that it is the intention 
that you use PrEP and condoms together. I thought that was nonsense at the time. 
Why use heavy medication if you still have to use a condom?” (P20)
Although there was a decrease in condom use for most PrEP users, there were situations in 
which most participants continued to use condoms. This was the case when the sex partner 
requested to use condoms, or when the participants assessed the sexual encounter as more 
risky. They evaluated this risk based on the level of familiarity with the sex partner, his PrEP 
use, and his assumed number of other sex partners: 
 “With a stranger I always do it safely, so with a condom. With a number of fuckbuddies 
I have unprotected sex. These are people who also use PrEP and I know that they do 
not have many changing contacts.” (P4)
Changes in sexual behavior were related to improvements in sexual well-being. Most partic-
ipants enjoyed sex without condoms more, and it contributed to a perceived increase in the 
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quality of their sex life. Sex felt more unrestrained and intimate, and they had less worries 
during sex:
 “For me a lot has changed [with anal intercourse]. It has mainly to do with condom 
use. [With condoms] it feels literally like there is no contact. When I am bottom, it is 
more painful. When I am top, I awfully quickly ejaculate. And a condom feels very 
unpleasant.” – Interviewer: “So the quality of your sex life improved enormously?”  - 
P7: “Enormous.” (P7)
The increased quality of their sex life was also reflected in changes in sexual experience. Par-
ticipants felt less worried about getting HIV, and this resulted in increases in sexual activity 
and less concerns about who to have sex with. They also reported being able to enact fantasies 
that they did not dare to before using PrEP. For example, some participants reported that they 
felt more comfortable now with being the receptive partner (bottom) during anal intercourse:
“I also notice that I now dare to give in to fantasies that I have always been cautious 
about. […] I also have sex with more men now. […] Now I can do things that I like. 
Before, I found it scarier to be fucked in the passive role. Even with a condom. Does it 
slide off, or would someone take it off without a word? I was more preoccupied with 
these control thoughts, while one wants to indulge in sex. These thoughts restrained 
me in experiencing sex spontaneously.” (P5)
For some participants the use of PrEP felt liberating, mostly because they felt less fear of HIV. 
About half of the participants reported memories of the early days AIDS, and some of them 
reported that they always associated sex with fear of HIV, which limited their sexual pleasure: 
“Every morning after having sex with a guy, I start thinking about whether there has 
been a risk of HIV. So instead of feeling comfortable [with having sex with a guy], the 
fear dominates. Since I take PrEP, the fear has been gone. […] Gay sex and HIV are 
almost directly related to each other. […] Instead of sex being something pleasant, it 
is something dangerous for gays because one can run into a serious problem.” (P17)
Also younger participants, who became sexually active in a time when HIV was a manageable 
condition, reported fear of HIV, which was reduced by the use of PrEP:
“Before I used PrEP, I sometimes could not sleep well, and I regretted often having sex. 
Also I could not really enjoy sex fully. I was aware that I would ever get HIV, the only 
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question was when.” (P12)
For others, condomless sex itself felt liberating. After many years of using condoms, they felt 
hesitation about not using condoms, but they got easily accustomed to it:
 “It took me some effort to accept the idea that sex without a condom was also “safe” 
for HIV. But after having bare sex with my regular sex partner, it was such a liberation 
that I was soon over it.” (P28)
About half of the participants reported using recreational drugs during sex. Most of them 
already used drugs before they started using PrEP. For some participants drug use increased, 
as it often co-occurred with going to sex parties. PrEP was beneficial for them as they had to 
worry less about condomless sex:
“I mostly use XTC [ecstasy/MDMA] and GHB [when going to sex parties]. I do not 
use it always, but when I do, the use of PrEP is nice, because you do not always know 
afterwards what happened. [The use of PrEP and drugs] are independent of each other. 
But the use of PrEP has many advantages, I think. I do not have to worry about how 
the sex is being done.” (P6)
Discussion
The aim of this study was to explore the experiences of informal PrEP users in a context 
where PrEP is formally available, but formal implementation is still limited. We in particular 
explored the experiences of informal PrEP users across three domains: Access to PrEP and 
PrEP-related healthcare, community responses, and sexual behavior and well-being.
Access to PrEP and PrEP-related healthcare
We found that informal PrEP users have found their own ways and routines in accessing PrEP 
and PrEP-related healthcare. Many of our participants switched from obtaining PrEP abroad 
to obtaining PrEP via local pharmacies in the Netherlands, as soon as generic PrEP became 
more affordable in the Netherlands. In contrast with earlier studies that found that informal 
PrEP users are less likely to undergo frequent HIV and STI testing (AIDES, 2016; Buttram, 
2018; Dimitrov et al., 2013), most participants in our interviews tested regularly. While this 
paints a positive picture of the uptake of PrEP healthcare services among informal PrEP users, 
findings also identify several major concerns.
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Firstly, GPs, who play a critical role as gatekeepers in the Dutch healthcare system, were not 
always able or willing to support the needs of informal PrEP users. The participants in our 
study were well-informed about PrEP, and that helped them to either educate their GPs, or to 
change to another GP that did support their needs. MSM who are less informed about PrEP 
may however not be able to get the support they need from their GP, which would preclude 
them from accessing PrEP, or could force them to obtain PrEP via informal channels.
Secondly, some participants experienced long waiting lists for HIV and STI testing at public 
health clinics. While this not only puts PrEP users at risk of having and transmitting an unde-
tected STI, it may also result in them doing less testing, not testing, or discontinuing PrEP use 
(Whitfield et al., 2018), which eventually may increase their risk of HIV. 
Thirdly, renal function testing was not always optimal, as was also found before among infor-
mal PrEP users in Germany (Koppe et al., 2019). Similar to the “DIY PrEP” study (Paparini 
et al., 2018), we found that some PrEP users find renal function testing not always necessary, 
but also that some PrEP users did not know where to go for these tests, as it was not available 
in the public health clinics where HIV and STI testing are offered. In addition to setting up 
adequate PrEP consultations to inform MSM about the use and potential side effects of PrEP, 
a convenient testing location should be organized where informal and formal PrEP users can 
go for all the necessary tests on a regular basis. 
Community responses
PrEP users mostly got positive reactions. For example, they were seen as more desirable sex 
partners. It has been suggested that PrEP users are more likely to be seen as HIV-negative, 
and therefore have a lower chance to transmit HIV, making them a more desirable sex partner 
(Martinez & Jonas, 2019; Medina et al., 2019). While media outlets can present PrEP use in 
a stigmatizing way (i.e. “Truvada whores” (Calabrese & Underhill, 2015; Schwartz & Grimm, 
2017)), and stigmatizing reactions even occur among PrEP users themselves (Puppo et al., 
2020), our study provides a more nuanced view on how informal PrEP users are seen by com-
munity members in which general PrEP knowledge is emerging. 
PrEP users nevertheless encountered negative, or stigmatizing, reactions. This included being 
rejected by a potential sex partner, or receiving negative comments in dating apps. Negative 
responses were found to be especially common in the early years of PrEP availability in the 
Netherlands and in rural areas, suggesting that unfamiliarity with PrEP may lead to negative 
responses. The informal PrEP users in this study were able to deal with negative reactions, and 
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were able to educate other MSM about their PrEP use, because they were well-informed. Es-
pecially in countries where PrEP is not formally implemented, MSM are more likely to be in-
formed about PrEP via peers, and they may find it challenging to obtain reliable information. 
Sexual behavior and well-being
Most informal PrEP users reported an increased quality of their sex life, mainly driven by less 
fear for HIV infection and decreased condom use. Although it is not surprising that condom 
used decreased, and this has been found before (Traeger et al., 2018), it is an important find-
ing that condom use was a prominent topic in many of the interviews. It often played a role 
in participants’ considerations on how PrEP increased the quality of their sex life, as PrEP use 
helped participants to explore ways of having sex, for example by switching sexual positions 
(insertive/receptive) or by experimenting with substance use and participating in sex parties. 
This is in line with findings from other countries and in earlier studies (Collins et al., 2017; 
Hojilla et al., 2016; Mabire et al., 2019; Paparini et al., 2018), and seems to reflect an overall 
trend, regardless of whether the type of procurement and use is informal or formal. Partic-
ipants noted that the reduced fear for HIV felt liberating and improved their sex life. The 
sexual liberation related to PrEP use has been found before (Collins et al., 2017; Grace et al., 
2018), and indicates that PrEP users feel more in control of their sex life (Philpot et al., 2020).
Continuing informal PrEP use or moving towards formal PrEP
In our study we found that many PrEP users switched from the informal procurement of PrEP 
to a formal procurement of PrEP in local pharmacies. At the same time, PrEP implementa-
tion programs were not in place yet, so PrEP-related healthcare, in particular counseling, and 
regular HIV, STI and renal function testing was not formally accessible for them. The partic-
ipants in our study had to organize this themselves, and most were quite well able to do so. 
Informal PrEP procurement may continue to exist, even when the formal accessibility of PrEP 
is improved. On a personal level, MSM might prefer to continue obtaining PrEP via informal 
channels, as one participant mentioned in our study that he did this out of convenience. A 
study in Germany found that, despite the formal availability of PrEP, 17.4% of PrEP users con-
tinued to obtain PrEP informally, mainly because the price of generic PrEP (€ 50 per month) 
was still unaffordable to them (Koppe et al., 2019). On a structural level, there are many coun-
tries in the world where no steps are taken (yet) to make PrEP available (see www.prepwatch.
org for country updates, and for Europe the ECDC report (European Centre for Disease Pre-
vention and Control, 2019c)), so for many (potential) PrEP users around the world there are 
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no opportunities yet to formally access PrEP use. 
We found that even when participants switched to formal PrEP procurement, formal 
PrEP-related healthcare was not always readily accessible. To facilitate a transition into formal 
PrEP-related healthcare, it is important to consider the needs of PrEP users. The PrEP-relat-
ed healthcare service should provide one-stop access to counseling, renal function testing, 
and HIV and STI testing. The service should not only be affordable, but also convenient and 
non-judgmental. There are already several initiatives to offer these services to informal PrEP 
users, such as the InPrEP project in Amsterdam (GGD Amsterdam, 2017) and CheckpointLX 
in Lisbon, Portugal (Ribeiro & Rocha, 2019).    
Limitations
Several limitations of this study should be noted. We recruited participants via a survey that 
was posted on the advocacy website PrEPnu.nl, which provides information on accessing and 
using PrEP. This means that our participants had access to extensive information on PrEP. It is 
also important to note that the informal PrEP users in this study can be considered innovators 
or early adopters of PrEP, who had to be well-informed in order to be able to obtain PrEP. 
Their knowledge also allowed some of them to convince their GP to prescribe PrEP, and to 
arrange regular HIV and STI testing themselves. The recruitment and sample characteristics 
may limit the generalizability of the results of our study.
Furthermore, we used online chat messaging to conduct the interviews. While this may lead 
to less detailed responses (Davis et al., 2004), the results are overall comparable to those of 
studies based on face-to-face interviews (Ayling & Mewse, 2009; Opdenakker, 2006). The 
interviewers were specifically instructed to invite participants to elaborate, in particular re-
garding their emotions or feelings. Nevertheless, some participants kept their answers rather 
short. We believe that online chatting is a valuable data collection tool, as it facilitates anon-
ymous interaction. Moreover, in the context of e-health interventions it is not uncommon 
for MSM to discuss PrEP and sexual behavior online (Schnall et al., 2014). This makes the 
transition to discuss these topics in an online chat interview relatively easy. 
Conclusions
This study highlighted the experiences and behaviors of informal PrEP users in a context 
of transition to full formal PrEP healthcare implementation. Overall, informal PrEP users 
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were doing quite well regarding PrEP use and accessing PrEP-related healthcare. PrEP health-
care services should not only be accessible to formal PrEP users, but also to PrEP users who 
procure PrEP informally. Global and national guidelines may be helpful to implement these 
services, but as the example of the Netherlands in this study shows, the availability of nation-
al guidelines alone does not directly make practice. Informal PrEP users still have to take 
the initiative to inform their healthcare providers about their self-medication, which may be 
frowned upon, and bears the risk of not receiving the necessary care due to avoiding disclo-
sure of PrEP use. The experiences of informal PrEP users regarding community responses 
and sexual behavior were in line with findings of studies of PrEP use in a formal context. The 
findings of our study are not only relevant for the Netherlands, but also for other high-income 
countries where formal PrEP is not implemented yet.
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Despite the improved availability and affordability of PrEP in the Netherlands, PrEP uptake is 
low among men who have sex with men (MSM). To optimize uptake, it is important to iden-
tify facilitators and barriers of PrEP use. During our study period, the price of PrEP dropped 
significantly after generic PrEP was introduced. We investigated whether the price drop pre-
dicts PrEP uptake, alongside behavioral and demographic characteristics. Participants (N = 
349) were recruited online and completed three questionnaires over a period of six months, 
between February 2017 and March 2019. After six months, 159 (45.6%) participants were 
using PrEP. PrEP uptake was greater among MSM who ever had postexposure prophylaxis 
(PEP) treatment, among MSM with a better perceived financial situation, and when the price 
of PrEP dropped. MSM in a tighter perceived financial situation may use PrEP more when it 
would be free or fully reimbursed. 




Pre-Exposure Prophylaxis (PrEP) has been found to be an effective biomedical intervention 
for HIV prevention (Fonner et al., 2016; Grant et al., 2010, 2014; J. M. Molina et al., 2017). 
The World Health Organization (WHO) recommends PrEP for people who are at substan-
tial risk of HIV infection, for example men who have sex with men (MSM) (World Health 
Organization, 2015). In the past years, efforts have been made to make PrEP accessible, for 
example by setting up national PrEP implementation guidelines (CDC, 2017; Hoornenborg 
& Rijnders, 2016). Despite its effectiveness and these efforts, the accessibility of PrEP varies 
greatly per country (AVAC, 2020), the uptake of PrEP has been low (Parsons et al., 2017), and 
the full potential of PrEP at population level has not been reached yet (Pyra et al., 2019). In 
the Netherlands, it is estimated that there are currently 3,500 individuals on PrEP (AVAC, 
2020), of which 95% are MSM (Staritsky et al., 2020), while it is estimated that 10,000 MSM 
meet eligibility criteria for PrEP (Hoornenborg, Krakower, et al., 2017; Reitsema et al., 2020). 
To increase uptake, it is therefore important to identify facilitators and barriers of PrEP use. 
While earlier studies investigated behavioral and psychological factors of PrEP uptake, such 
as sexual risk behaviors, perceived HIV risk, and stigma (Blumenthal et al., 2019; Dubov, 
Altice, et al., 2018; Golub, Fikslin, Goldberg, et al., 2019; Haire, 2015) , the influence of actual 
price changes on PrEP use has not been fully investigated, especially not in contexts where 
universal health care coverage of PrEP is not (yet) available.
Previous studies found several behavioral factors to be related to PrEP use. Compared to 
MSM who were not using PrEP, PrEP users were more likely to have had a recent STI diagno-
sis, have used post-exposure prophylaxis (PEP) before, have had condomless anal intercourse, 
have used recreational drugs or practiced chemsex (i.e., use of certain stimulants in the con-
text of sex), have had sex with HIV positive sex partners, and have a greater number of sex 
partners (Bourne et al., 2019; Eaton et al., 2018; Holloway et al., 2017; Okafor et al., 2017). In 
terms of demographic characteristics, PrEP users were found to be of middle age and to have 
a higher income (Bourne et al., 2019; Holloway et al., 2017). While it is reassuring to see that 
MSM at higher risk of HIV are more likely to be interested in PrEP and to use PrEP, overall 
PrEP remains “underused”, and some population strata at higher risk are less likely to use 
PrEP (Kuhns et al., 2017; Marcus et al., 2016; Shover et al., 2018).
The slow uptake of PrEP so far has been explained by structural and psychosocial barriers, in-
cluding lack of access to PrEP, doubts about effectiveness, concerns about side-effects, and ex-
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pected stigma (Calabrese & Underhill, 2015; Golub et al., 2013; Hannaford et al., 2018; Pinto 
et al., 2018; Thomann et al., 2017). Moreover, the costs of PrEP have been noted as one of the 
main barriers for PrEP uptake in cross-sectional analysis (Arnold et al., 2017; Bauermeister 
et al., 2014; Dubov et al., 2019; Goparaju et al., 2017; Kubicek et al., 2015; Pérez-Figueroa et 
al., 2015; Rice et al., 2019; Schwartz & Grimm, 2017). Notably, in a report drawing on data 
from 32 European and Asian countries, the price of PrEP was the most common barrier for 
PrEP uptake (Hayes et al., 2019). With prices of around € 500 per month for patented Teno-
fovir-Emtricitabine formulations in Europe and $ 1600 per month in the U.S., branded PrEP 
is likely unaffordable for most people in many countries.
In recent years, PrEP has however become more affordable and accessible as a result of the in-
troduction of generic formulations of PrEP and the inclusion of PrEP in health care packages 
or insurance coverage (AVAC, 2020; PrEPnu, 2017). PrEP uptake may increase as it becomes 
more affordable, and this hypothesis is further supported by the finding that uninsured MSM 
are less likely to use PrEP (Kuhns et al., 2017; Patel et al., 2017), if PrEP is included in health 
insurance coverage. Yet, even though the affordability of PrEP is increasing, current pricing 
may still be a barrier for certain individuals and groups, notably MSM with lower incomes.
In the current study we examine whether the costs of PrEP indeed predict PrEP uptake, 
alongside behavioral and demographic characteristics. As of 1 January 2018 the price of PrEP 
in the Netherlands decreased from € 500,- to € 50,- per month, as a result of the introduction 
of generic formulations of PrEP (PrEPnu, 2017). This introduction of generic PrEP allowed 
us to look more closely into the effects of price on the uptake of PrEP. At the time of our study, 
PrEP was not included in reimbursement schemes of the national health insurance. The pri-
mary way of obtaining PrEP was to buy PrEP at the pharmacy on prescription from the gen-
eral practitioner (Van Bergen, 2019). Formal PrEP services, offering PrEP in a co-payment 
scheme, were implemented in the public health centers as of July 2019, after data collection 
of our study was finished (Ministry of Health Welfare and Sport, 2019; Staritsky et al., 2020).
Methods
Participants and procedure
Participants were recruited via PrEPnu.nl, the website of the Dutch PrEP advocacy group 
PrEPnu (Dutch for PrEPnow), between February 2017 and March 2019. Every consenting 
participant in the baseline survey (T0) received follow-up questionnaires via email after three 
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(T1) and six months (T2). Participants who did not complete the T1 questionnaire were still 
encouraged to complete the T2 questionnaire. Participants younger than 18 years old or liv-
ing with HIV were excluded from participation. All participants who completed at least two 
questionnaires (T0 + T1/T2) could enter into a raffle to win a € 100,- gift card. The Ethics Re-
view Committee Psychology and Neuroscience of Maastricht University approved this study 
(ERCPN-174_10_12_2016). In the current study, we did not use the data from the T1 ques-
tionnaire, as this resulted in a smaller sample size because some T0 and T2 participants did 
not complete the T1 questionnaire.
In total, 766 participants completed the baseline (T0) questionnaire. For the current analysis, 
we only included MSM who were not using PrEP at baseline, and completed the items in the 
T2 questionnaire that are pertinent for the current analyses. This resulted in a sample size of 
N = 349. 
Measures
Given the lack of published or validated instruments at the onset of the study, questionnaire 
items were drawn from the earlier Flash PrEP in Europe study (AIDES, 2016), or newly de-
signed by the researchers. Questionnaires were administered online using Qualtrics.com; 
participants could not revert back to previous questions. The questionnaire was offered in 
Dutch and English. The full questionnaire can be found on https://osf.io/dm79v/. Below we 
describe the relevant variables for the current analyses.
Sociodemographic characteristics
In the first questionnaire (T0) participants were asked to indicate their gender, age, relation-
ship status, educational level, financial situation, country of birth, and country of residence. 
Gender was determined using two questions: gender assigned at birth and current gender. 
Educational level was indicated by five levels, ranging from no tertiary education to PhD 
degree. Financial situation was assessed with a 6-point scale: (1) ‘you can’t make ends meet 
without borrowing’, (2) ‘you are having problems making ends meet’, (3) ‘you are getting by 
but have to be careful’, (4) ‘things are all right’, (5) ‘you are doing rather well’, and (6) ‘you are 
doing really well’. The sociodemographic items were not repeated at T1 or T2, as we consid-
ered these characteristics to be stable over a period of 6 months. Relationship status was again 
asked at T2, as this is more likely to change over time. 
PrEP related items
At T2, we asked whether participants were taking PrEP, using a question with sex response 
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options (Yes, I use PrEP daily / Yes, I use PrEP intermittently (more or less every time I have 
sex) / Yes, I use PrEP recreationally (on demand; during special phases/moments when I have 
sex) / No, but I have used PrEP before (less than six months ago) / No, but I have PrEP used 
before (more than six months ago) / No, I haven’t used PrEP at all). We decided to distin-
guish between “intermittent” and “recreational” PrEP to capture a possible difference between 
MSM who use PrEP more frequently (but not daily) and others who use PrEP less systemati-
cally and more recreationally or season-based (Elsesser et al., 2016; Hojilla et al., 2016; Under-
hill et al., 2018). Since the development of our questionnaire (2017) there have been changes 
in terminology. Currently the common term for “intermittent PrEP” is “on demand PrEP”. 
There is no consensus regarding the terminology to refer to more recreational or seasonal 
PrEP use, although it is noted “recreational” use may inadvertently imply non-prescribed 
PrEP use (Kuo et al., 2020). Participants who were using PrEP were asked to indicate how 
they obtained PrEP, with seven response options: via HIV positive friend(s), through PEP 
treatment, through a PrEP research trial, at a local pharmacy, via a buyers club, at pharmacies 
abroad, and at online pharmacies.
Sexual risk behavior
Participants were asked whether they used a condom the last time they had anal intercourse 
(yes / no). In addition, we asked whether participants had used drugs in a sexual context (yes 
/ no). Participants were also asked to indicate the number of sex partners they had in the past 
six months.
Sexual health
Participants were asked whether they ever had PEP treatment (yes / no) and whether they 
ever had an STI (yes, in the past 12 months / yes, more than 12 months ago / no). 
PrEP pricing
Price of PrEP was dummy coded as “0”, indicating that when the participant completed the 
T2 questionnaire only branded PrEP was available at pharmacies in the Netherlands at a cost 
of € 500 (until 01-01-2018), or “1”, indicating that when the participant completed the T2 
questionnaire generic PrEP was available at pharmacies in the Netherlands, at a price of €50 
or lower (after 01-01-2018).




We analyzed the data using IBM SPSS Statistics version 26. We controlled for duplicate par-
ticipation by participant identifiers. We used descriptive statistics to describe the sociode-
mographic characteristics of the sample. We analyzed only the data of participants who were 
not using PrEP at T0 (N=344), to investigate the factors at baseline (T0) potentially related 
to PrEP initiation after six months (T2), using multivariate logistic regression analysis. The 
following independent variables were included in the model: age, number of sex partners in 
the past six months, educational level, perceived financial situation, relationship status, STI 
history, having used a condom at last anal intercourse, having used drugs in a sexual context, 
and having ever had PEP treatment. Additionally, we added the variable ‘price of PrEP’ (at 
T2) to the model to investigate the influence of the price of PrEP on PrEP initiation. We con-
ducted a post-hoc interaction analysis of the effect of the price of PrEP on PrEP initiation, 




Descriptive characteristics of the sample are shown in Table 4.1. Most participants identified 
their gender as male (344; 98.6%), and the remaining five identified as non-binary or pre-
ferred not to answer. The average age of participants was 41 years (range: 18 – 75). About half 
of participants were single (196; 56.2%), 136 (39.0%) were in an open relationship, and 17 
(4.9%) were in a monogamous relationship. More than half of the participants had a Bachelor 
degree or higher (218; 62.4%), and on average they perceived their financial situation as quite 
favorable (M = 4.35, SD = 1.13, median = 4).
At T2, 159 (45.6%) participants were using PrEP or had ever used PrEP in the past. Almost 
half had used PrEP daily (75; 47.2%), 40 used PrEP on demand (25.2%), 32 used PrEP recre-
ationally (20.1%), and 12 had (temporarily) stopped taking PrEP (7.5%). Most participants 
obtained PrEP via a doctor’s prescription and paid for PrEP themselves at a pharmacy in the 
Netherlands (104; 65.4%), 31 (19.5%) obtained PrEP from a pharmacy abroad, 10 (6.3%) 
obtained PrEP through participation in a research trial, 9 (5.7%) obtained PrEP via a buyer’s 
club, 8 (5.0%) obtained PrEP via online pharmacies abroad, 6 (3.8%) obtained PrEP via PEP 
treatment, and 3 (1.9%) obtained PrEP via HIV-positive friends. Some participants obtained 
PrEP via multiple channels. When stratified by financial situation, we found that participants 
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Age (years; M, range) 41 (18-75) 42 (20-66) 40 (18-75)
Gender
Male 344 (98.6%) 157 (98.7%) 187 (98.4%)
Non-binary / unknown 5 (1.4%) 2 (1.3%) 3 (1.6%)
Born in the Netherlands 281 (80.5%) 125 (78.6%) 156 (82.1%)
Living in the Netherlands 335 (96.0%) 154 (96.9%) 181 (95.3%)
Perceived financial situation (M, SD; 
scale 1 = You can't make ends meet 
without borrowing, to 6 = You are doing 
really well)
4.35 (1.13) 4.62 (1.02) 4.12 (1.16)
Education level
Master and PhD 101 (28.9%) 49 (30.8%) 52 (27.4%)
Bachelor 117 (33.5%) 48 (30.2%) 69 (36.3%)
High school and Professional  
qualification
131 (37.5%) 62 (39.0%) 69 (36.3%)
Relationship status
Single 196 (56.2%) 86 (54.1%) 110 (57.9%)
In a relationship 17 (4.9%) 5 (3.1%) 12 (6.3%)
In an open relationship 136 (39.0%) 68 (42.8%) 68 (35.8%)
STI
No 92 (26.4%) 38 (23.9%) 54 (28.4%)
Yes in the past 12 months 116 (33.2%) 65 (40.9%) 51 (26.8%)
Yes more than 12 months ago 141 (40.4%) 56 (35.2%) 85 (44.7%)
Used a condom the last time 161 (46.1%) 76 (47.8%) 85 (44.7%)
Used drugs in a sexual context 174 (49.9%) 85 (53.5%) 89 (46.8%)
Ever had a PEP treatment 41 (11.7%) 24 (15.1%) 17 (8.9%)
Number of sex partners in past 6 months 
(M, SD)
14.96 (19.12) 18.26 (24.18) 12.19 (12.95)
who perceived their financial situation as “really well” were more likely to buy PrEP from 
pharmacies abroad compared to participants with a lower perceived financial situation (see 
Appendix A of this chapter). Participants who perceived their financial situation as “having to 
be careful about expenses” or lower were less likely to use PrEP at all.
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Table 4.2. Bivariate and multivariate logistic regression examining correlates of PrEP initiation.
Bivariate Multivariate
OR 95% CI OR aOR 95% CI aOR
Age 1.01 1.00 - 1.03 1.01 0.99 – 1.03
Number of sex partners in past 
6 months
1.02** 1.01 - 1.04 1.01 1.00 – 1.03
Perceived financial situation 1.52*** 1.24 - 1.86 1.50*** 1.21 – 1.87
Education level
Master and PhD Ref Ref
Bachelor 0.74 0.43 - 1.26 0.97 0.54 – 1.74
High school and  
Professional qualification
0.95 0.57 - 1.60 1.11 0.63 – 1.96
Relationship status
Single Ref Ref
In an open relationship 1.28 0.83 - 1.98 1.15 0.70 – 1.87
In a relationship 0.53 0.18 - 1.57 0.46 0.14 – 1.51
STI
Never had an STI Ref Ref
Had an STI in the past 12 
months
1.81* 1.04 - 3.15 1.57 0.83 – 2.95
Had an STI more than 12 
months ago
0.94 0.55 - 1.60 0.72 0.40 – 1.31
Not used a condom the last 
timea
1.13 0.74 - 1.73 1.17 0.72 – 1.88
Used drugs in a sexual contexta 1.30 0.86 - 1.99 1.26 0.78 – 2.06
Ever had a PEP treatmenta 1.81 0.93 - 3.50 2.34* 1.12 – 4.86
Price of PrEPb 1.71* 1.03 - 2.84 1.91* 1.09 – 3.32
a The reference category for these variables is “no”.
b The variable ‘Price of PrEP’ was coded with 0 (when the participant completed the survey at the 
time when PrEP was € 500 per month, before 01-01-2018) and 1 (when the participant completed 
the survey at the time when PrEP was € 50 per month, after 01-01-2018).
* p < .05, ** p < .01, *** p < .001
χ2 (13, N = 349) = 46.08, p < .001, Nagelkerke R2 = .165
Predictors of PrEP initiation after six months
The outcomes of the logistic regression analysis of correlates of PrEP initiation are shown in 
Table 4.2. Significant multivariable correlates of PrEP initiation included perceived financial 
situation (aOR = 1.50, 95% CI 1.21 – 1.87), having ever had PEP treatment (aOR = 2.34, 95% 
CI 1.12 – 4.86), and the price of PrEP (aOR = 1.91, 95% CI 1.09 – 3.32). 
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Table 4.3. Examining the conditional effect of price of PrEP on PrEP use at different levels of per-
ceived financial situation in the multivariate logistic regression.
  aOR 95% CI aOR
One SD below mean financial situation (3.22) 2.06 0.88 - 4.82
At mean financial situation (4.35) 1.83* 1.06 - 3.17
One SD above mean financial situation (5.47) 1.62 0.75 - 3.50
* p < .05
In a post-hoc analysis we investigated the effect of the price of PrEP on PrEP initiation at three 
levels of perceived financial situation: The average level of perceived financial situation in the 
sample and at levels of perceived financial situation one standard deviation below as well as 
one standard deviation above the average perceived financial situation (Table 4.3). We found 
that the price of PrEP was only related to PrEP initiation when perceived financial situation 
was at an average level (aOR = 1.83, 95% CI 1.06 – 3.17).
Discussion
The aim of this study was to investigate what sociodemographic and behavioral factors predict 
PrEP uptake. We in particular investigated whether the price decrease of PrEP, from € 500,- to 
€ 50,- per month, resulting from the introduction of generic formulations of PrEP, is associat-
ed with an increased PrEP uptake. This study found that a better perceived financial situation, 
having ever had PEP treatment, and the price decrease of PrEP were significantly related to 
PrEP initiation. This is in line with our hypotheses and findings of earlier studies. However, 
while earlier cross-sectional studies reported the price of PrEP to be an important overall 
barrier for intended PrEP uptake (Arnold et al., 2017; Bauermeister et al., 2014; Alex Dubov 
et al., 2019; Goparaju et al., 2017; Hayes et al., 2019; Kubicek et al., 2015; Pérez-Figueroa et al., 
2015; Rice et al., 2019; Schwartz & Grimm, 2017), we found more specifically that the price 
decrease of PrEP was only related to an increase in PrEP uptake among participants with an 
average perceived financial situation. This might indicate that the current price reduction of 
PrEP (from € 500 to € 50 per month for the Dutch context) did not impact MSM in more 
unfavorable nor more favorable financial situations, likely for different reasons. MSM in a 
favorable perceived financial situation may use PrEP anyway, regardless of price level, because 
the use of PrEP does not have a substantial impact on their financial situation. On the other 
hand, MSM in an unfavorable perceived financial situation may find the price of € 50 per 
month still too high and may be not be able to afford PrEP at this price. This indicates a need 
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for the inclusion PrEP in health insurance or the implementation reimbursement schemes to 
increase PrEP uptake among less affluent MSM (Kuhns et al., 2017; Patel et al., 2017). 
While having ever had PEP treatment was a significant predictor of PrEP initiation, other var-
iables related to sexual risk behavior, such as number of sex partners in the past six months, 
history of STIs, condom use, and substance use were not significantly related to PrEP initi-
ation after six months. These variables are considered key indicators for PrEP use and eligi-
bility for PrEP, as they reflect an increased risk of HIV, and we therefore expected these to be 
significant predictors of PrEP initiation. A possible explanation for the lack of such a relation-
ship is that participants in our sample overall had a high prevalence of sexual risk behaviors; 
most would be eligible for PrEP. Hence, their sexual risk behaviors are unlikely to distinguish 
between those who start taking PrEP or not (i.e, ceiling effect). This is in line with an earlier 
study that found that despite being an appropriate candidate for PrEP, and contemplating 
PrEP use, MSM do not always initiate PrEP use (Parsons et al., 2017). It was argued that PrEP 
initiation could be increased if PrEP providers apply motivational interviewing techniques to 
help MSM decide on PrEP use. It is important to recognize the role of healthcare providers 
in PrEP initiation. In our study we found that having had PEP treatment is related to PrEP 
use. This might be a result of the Dutch national guideline that instructs health care providers 
to encourage MSM to continue PrEP use directly after a PEP treatment (Hoornenborg & Ri-
jnders, 2016). This indicates that health care providers should be trained to recognize eligible 
candidates for PrEP and to be confident to prescribe PrEP to them. 
Notably, only 45.6% of the participants in our study were using PrEP after six months fol-
low-up. In this sample, we expected a higher PrEP uptake because of the high interest in PrEP 
among the participants. Moreover, the participants were recruited on a website where they 
could find detailed information on how to obtain PrEP, so interest and knowledge would 
not be limiting factors to procure PrEP for the participants in this sample. Also other studies 
found large gaps between interest in PrEP and PrEP uptake (Blashill et al., 2020; Parsons et 
al., 2017; Rolle et al., 2017). It seems that structural barriers play a larger role in explaining 
this gap compared to psychosocial and behavioral factors. For example, among young Latino 
MSM it was found that structural syndemic factors, such as poverty and unstable housing, 
limit PrEP uptake despite high interest in PrEP (Blashill et al., 2020). In our study we found 
that the perceived financial situation and the price of PrEP were the most important factors 
in predicting PrEP uptake.
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There are a few limitations to this study. We recruited participants using convenience sam-
pling, limiting the representativeness of this study for the whole MSM population. The sample 
consisted mostly of highly educated MSM who were born in the Netherlands. MSM with low-
er education levels and migrant MSM may face other challenges when accessing PrEP. It is im-
portant to study the specific needs of these MSM subgroups, in particular because non-West-
ern migrant MSM in the Netherlands have an increased risk of acquiring HIV (Visser et al., 
2017). Still, our study highlights that even among non-minority MSM in the Netherlands 
the price of PrEP and their financial situation are significant factors determining access to 
PrEP. The findings relate specifically to MSM with a high interest in PrEP, and are therefore 
mostly relevant for explaining the gap between a high interest in PrEP and a low uptake of 
PrEP (Hayes et al., 2019). Another limitation of this study is related to the assessment of the 
price of PrEP. We used the price of PrEP in pharmacies in the Netherlands to construct a var-
iable for the price of PrEP that could be included in the regression analysis. However, some 
participants obtained PrEP informally (e.g., via pharmacies abroad), so the price of PrEP in 
pharmacies in the Netherlands may not have influenced their PrEP initiation. Monitoring of 
prices for PrEP at the time of the study in online pharmacies and through health care provid-
ers showed prices quite similar to the reduced price in the Netherlands, with a lower bound 
of € 30,- in Thailand and average prices around € 50,-. Another limitation is that the variable 
“price of PrEP” may not merely reflect the change in the price of PrEP, but may also reflect 
time effects. We did an additional analysis (see Appendix B of this chapter) to control for pos-
sible time effects, and found no evidence that participants were more likely to use PrEP later 
in time. This indicates that the effect of the variable “price of PrEP” indeed captures an effect 
of the price drop of PrEP. 
A strength of this study is that it is the first to collect data over a time span in which the price 
of PrEP significantly changed, allowing us to investigate the relationship between an actual, 
real-world change in the price of PrEP and PrEP uptake. These findings are not only relevant 
for the Netherlands, but also for other countries. In 2019, PrEP was not included in reim-
bursement schemes in 37 (out of 53 reporting) countries in Europe, underscoring that costs 
of PrEP likely continue to impact PrEP use (European Centre for Disease Prevention and 
Control, 2019c). We further expect that the results of our study remain relevant in the future, 
even when the price of branded PrEP may be (further) lowered, as new types of formulation 
(e.g., Emtricitabine/tenofovir alafenamide; (U.S. Food and Drug Administration, 2019)) or 
administration (e.g., injectables, implants (Coelho et al., 2019)) may result in new pricing 
barriers. Pricing barriers may also continue to exist after the introduction of generic formula-
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tions of PrEP, because generic formulations of PrEP are not always substantially cheaper than 
branded Truvada (Poz.com, 2020).
To optimize PrEP uptake among MSM with a high interest in PrEP with limited financial 
resources, the cost of PrEP play an important role. The introduction of lower price generic 
formulations of PrEP led to an increase in PrEP uptake in the Netherlands. However, PrEP 
continued to be used by MSM in a favorable perceived financial situation. MSM in an unfa-
vorable perceived financial situation may be more likely to use PrEP if it is available free of 




Table 4.4. Source of PrEP procurement stratified by perceived financial situation. Please note that the 

































0 0 1 0 0 0 0 1
You are having 
problems mak-
ing ends meet
1 0 0 0 0 0 0 1
You are getting 
by but have to 
be careful
0 1 10 0 5 0 1 17
Things are all 
right
0 4 33 1 8 1 2 49
You are doing 
rather well
1 1 40 7 8 3 4 64
You are doing 
really well
1 0 20 1 10 4 3 39
Total 3 6 104 9 31 8 10 171




In our analysis, the variable “price of PrEP” reflected the introduction of generic formulations 
of PrEP, and the related price decrease, in the Netherlands. The variable “price of PrEP” was 
dummy coded with “0” when the participant completed the T2 questionnaire at the moment 
when PrEP costed € 500,- at Dutch pharmacies (until 01-01-2018) and with “1” when the 
participant completed the T2 questionnaire at the moment when PrEP costed € 50,- at Dutch 
pharmacies (after 01-01-2018). However, it can be argued that this variable may not merely 
reflect the decrease in the price of PrEP, but instead may also reflect time effects. For example, 
over time MSM may become more familiar with PrEP, and may therefore initiate PrEP use.
To investigate the effect of time more precisely, we added the variable “time” in the regression 
model, whereby “time” reflects the month in which the participant completed the T2 survey, 
coded as “1” for October 2017 up to “24” for September 2019. Since the variables “price of 
PrEP” and “time” have a high overlap regarding their underlying construct, the correlation 
between them is too high to include them as independent predictors at the same time in the 
regression model. Therefore, we conducted two logistic regression analyses including “time” 
but not “price of PrEP”: The first logistic regression analysis covered the data (n = 84) during 
the period when the price of PrEP was high (€ 500,-). The second logistic regression analysis 
covered the data (n = 265) during the period when the price of PrEP was low (€ 50,-).
Tables 4.5 and 4.6 show the results of these two logistic regression analyses. In both analyses, 
“time” is not significantly related to PrEP initiation, suggesting that PrEP use does not increase 
over time because of, for example, becoming familiar with PrEP. These findings strengthen 
our interpretation that the price decrease of PrEP is related to an increase in PrEP use. 
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Table 4.5. Multivariable logistic regression examining correlates of PrEP initiation during the period 
when the price of PrEP was high (€ 500,-).
aOR 95% CI aOR
Age 0.98 0.93 – 1.04
Number of sex partners in past 6 months 1.02 0.99 – 1.05
Perceived financial situation 1.51 0.91 – 2.52
Education level
Master and PhD Ref
Bachelor 0.31 0.08 – 1.21
High school and Professional qualification 0.75 0.21 – 2.66
Relationship status
Single Ref
In an open relationship 0.76 0.23 – 2.49
In a relationship 1.34 0.15 – 12.28
STI
Never had an STI Ref
Had an STI in the past 12 months 2.41 0.53 – 11.03
Had an STI more than 12 months ago 0.97 0.21 – 4.55
Not used a condom the last timea 1.30 0.39 – 4.28
Used drugs in a sexual contexta 1.10 0.34 – 3.49
Ever had a PEP treatmenta 1.44 0.29 – 7.27
Timeb 0.70 0.36 – 1.35
a The reference category for these variables is “no”.
b The variable “time” reflects the month in which the participant completed the T2 survey, coded as 
“1” for October 2017 up to “24” for September 2019.
χ2 (13, n = 84) = 16.14, p = .24, Nagelkerke R2 = .240
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Table 4.6. Multivariable logistic regression examining correlates of PrEP initiation during the period 
when the price of PrEP was low (€ 50,-).
aOR 95% CI aOR
Age 1.01 0.99 – 1.04
Number of sex partners in past 6 months 1.02 1.00 – 1.03
Perceived financial situation 1.47** 1.15 – 1.89
Education level
Master & PhD Ref
Bachelor 1.25 0.64 – 2.45
High school & Professional qualification 1.27 0.66 – 2.44
Relationship status
Single Ref
In an open relationship 1.36 0.77 – 2.39
In a relationship 0.32 0.07 – 1.39
STI
Never had an STI Ref
Had an STI in the past 12 months 1.51 0.73 – 3.13
Had an STI more than 12 months ago 0.64 0.33 – 1.25
Not used a condom the last timea 1.28 0.73 – 2.22
Used drugs in a sexual contexta 1.47 0.83 – 2.61
Ever had a PEP treatmenta 2.56* 1.08 – 6.09
Timeb 1.04 0.98 – 1.09
a The reference category for these variables is “no”.
b The variable “time” reflects the month in which the participant completed the T2 survey, coded as 
“1” for October 2017 up to “24” for September 2019.
* p < .05
** p < .01
χ2 (13, n = 265) = 35.83, p < .001, Nagelkerke R2 = .169
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Quality of sex life and perceived sexual pleasure 





Next to its benefits for HIV prevention, PrEP may have psychosocial benefits relating to im-
proved quality of sex life. The aim of the current study was to investigate the onset of changes 
in quality of sex life and sexual pleasure of PrEP users in the first months of commencing 
PrEP use. Moreover, we investigated what factors were related to the quality of sex life of PrEP 
users. We recruited 145 participants via the Dutch PrEP-advocacy website PrEPnu.nl, and 
they received follow-up questionnaires after three and six months. We found that PrEP users 
reported an increase in the quality of their sex life, which was related to reduced fear of HIV 
since they started using PrEP, but not to decreased condom use. PrEP users were more inter-
ested in experimenting with sex practices, but they did not always feel more desirable as a sex 
partner because of PrEP use. Health care providers and health promotion campaigns could 
emphasize the positive effects of PrEP on the quality of sex life, in addition to the HIV-pre-
ventive effects of PrEP, to decrease PrEP stigma and increase PrEP uptake. 




Men who have sex with men (MSM) are disproportionally affected by HIV. In the Nether-
lands, about two-third of HIV infections are among MSM, and in the European Union sex 
between men is the predominant mode of HIV transmission (European Centre for Disease 
Prevention and Control, 2019b). Pre-exposure prophylaxis (PrEP) is an effective biomedical 
HIV-prevention tool (Fonner et al., 2016; Grant et al., 2010, 2014; J. M. Molina et al., 2017), 
that has shown promising results in decreasing new HIV infections among MSM (Grulich 
et al., 2018; Public Health England, 2019; Smith et al., 2020). Initially, PrEP uptake was slow 
(Kirby & Thornber-Dunwell, 2014; Parsons et al., 2017; Rana et al., 2018), but uptake is in-
creasing in contexts where PrEP became more easily available and affordable, for example in 
San Francisco and Australia (Medland et al., 2020; Volk et al., 2020), but also in European 
countries like Germany and Belgium (Mysior et al., 2020; Vuylsteke et al., 2019). PrEP uptake 
and continuous use may further increase if psychosocial benefits of PrEP are better under-
stood and promoted.
Many MSM experience fear of HIV infection (Koester et al., 2017; Prestage et al., 2012; Whit-
field et al., 2019), which affects their quality of sex life and perceived sexual pleasure, and 
creates barriers for HIV testing (Dowson et al., 2012). It has been found that PrEP reduces 
HIV-related fear (Collins et al., 2017; Hojilla et al., 2016; Keen et al., 2020; Koester et al., 2017; 
Moeller et al., 2020; Whitfield et al., 2019), and consequently it may increase the quality of 
MSM’s sex life. While it has been suggested that PrEP may have benefits for quality of sex life 
in addition to its benefits for HIV prevention (Calabrese & Underhill, 2015; Grant & Koester, 
2016; Race, 2016), there are only a limited amount of studies that investigated the relationship 
between PrEP use and quality of sex life, and to our best knowledge there are no studies that 
investigated the onset of such effects after starting to use PrEP. In an analysis of Facebook 
posts of PrEP users in the USA, it was found that PrEP enables PrEP users to explore sexual 
desires and practices in their search for pleasurable sexual relations (Da Silva-Brandao & Ian-
ni, 2020). In a qualitative study in France, PrEP users in a community-based trial reported an 
increase in sexual pleasure and quality of sexual life (Mabire et al., 2019). PrEP users related 
improvements in sexual pleasure to greater feelings of sexual freedom, and the flexibility to 
(not) use condoms (Mabire et al., 2019). Condomless anal intercourse has already been relat-
ed to greater sexual pleasure (Carballo-Diéguez et al., 2011), even before the introduction of 
PrEP. Two systematic reviews found that condom use significantly decreases among PrEP us-
ers (Freeborn & Portillo, 2018; Traeger et al., 2018). In sum, there is initial evidence that PrEP 
Chapter 5
84
use also has (positive) psychosocial effects due to change of condom use, increased sexual 
exploration and perceived sexual freedom. So far, PrEP use is mostly studied in the context 
of demonstration trials, in which PrEP users received counseling and medical supervision. 
In the current study, we assessed the experiences of PrEP users in the Netherlands outside of 
clinical trials. At the time of our study, many PrEP users obtained PrEP via informal channels 
(i.e. pharmacies abroad), because formal PrEP services were not implemented yet. 
The aim of the current study was to document the onset of changes in behaviors and attitudes 
of PrEP users in a longitudinal design (first six months of PrEP use) and to investigate fac-
tors that are related to the quality of sex life of PrEP users. As prior qualitative studies point 
out, we expect that less fear of HIV and a decrease in condom use are related to an improved 
quality of sex life among PrEP users. We also expect that greater feelings of sexual freedom, as 
reflected by experimenting with sex practices or recreational substance use, are related to an 
improved quality of sex life. We first analyzed whether these behaviors and attitudes change 
in the first months of commencing PrEP users. Next, we analyzed how the behaviors and 
attitudes are related to the quality of sex life.
Methods
Participants and procedure
Between February 2017 and March 2019, participants were recruited via the Dutch PrEP-ad-
vocacy website PrEPnu.nl. This website provides information about using and obtaining PrEP 
aimed at potential PrEP users in the Netherlands. Participants received a follow-up ques-
tionnaire via email after three (T1) and six months (T2). All participants who completed at 
least two questionnaires (Baseline T0 + T1/T2) were entered into a raffle to win a € 100,- gift 
card. This study was approved by the Ethics Review Committee Psychology and Neuroscience 
of Maastricht University (ERCPN-174_10_12_2016). The full details of the methods of this 
study have been described elsewhere (Van Dijk et al., 2020).
Participants younger than 18 years old or living with HIV were excluded from participation. 
For the current analysis, we only included participants who reported using PrEP at T1 and T2, 
regardless of their PrEP use at baseline (T0). We did not include data from T0, because not all 
relevant items for the current analysis were assessed at T0.




The questionnaires were administered online using Qualtrics. The questionnaires were of-
fered in Dutch and English, and included the following assessments.
Sociodemographic characteristics
In the baseline questionnaire (T0) participants were asked to indicate their gender (gender 
assigned at birth and current gender), age, relationship status, educational level, financial sit-
uation, country of birth, and country of residence. We assessed perceived financial situation 
with a 6-point scale; (1) ‘you can’t make ends meet without borrowing’, (2) ‘you are having 
problems making ends meet’, (3) ‘you are getting by but have to be careful’, (4) ‘things are all 
right’, (5) ‘you are doing rather well’, and (6) ‘you are doing really well’. 
Quality of sex life and quality of life
At T1 and T2, we asked participants whether their perceived quality of sex life changed since 
they started taking PrEP, with responses indicated on a 5-point scale ranging from (1) ‘a lot 
worse’ to (5) ‘a lot better’. We included a separate item to assess perceived change in quality of 
life in general to investigate whether quality of sex life explains additional variance.
PrEP-regimen and consequences of PrEP use
We asked current PrEP users whether they used PrEP daily or on demand. At T1 and T2, we 
also asked them to indicate their agreement, using a 5-point scale ranging from (1) strongly 
disagree to (5) strongly agree, with the following five items that were phrased for the period 
since they started using PrEP: ‘I feel less anxious when having sex’, ‘I feel more safe when 
having sex’, ‘I feel I am a more desirable sex partner because of PrEP’, ‘I feel more interested 
in experimenting with novel sex practices’, and ‘I am interested in using (novel) recreational 
drugs while having sex’. Due to the conceptual overlap of the first two items, (less) anxious 
and (more) safe, (r = .72 at T1 and r = .57 at T2), we computed a new variable based on the 
mean of these two items.
Condom use
To assess condom use, we asked participants whether their condom use changed since they 
started taking PrEP on a scale from (1) ‘a lot lower than before’ to (5) ‘a lot higher than before’. 
Data analysis
We analyzed the data using IBM SPSS Statistics version 26. To assess changes in quality of sex 
life, condom use, and the PrEP-related items over a period of three months, we conducted a 
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repeated measures ANOVA to compare the two measurements (T1 and T2) of each variable. 
To assess if quality of life, condom use and the PrEP-related items were related to quality of 
sex life, we conducted a linear regression analysis with quality of sex life at T2 as dependent 
variable. In addition, we conducted a mediation analysis to assess if reduced fear of HIV was 
associated with improved quality of sex life as mediated by decreased condom use, using 5000 
bootstrapped standard errors in PROCESS version 3 for SPSS (Hayes, 2017).
Results
Participant characteristics and PrEP regimen
Table 5.1 shows the participant characteristics. All 145 participants were cisgender males. 
Their mean age was 43 years (range: 20 – 71). Most participants were single (70; 48.3%) or in 
an open relationship (66; 45.5%). Overall, the sample was relatively high educated (95 par-
ticipants (65.6%) had a Bachelor degree or higher) and in a comfortable perceived financial 
situation (128 participants (88.4%) evaluated their financial situation as “all right” or higher).
More than half of the participants used PrEP daily (T1: 109 participants (75.2%), T2: 101 par-
ticipants (69.7%)), and the remainder used PrEP on demand (T1: 36 (24.8%), T2: 44 (30.3%)). 
Recreational drug use in a sexual context was common: 66 participants (45.5%) indicated to 
have used XTC (ecstasy/MDMA) while on PrEP, and 61 participants (42.1%) indicated to 
have used GHB/GHL. Use of other drugs are reported in table 5.1. 
Changes in behavior and attitudes 
Table 5.2 shows the descriptive statistics of quality of sex life, condom use, and the PrEP-re-
lated items, including the results of the repeated measures ANOVA. PrEP users reported im-
provements in their perceived quality of sex life with an average score of 4.24 (SD = 0.71) at 
T1. The improvements in quality of sex life maintained over time; the score at T2 did not differ 
from the score at T1 (M = 4.19, SD = 0.69; F < 1). PrEP had less impact on quality of life in 
general. Compared to quality of sex life, the scores on quality of life in general were closer to 
the middle value (3), indicating that perceived quality of life was “the same” as before using 
PrEP. At T2, perceived improvements in quality of life were lower than at T1 (F (1, 144) = 
8.78, p = .004, ηp
2  = .06), indicating that improvements in quality of life in general did not 
maintain over time.
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Table 5.1. Frequencies of participant characteristics (N = 145).
Age (years; mean, range) 43 (20-71)
Born in the Netherlands 119 (82.1%)
Living in the Netherlands 140 (96.6%)
Perceived financial situation
You can't make ends meet without borrowing 1 (0.7%)
You are having problems making ends meet 2 (1.4%)
You are getting by but have to be careful 14 (9.7%)
Things are all right 43 (29.7%)
You are doing rather well 52 (35.9%)
You are doing really well 33 (22.8%)
Education level
No tertiary education 21 (14.5%)
Professional / vocational qualification 29 (20.0%)
Bachelor degree 43 (29.7%)
Master degree 43 (29.7%)
PhD degree 9 (6.2%)
Relationship status
Single 70 (48.3%)
In a relationship 9 (6.2%)
In an open relationship 66 (45.5%)





Crystal meth 9 (6.2%)
GHB/GHL 61 (42.1%)
Ketamine 34 (23.4%)
Methoxetamine (MXE) 6 (4.1%)
XTC (ecstasy / MDMA) 66 (45.5%)
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Table 5.2. Descriptive statistics and repeated measures ANOVA to compare the scores on the varia-
bles of interest between the two time points.
M T1 SD T1 M T2 SD T2 F p ηp
2
Quality of life1 3.76 0.72 3.59 0.66 8.78 .004 .06
Quality of sex life1 4.24 0.71 4.19 0.69 0.94 .33 .01
I feel less anxious 
/ more safe when 
having sex 2
4.53 0.86 4.65 0.72 1.84 .18 .01
I feel I am a more 
desirable sex partner 
because of PrEP2
3.08 1.21 3.04 1.24 0.09 .77 .001
I feel more interested 
in experimenting 
with novel sex prac-
tices2
3.47 1.20 3.70 1.13 4.88 .03 .03
I am interested in 
using (novel) recre-
ational drugs while 
having sex2
2.01 1.29 2.04 1.28 0.17 .68 .001
Condom use3 2.19 0.79 2.03 0.78 9.49 .002 .06
Degrees of freedom = 1, 144
1 Change in quality of life and quality of sex life since taking PrEP on a scale from (1) ‘a lot worse’ to 
(5) ‘a lot better’.
2 All items began with ‘Since I started using PrEP…’. Participants indicated their agreement using a 
5-point scale ranging from (1) strongly disagree to (5) strongly agree.
3 Change in condom use since taking PrEP on a scale from (1) ‘a lot lower than before’ to (5) ‘a lot 
higher than before’.
PrEP users reported high agreement with feeling less anxious when having sex since they 
started PrEP use, both at T1 and T2. PrEP use however did not make them feel more desir-
able as a sex partner at T1 nor T2. PrEP use did make them somewhat more interested in 
experimenting with sex practices, and this increased over time (F (1, 144) = 4.88, p = .03, ηp
2 
= .03). Notably, this increased interest in sexual experimentation did not involve the use of 
recreational drugs, as PrEP users indicated that they were not interested in using new types 
of drugs while having sex. Furthermore, PrEP users reported a decrease in perceived condom 
use at T1 since they started using PrEP, and condom use further decreased at T2 (F (144, 1) 
= 9.49, p = .002, ηp
2 = .06).
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Table 5.3. Multivariable regression analysis with quality of sex life at T2 as outcome variable.
B S.E. Beta t p
(Constant) 0.44 0.53 0.83 0.41
Quality of sex life (T1) 0.31 0.08 0.32 3.65 <0.001
Condom use (T1) -0.01 0.08 -0.01 -0.15 0.88
Condom use (T2) 0.00 0.08 0.00 0.03 0.98
I feel less anxious / more 
safe when having sex (T1) 0.01 0.06 0.01 0.13 0.90
I feel less anxious / more 
safe when having sex (T2) 0.17 0.07 0.18 2.52 0.01
I feel more interested in 
experimenting with novel 
sex practices (T1) 0.02 0.05 0.04 0.47 0.64
I feel more interested in 
experimenting with novel 
sex practices (T2) 0.02 0.05 0.03 0.38 0.71
I feel I am a more desira-
ble sex partner because of 
PrEP (T1) -0.02 0.05 -0.03 -0.42 0.67
I feel I am a more desira-
ble sex partner because of 
PrEP (T2) 0.08 0.04 0.15 1.88 0.06
Quality of life (T1) 0.01 0.08 0.01 0.11 0.91
Quality of life (T2) 0.37 0.08 0.35 4.53 <0.001
I am interested in using 
(novel) recreational drugs 
while having sex (T1) -0.08 0.05 -0.15 -1.51 0.13
I am interested in using 
(novel) recreational drugs 
while having sex (T2) 0.07 0.05 0.13 1.27 0.21
R2 = .47, F (13, 144) = 8.92, p <.001
Predictors of quality of sex life 
To investigate what factors were related to quality of sex life at T2, we conducted a linear re-
gression analysis (Table 5.3). Significant predictors of quality of sex life at T2 were quality of 
sex life at T1 (B  = 0.31, t = 3.65, p <.001), quality of life in general at T2 (B  = 0.37, t = 4.53, p 
<.001), and feeling less fear of HIV at T2 (B  = 0.17, t = 2.52, p = .01). 
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In order to better understand the relationship between reduced fear of HIV and increased 
quality of sex life, we assessed if this relationship was mediated by condom use (Figure 5.1). 
These analyses showed no indirect effect of condom use (b = 0.02, 95% CI = -0.01 – 0.06), but 
did show a direct effect of fear of HIV on quality of sex life (b = 0.23, t (142) = 2.98, p = .003) 
that was not mediated by condom use.
Condom use




** p < .01
Figure 5.1. Mediation analysis investigating the relationship between fear of HIV and quality of sex life 
mediated by condom use, all at T2.
Discussion
The aim of the current study was to assess the onset of changes in perceived quality of sex life 
and sexual pleasure of PrEP users in their first six months of PrEP use. We also assessed fac-
tors that were related to the quality of sex life of PrEP users. PrEP users reported an increase 
in quality of sex life, and, to a lesser extent, an increase in quality of life in general. Similar to 
earlier studies (Collins et al., 2017; Hojilla et al., 2016; Keen et al., 2020; Koester et al., 2017; 
Moeller et al., 2020; Whitfield et al., 2019), PrEP users also reported less fear of HIV when 
having sex since they started using PrEP. This reduced fear was positively related to improve-
ments in quality of sex life. The relationship between fear of HIV and quality of sex life was 
not found to be mediated by changes in condom use.
Regarding sexual pleasure, we found that PrEP users become somewhat more interested in 
experimenting with sex practices since they started using PrEP, and this interest increased 
over time. Although we did not ask our participants for any specification of these sex prac-
tices, earlier qualitative studies found that PrEP users indicated that they were more likely to 
switch their sexual position from top to bottom (Mabire et al., 2019; Quinn et al., 2019), and 
PrEP users were more likely to have attended sex parties (Meunier & Siegel, 2019). Also a 
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quantitative study among 1,500 MSM in Australia found that PrEP users had a more ‘adven-
turous’ sex life as they were more likely to have engaged in group sex and had higher number 
of sex partners (Prestage et al., 2019). Overall, we found that drug use in the context of sex was 
high, similar to other studies that  reported high levels of recreational drug use or chemsex 
(the use of drugs while having sex) among PrEP users (Closson et al., 2018; Gafos et al., 2019; 
Nöstlinger et al., 2020; Roux et al., 2018). However, PrEP users in our study did not have an 
increased interest in using (novel) recreational drugs while having sex since they started using 
PrEP. Notably, a study among PrEP users in a demonstration trial in the Netherlands found 
that (problematic) drug use actually decreased after PrEP initiation (Achterbergh et al., 2020). 
The authors propose the possible explanation that PrEP users in the demonstration trial re-
ceived counseling and motivational interviewing. In our study, no decrease in drug use was 
found. A possible explanation is that since we recruited participants in a context where formal 
PrEP services were not fully implemented yet, PrEP users may not have received counseling, 
and therefore did not change their drug use behavior. 
PrEP users reported a decrease in condom use, and this seemed to continue over time. PrEP 
users overall did not report a change in feeling a more desirable sex partner since they started 
using PrEP, while in the literature changes have been found in both directions: Some PrEP 
users feel being a less desirable sex partner, as they have encountered stigmatizing reactions 
from potential sex partners (Brooks et al., 2019; Grace et al., 2018). Other PrEP users feel 
being a more desirable sex partner, as they are seen as having a lower risk of having HIV 
(Martinez & Jonas, 2019).
The findings of our study contribute to the discourse of psychosocial benefits and sex-positive 
effects of PrEP. Initially, PrEP users were stigmatized, as reflected by the use of such terms 
as “Truvada whores” (Calabrese & Underhill, 2015). However,  a recent study in Australia, 
where PrEP is widely available, found that positive views of PrEP were twice as common than 
negative views of PrEP (Philpot et al., 2020).  Researchers have advocated to focus on the 
empowerment regarding sexual health and how PrEP fits in the complete panel of HIV and 
STI prevention strategies (Rojas Castro, Delabre, & Molina, 2019). To increase PrEP uptake 
and continuous use, health promotion campaigns should include the positive effects of PrEP, 
such as the improved quality of sex life and reduced anxiety for HIV. For example, a PrEP 
campaign in Chicago that underlined sexual pleasure was found to increase PrEP awareness 
and engagement (Dehlin et al., 2019; Keene et al., 2020).
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This study has several limitations. We recruited participants by convenience sampling through 
the PrEP advocacy website PrEPnu.nl, which limits the representativeness of the sample. Es-
pecially at the start of our recruitment, in early 2017, awareness and use of PrEP was still 
limited in the Netherlands. Hence, it was practical to recruit participants, that is (potential) 
PrEP users, through channels for this population group. By using this platform, we may have 
in particular recruited motivated and well-informed (potential) PrEP users, and we may have 
missed (potential) PrEP users who find PrEP information via other sources, such as social 
medial or their healthcare providers. As PrEP use is becoming more common in many coun-
tries, future studies may want to recruit a wider range of PrEP users. Another limitation is that 
the data is self-reported. While participants could complete the questionnaire anonymously, 
the responses could still be affected by social desirability biases. A final limitation is that we 
did not ask the questions to MSM who were not using PrEP, so we cannot compare quality of 
sex life of PrEP users with non-users. We asked PrEP users to indicate changes in quality of 
sex life since they started taking PrEP, so we can only make inferences about the effect of PrEP 
based on these self-reported changes.
To conclude, we found that early PrEP users in the Netherlands reported an increase in the 
quality of their sex life, which was associated with reduced fear of HIV while having sex since 
they started using PrEP. PrEP users also were more interested in experimenting with novel 
sex practices, but they did not always feel more desirable as a sex partner because of PrEP use. 
Health care providers and health promotion campaigns could point out the positive effects of 
PrEP on the quality of sex life, in addition to the HIV-preventive effects of PrEP, to decrease 
PrEP stigma and increase PrEP uptake and continuous use.




This chapter is based on:
Van Dijk, M., De Wit, J.B.F., Guadamuz, T., Martinez, J.E., & Jonas, K.J. (2020). Bridging the 
serodivide: Attitudes of PrEP users towards sex partners living with HIV [Manuscript sub-
mitted for publication].
Bridging the serodivide: Attitudes of PrEP users 





The introduction of biomedical HIV prevention methods, such as pre-exposure prophylaxis 
(PrEP), holds the potential to overcome the serodivide. We investigated the attitudes of PrEP 
users towards having sex with partners living with HIV. PrEP users in the Netherlands were 
recruited online and completed three questionnaires over a period of six months. We inves-
tigated changes over time in feelings of fear of HIV, comfort, and attitudes towards condom 
use when having sex with men living with HIV. A majority of PrEP users in our sample (up 
to 71.6%) had sex with men living with HIV. Feeling comfortable to have sex with men living 
with HIV did not change over time, but was already at a high level at T1. Most importantly, 
feeling safe not to use condoms with HIV positive partners significantly increased, and did so 
in a rather short period of time after the onset of PrEP use (3-6 months). Taken together, the 
findings suggest that that PrEP may contribute to decreasing the serodivide between MSM 
rather quickly after the onset of PrEP use.




The division between HIV-positive and HIV-negative men who have sex with men (MSM) 
has been described as the ‘serodivide’; defined as the avoidance of sex with a partner of a dif-
ferent (serodiscordant) HIV status (Koester et al., 2018). The serodivide is driven by concerns 
about HIV transmission, resulting in serosorting, an HIV-risk reduction strategy of limiting 
one’s sex partners the others of the same HIV status (Davis et al., 2006; Eaton et al., 2009; 
Golden et al., 2008). Furthermore, the serodivide is driven by HIV-related stigma and lack 
of contact with people living with HIV, indicative of a broad social exclusion (Murphy et al., 
2015; Smit et al., 2012). HIV-stigma has a negative impact on the mental health of gay men 
living with HIV as well as HIV-negative gay men (Courtenay-Quirk et al., 2006; Starks et al., 
2013; Stutterheim et al., 2009). 
The introduction of biomedical HIV prevention, such as pre-exposure prophylaxis (PrEP) 
and treatment-as-prevention (TasP), holds the potential to overcome the serodivide between 
serodiscordant MSM and to reduce HIV stigma (Brisson & Nguyen, 2017; Grant & Koester, 
2016; Haas et al., 2017; Jaspal & Daramilas, 2016; Malone et al., 2018; Persson, 2016). While 
there is initial evidence of this potential, it is important to know when such a serodivide re-
duction becomes psychologically and behaviorally relevant after the onset of PrEP use. 
In a qualitative study among young PrEP users in an urban setting, PrEP users were more 
likely to have dates with men living with HIV after starting PrEP because of a decreased fear 
for HIV (Koester et al., 2018). An experimental study found that PrEP users rated the dating 
profiles of men living with HIV as equally attractive as dating profiles of HIV-negative men, 
while MSM with no history of PrEP use rated dating profiles of men living with HIV as less 
attractive (Golub et al., 2018). Moreover, while MSM who did not use PrEP had a higher 
intention to use condoms with sex partners living with HIVs, PrEP users had the same (and 
overall lower) level of intention to use condoms with HIV-positive and HIV-negative partners 
(Golub et al., 2018). While these initial findings are promising, more empirical research is 
needed to investigate the potential effect of PrEP on decreasing the serodivide in other con-
texts and if this effect is persistent over time.
There are several factors that may play a role in the potential of PrEP to facilitate sexual inter-
actions between serodiscordant sex partners. Firstly, PrEP users have been found to report in-
creased comfort and confidence in connecting with other men sexually, particularly with men 
living with HIV (Storholm et al., 2017). Secondly, gay men in serodiscordant relationships 
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have been found to expect that PrEP use would increase their sexual comfort, as they would 
feel less fear of HIV (Brooks et al., 2011). Thirdly, PrEP users have reported reduced fear of 
HIV (Collins et al., 2017; Hojilla et al., 2016; Keen et al., 2020; Koester et al., 2017; Whitfield 
et al., 2019). It is expected that this reduced fear of HIV may be related to decreased condom 
use, as PrEP users may feel sufficiently protected against HIV by PrEP. Fourthly, compared to 
gay men who were not using PrEP, PrEP users felt more comfortable having condomless anal 
sex with men living with HIV, especially when the partner living with HIV had an undetecta-
ble viral load (Holt, Draper, et al., 2018). Hence, (non-)condom use can serve as an indicator 
of PrEP user’s fear of HIV and sexual comfort when having sex with a partner living with HIV. 
The aim of the current study was to investigate the onset and the change in attitudes of PrEP 
users regarding having sex with men living with HIV. We in particular investigated whether 
PrEP users who have sex with men living with HIV over time feel less fear of HIV, feel more 
comfortable when having sex with men living with HIV, and feel safe to not use condoms. 
To investigate these questions, we recruited PrEP users in the Netherlands at a time (2017 
– 2019) when PrEP availability was still limited in the Netherlands, and not formally imple-
mented yet. As a consequence, most PrEP users were informal PrEP users, meaning that they 
either procured PrEP via informal channels (i.e. pharmacies abroad or pill sharing of people 
living with HIV), or had limited access to PrEP-related medical services (Buttram, 2018). 
We followed early PrEP users over a period of six months, and this longitudinal assessment 
allowed us to investigate changes over time in fear of HIV, feeling comfort in having sex with 
men living with HIV, and feeling safe to not use condoms.
Methods
Participants and procedure
We recruited participants via the Dutch PrEP-advocacy website PrEPnu.nl, between Febru-
ary 2017 and March 2019. After the intake questionnaire (T0), every participant received a 
follow-up questionnaire via email after three (T1) and six months (T2). Participants who did 
not complete the T1 questionnaire were still encouraged to complete the T2 questionnaire. 
All participants who completed at least two questionnaires (T0 + T1/T2) were entered into a 
raffle to win a € 100,- gift card. The Ethics Review Committee Psychology and Neuroscience 
of Maastricht University approved this study (ERCPN-174_10_12_2016). The full details of 
the methods of this study have been described before (Van Dijk et al., 2020).
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Participants younger than 18 years or living with HIV were excluded from participation. For 
the current analysis, we only included participants who reported using PrEP both at T1 (3 
months after baseline) and T2 (6 months after baseline), regardless of their PrEP use at T0 to 
be able to assess the onset of serodivide decrease effects. We did not include data from T0, 
because not all relevant items for this analysis were assessed at T0. 
Materials
The questionnaires were administered online using Qualtrics; participants could not click 
back to previous questions. The questionnaires were offered in Dutch and English. We asked 
current PrEP users whether they used PrEP daily, on demand, or recreationally (i.e. season 
based (Elsesser et al., 2016; Hojilla et al., 2016; Underhill et al., 2018)). At T1 and T2, PrEP 
users were asked if they have had sex with HIV-positive men (yes/no). If yes, we asked them 
to indicate their agreement, using a 5-point scale ranging from (1) strongly disagree to (5) 
strongly agree, with on the following three items which were asked with respect to the period 
since they started using PrEP: “I feel more comfortable when I have sex with HIV positive 
men”, “I have less fear of HIV when I have sex with HIV positive men”, and “I feel safe to not 
use condoms with HIV positive sex partners”.
Data analysis
We analyzed the data using IBM SPSS Statistics version 26. A chi-square test was conducted 
to assess any differences between T1 and T2 in the percentage of PrEP users who had sex with 
HIV-positive men and in PrEP regimen. To assess any change in attitudes between T1 and T2, 
we conducted a repeated measures analysis of variance (ANOVA) for each variable. 
Results
Participant characteristics and prevalence of sexual encounters with men living with HIV
There were 183 PrEP users in our sample who answered the question whether they had sex 
with men living with HIV at both points of assessment. At T1, 121 (66.1%) PrEP users indi-
cated to have sex with men living with HIV. At T2, 131 (71.6%) PrEP users reported having 
sex with men living with HIV, which is a significant higher amount compared to T1 (χ2 (1, 
183) = 89.92, p <.001). For the analyses below, we only use data of the PrEP users who had 
sex with men living with HIV at both assessments (N = 112) to correct for incidental sexual 
experiences with men living with HIV at either T1 or T2.
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All of these 112 participants were cisgender males, with a mean age of 45 years (range: 
22 – 71). The majority of the participants used PrEP daily (T1: 67 (59.8%) participants, T2: 
61 (54.5%) participants), followed by PrEP on demand (T1: 28 (25.0%) participants, T2: 34 
(30.4%) participants), and recreationally / season based (17 (15.2%) participants at both T1 
and T2). 
Changes in attitudes 
Table 6.1 shows the descriptive statistics of the attitude items, including the test results of the 
repeated measures ANOVA. The scores on the variables ‘feeling more comfortable having sex 
with HIV positive men’ and ‘having less fear of HIV when I have sex with HIV positive men’ 
did not change between T1 and T2 (F < 1), and were already relatively high at T1. Scores on 
the variable ‘feeling safe to not use condoms with HIV positive sex partners’ increased signif-
icantly from T1 to T2 (F (1, 111) = 5.57, p = .02, ηp
2 = .048).
Table 6.1. Descriptive statistics and repeated measures ANOVA to compare the scores on the varia-
bles of interest between the two assessments (T1 and T2).
M T1 SD T1 M T2 SD T2 F df p ηp
2
I have less fear of HIV 
when I have sex with 
HIV positive men
4.33 1.06 4.33 1.01 <0.001 1, 111 1.00 <.001
I feel more comfort-
able when I have sex 
with HIV positive 
men
4.16 1.11 4.26 1.08 0.58 1, 111 .45 .005
I feel safe to not 
use condoms with 
HIV-positive sex 
partners
3.70 1.39 4.01 1.23 5.57 1, 111 .02 .048
All items began with ‘Since I started using PrEP…’. Participants indicated their agreement using a 
5-point scale ranging from (1) strongly disagree to (5) strongly agree.
Discussion
The aim of this study was to investigate changes in attitudes of PrEP users regarding sex with 
men living with HIV. We in particular investigated whether PrEP users who had sex with 
HIV-positive men over time had less fear of HIV, felt more comfortable having sex with men 
with HIV, and felt safe to not use condoms. We found that about 70% of PrEP users (66.1% 
at T1 and 71.6% at T2) indicated they had sex with men living with HIV. Feeling comfortable 
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having sex with men living with HIV did not change over time, but was already at a high level 
at T1. Most importantly, feeling safe not to use condoms with HIV positive partners signifi-
cantly increased, and did so in a rather short period of time after the onset of PrEP use (3-6 
months)
Putting our findings into context, the amount of PrEP users having sex with men living with 
HIV was a relatively large proportion of the overall sample, and much higher than what was 
found in another study of MSM in Canada (Wang et al., 2020). This study found that only 
17% of PrEP users indicated having sex with men living with. There was also less serosorting 
among PrEP users, as PrEP users were more likely to have sex with men living with HIV than 
those who did not use PrEP. An increase in having sex with men living with HIV over time 
was also found in another longitudinal study with a longer timeframe (up to 18 months) 
(Zablotska et al., 2019) while our results show an earlier onset of a serodivide decrease. The 
findings of our and earlier studies point to the potential that PrEP use may help overcome the 
divide between serodiscordant MSM. 
PrEP users reported a robust decrease in fear of HIV and feeling more comfortable having 
sex with partners living with HIV, and this did not change over a period of three months. 
While reduced fear of HIV and increased sexual comfort have been reported in qualitative 
studies (Collins et al., 2017; Hojilla et al., 2016; Koester et al., 2017; Storholm et al., 2017), our 
study, to the best of our knowledge, is the first quantitative study to report this reduced fear 
and increased comfort in a longitudinal design with informal PrEP users. Our findings are 
similar to those of an earlier longitudinal study with formal PrEP users in the United States 
(Whitfield et al., 2019), however the focus of our study is specifically on sexual interaction 
with sex partners living with HIV. In addition to the reduced fear of HIV, we found that PrEP 
users felt safe to not use condoms with sex partners living with HIV, and this increased over 
time. This suggests that, over time, PrEP users who have sex with men living with HIV may 
feel more confident to rely on the protective effect of PrEP. The decreased condom use could 
further indicate an increase in sexual comfort.
Our results dovetail nicely with findings regarding the impact of other forms of bio-medical 
HIV prevention. Notably, treatment as prevention (TasP) has also been shown to play a role 
in reducing fear and HIV-related stigma (Persson, 2016). So far, awareness and acceptability 
of TasP has however been limited (Card et al., 2018; Young & McDaid, 2014), despite the 
strong evidence of its effectiveness (Cohen, 2019; Rodger et al., 2019). In recent years, TasP 
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has become more prominent in health promotion campaigns using the slogan “Undetectable 
is Untransmittable”, aiming to increase awareness of TasP among MSM (Eisinger et al., 2019; 
Rendina & Parsons, 2018). PrEP and TasP may complement each other (Tester & Hoxmeier, 
2020), as it is suggested that PrEP users have greater knowledge of TasP and greater willing-
ness to rely on TasP (Holt, Draper, et al., 2018). The emergence of PrEP and TasP adds new 
possibilities for partner selection among MSM who want to mitigate their HIV risk. Instead 
of selecting a sex partner based on HIV-status (serosorting), MSM can now select partners 
based on PrEP use (‘PrEP sorting’; Martinez & Jonas, 2019; Wang et al., 2020) or viral load 
(‘biomed matching’; Grov et al., 2018; Newcomb et al., 2016). Both TasP and PrEP can con-
tribute to a decrease in HIV stigma and more comfort during with sex with men living with 
HIV.
This study has several strengths and limitations. This study is one of the first to investigated 
changes regarding feelings of fear and comfort related to having sex with HIV-positive men 
among PrEP users using a quantitative, longitudinal design covering the first 6 months of 
PrEP use. Moreover, we investigated this in a Dutch context with mostly informal PrEP users, 
while earlier similar studies were conducted in Australia and the United States where the for-
mal availability of PrEP is much higher (Keen et al., 2020; Whitfield et al., 2018). At the time 
of our study, formal PrEP services were not implemented yet, and early PrEP adopters there-
fore had to rely on community information regarding accessing and using PrEP. A limitation 
is that participants’ behaviors and attitudes are assessed by self-report and may be susceptible 
to social desirability bias. Another limitation is that we did not assess attitudes regarding sex 
with men living with HIV of PrEP users who indicated not having sex with men living with 
HIV, so we could not compare attitudes. Also, we did not ask about motives why some PrEP 
users did not have sex with sex partners living with HIV. This could be a direction for future 
research, for example to investigate whether this relates to HIV-stigma or to a lack of trust 
in biomedical protection (i.e. PrEP and TasP). A further limitation is that our sample was re-
cruited via convenience sampling, limiting the representativeness of the sample. We recruited 
participants via the PrEP advocacy website PrEPnu.nl. Because this website provides infor-
mation about using PrEP and obtaining PrEP in a context of limited availability, our sample 
may have an overrepresentation of PrEP users who are well-informed and are more engaged 
in sexual health. It is possible that these MSM are also more likely to have sex with men living 
with HIV for other reasons. We could not rule out that other characteristics of these PrEP 
users are contributing to their attitudes regarding sex with men living with HIV, next to their 
PrEP use. Put differently, PrEP use could be a proxy for these underlying characteristics. A 
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final limitation is that we only analyzed the data of participants who indicated to have sex with 
men living with HIV at both points of assessment (T1 and T2) to be able make a comparison 
between these two measurements. However, consequently, participants who indicated to have 
sex with men living with HIV at T1 but not at T2 (n = 7) and vice versa (n = 17) were not 
included in the analysis, as they only answered the items at one point of assessment. 
To conclude, our findings suggest that PrEP helps to reduce fear of HIV and to increase com-
fort having sex with sex partners living with HIV. Over a rather short period of time (3-6 
months after the onset of PrEP use), PrEP users also felt safer to not use condoms when 
having sex with sex men living with HIV. Taken together, the findings suggest that PrEP use 
may contribute to decreasing HIV-related stigma and to improve sexual interactions between 
serodiscordant MSM. Together with earlier findings, our results provide evidence for the psy-






In this general discussion, I will discuss the main findings regarding the aims of this thesis. 
This thesis aimed to answer the following four research questions: 
1. What are the attitudes and usage intentions of MSM for PrEP in the Netherlands?
2. How do high-risk MSM in the Netherlands obtain PrEP and access PrEP-related 
healthcare?
3. What are the hurdles for PrEP use in the Netherlands?
4. What is the sexual behavior of PrEP users after PrEP initiation?
After describing the main findings, the implications of these findings for the societal and 
scientific debates around PrEP are discussed. Subsequently, the strengths and limitations of 
this thesis are discussed. Finally, the directions for future research and the conclusions are 
discussed.
Main findings
First, we examined the attitudes towards PrEP and interest in PrEP in the study described in 
chapter 2. We conducted this study in the summer of 2016, before the European Medicines 
Agency (EMA) approved PrEP and before PrEP was available in the Netherlands. At that 
time, many MSM were already aware of PrEP: 89.9% of the participants had heard of PrEP 
and 85.4% of them had correct knowledge of PrEP. About half of the participants were in-
terested in PrEP and had the intention to start using PrEP when it would become available. 
Factors associated with interest in PrEP were being single, having correct prior PrEP knowl-
edge, not having used a condom the last time when having sex, and having ever used drugs 
in a sexual context. This suggests that MSM who may benefit from PrEP (i.e. those with high-
risk behavior) are indeed those who are more interested in PrEP. In addition, we found that 
the recruitment strategy was also significantly related to interest in PrEP: Participants of the 
research panel AmsterdamPinkPanel were less interested in PrEP compared to participants 
recruited via convenience sampling. Other studies also demonstrated differences in interest 
in PrEP when participants are recruited in various ways, for example in STI clinics or online 
(Beymer et al., 2018; Ferrer et al., 2016). This indicates that it is important to take recruitment 
strategies and sample characteristics into account in explaining study findings.
For the second research question, we examined how MSM in the Netherlands obtain PrEP 
and access PrEP-related healthcare. Although PrEP was not formally available in the Neth-
erlands in 2016, 6.6% of the participants in the study described in Chapter 2 already used 




in chapter 3 we qualitatively explored the ways in which PrEP users obtained PrEP and what 
their experiences were regarding accessing PrEP. This study was conducted in the beginning 
of 2018, when PrEP was available for an affordable price (€ 50 per 30 pills) in the Netherlands. 
Participants who first bought PrEP informally abroad or online, had mostly switched to buy-
ing PrEP formally at a pharmacy in the Netherlands. Still, there were some PrEP users who 
remained procuring PrEP via informal channels, because they found it to be more convenient 
or cheaper. In addition to access to PrEP, we also explored access to PrEP-related healthcare. 
Some participants indicated that they had to switch general practitioners (GP) because their 
previous GP had moralistic ideas about sex and PrEP and therefore did not want to pre-
scribe PrEP. According to the participants, PrEP knowledge was limited among GPs, but they 
were willing to be informed by PrEP users. Renal function testing was usually conducted via 
the GP, but not all PrEP users found it necessary to do this regularly. Sexually transmitted 
infection (STI) testing was usually conducted in the public health centers, but waiting lists 
discouraged some PrEP users to test every three months as is recommended in the national 
PrEP guidelines. Overall, informal PrEP users were quite capable of arranging PrEP and the 
care associated with PrEP for themselves. 
The third research question was to identify barriers for PrEP use. Since it was assumed that 
PrEP-related stigma could be a barrier for PrEP use (Calabrese & Underhill, 2015), we ex-
plored the topic of stigma in the qualitative study in chapter 3. PrEP-related stigma seemed 
to be limited. Most PrEP users received positive responses to their PrEP usage. For example, 
they were seen as a favorable sex partner, because other MSM assumed that PrEP users want-
ed to have sex without a condom. However, stigmatizing reactions also emerged. For example, 
PrEP users were rejected for sex because other MSM thought that PrEP users would have STIs 
due to irresponsible sexual behavior. In the study in chapter 4 we examined correlates, and 
potential barriers, for PrEP uptake in more detail. We found that PrEP uptake was higher after 
the price drop of PrEP, among MSM who were in a favorable financial situation, and among 
MSM who had previously had a post-exposure prophylaxis (PEP) treatment. The price of 
PrEP is thus an important barrier for PrEP uptake, and it was the most common barrier for 
PrEP uptake in a report of 32 other European and Asian countries (Hayes et al., 2019). Our 
study showed that the price of PrEP mainly played a role in the PrEP uptake among MSM 
in an average financial situation. MSM with a low financial status still could not afford to 
pay PrEP despite the price drop, while MSM with a high financial status could afford PrEP 
regardless of the price.  
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The fourth research question was to investigate the sexual behavior of PrEP users in the Neth-
erlands. This subject was addressed in multiple studies. We explored the sexual behavior of 
PrEP users in the qualitative study in chapter 3. PrEP users described that their condom use 
had generally decreased since they started using PrEP.  However, they still used condoms in 
certain situations, depending on the perceived risk and their familiarity with the sex partner. 
An important benefit of PrEP use was a reduced fear of HIV. PrEP users felt more in control of 
their sex life and experienced more sexual freedom, which made them more willing to experi-
ment with sex practices they did not dare before. In the study in chapter 5 we investigated the 
psychosocial benefits of PrEP quantitatively. PrEP users reported consistent improvements in 
quality of sex life after PrEP initiation. Reduced fear for HIV was related to improved quality 
of sex life. In contrast to our expectations, this association was not mediated by condom use. 
Drug use in a sexual context (chemsex) was high in this group, but PrEP users reported no 
increase in experimentation with drugs not previously used since PrEP initiation.
In the study in chapter 6 we investigated more in detail the attitudes of PrEP users when 
having sex with men living with HIV. The majority of PrEP users indicated to have sex with 
men living with HIV. They reported high levels of reduced fear for HIV and increased comfort 
when having sex with men living with HIV. They also indicated that since their PrEP use they 
felt safer to have condomless sex with men living with HIV. These feelings increased over time 
and showed that PrEP users may have been more confident relying on PrEP over time. The 
findings suggest that PrEP can play a role in overcoming the serodivide, and that this mani-
fests quite soon after the onset of PrEP use.
Implications
Below I describe the implications of the findings, first for the Dutch context, then in the 
context of other countries with a similar PrEP situation, and finally the implications for the 
promotion of PrEP internationally.
Implications for PrEP use in the Netherlands
A first implication is that we notice that there is a gap between interest in PrEP and actual 
uptake of PrEP among MSM in the Netherlands. In the study in chapter 2 we found that the 
interest in PrEP, and the intention to start using PrEP is quite high. Interest in PrEP was re-
lated to being single, having correctly prior PrEP knowledge, not having used a condom the 
last time when having sex, and having ever used drugs in a sexual context. These are exactly 




MSM with a high interest in PrEP, that ultimately the price of PrEP and the financial situation 
of the participants is significantly related to actual PrEP uptake. Sexual risk behaviors were 
not significant predictors of PrEP uptake, while they were related to interest in PrEP. This 
demonstrates that PrEP mainly reaches those MSM who can afford it, even though there is 
high interest from other MSM with high-risk behaviors. In order to increase the impact of 
PrEP on the reduction of new HIV infections, it is important that PrEP is used as much as 
possible by MSM who are eligible for PrEP. The price of PrEP should not be a deciding factor 
in the use of PrEP. PrEP uptake can increase if the price is at the lowest possible level. At the 
time of our research PrEP was available for € 50 per 30 pills (AidsFonds, 2018). PrEP is now 
available through the public health centers and is partially reimbursed through the national 
health insurance scheme (Ministry of Health Welfare and Sport, 2019). This has made PrEP 
more accessible for a larger group of MSM. Nevertheless, it remains important to focus on 
MSM in less favorable (financial) positions; the price of PrEP can still be a barrier for them, 
while they may be at increased risk of HIV.
Secondly, this thesis shows that informal PrEP use exists, and may continue to exist. Studies 
on informal PrEP use are scarce, and our research is the first study investigating informal 
PrEP use in the Netherlands. Most of the informal PrEP users switched to formal PrEP use 
as soon as PrEP became more affordable in the Netherlands. However, some PrEP users con-
tinued informal PrEP procurement. Continued informal PrEP use was also found in a study 
in Germany, in which 17.4% of the 2000 PrEP users obtained PrEP informally, despite the 
formal availability of generic PrEP in Germany (Koppe et al., 2019). A possible explanation 
is that the price of generic PrEP is still not affordable for some MSM. In the study in chapter 
3, we also found that some participants continued informal PrEP procurement out of con-
venience, since they received PrEP through friends who bought PrEP abroad. Most informal 
PrEP users were well informed about PrEP, and therefore used PrEP correctly and followed 
the guidelines for regular testing. However, there were also some informal PrEP users who 
did not get tested regularly, particularly regarding renal function testing. They considered 
this not necessary or they did not know where to get tested. It is important that also informal 
PrEP users have barrier-free access to HIV, STI, and renal function testing to enable them to 
follow the guidelines for safe PrEP use. In the Netherlands, the Amsterdam Municipal Health 
Service (GGD) already organized consultations for the guidance of 250 informal PrEP users 
over a period of 24 months (GGD Amsterdam, 2017).
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Implications for PrEP use in other countries with informal PrEP use
It is remarkable that studies on informal PrEP use are so scarce, as informal PrEP use occurs 
in many countries in Europe. The findings of the studies in this thesis on informal PrEP use 
are therefore not only relevant for the Netherlands, but also for other countries, in particular 
these where PrEP is not yet formally available. A report of the European Centre for Disease 
Prevention and Control (ECDC, 2019) shows that in 2017 in some countries informal PrEP 
use was the most common form of PrEP procurement. For example, in Switzerland 67% of 
the PrEP users obtained PrEP informally, and in the UK 59%. These figures are likely to have 
changed by now as the availability and affordability of PrEP has increased in a number of 
countries. However, in 2019 there were still 37 out of 53 reporting countries in Europe and 
neighboring countries that had not implemented formal access to PrEP (European Centre 
for Disease Prevention and Control, 2019c). As long as PrEP is not formally available, PrEP 
is likely used informally in these countries. For example, in countries in Eastern Europe and 
Central Asia nongovernmental organizations (NGOs) and community organizations are ac-
tively promoting PrEP and making PrEP (informally) available (Begovac et al., 2019; Zardi-
ashvili, 2019). The studies in this thesis show that this informal use of PrEP can work quite 
well, but it may mainly reach MSM who have a high community engagement, and who are 
consequently well informed about PrEP. For them, the transition to formal PrEP likely pro-
ceeds smoothly as soon as formal PrEP is accessible and affordable.
Implications for PrEP use at a global level
Furthermore, the studies in this thesis have implications for PrEP use on a global level, which 
are not limited to a Dutch or European context. The studies in this thesis provide insight 
into the role of PrEP in relation to other HIV prevention strategies. In the media PrEP was 
sometimes presented as an alternative to condoms, and the use of terms such as ‘PrEP whores’ 
created the impression that PrEP was used to facilitate frequent condomless anal sex (Spield-
enner, 2016). This gives a distorted depiction of PrEP. Although we indeed observed in the 
studies in chapter 5 and 6 that PrEP users had a decreased condom use after PrEP initiation, 
we also observed in the qualitative study in chapter 3 that PrEP users often make an appraisal 
per situation whether they still use a condom, depending on the perceived risk. This demon-
strates that PrEP should be seen as part of a range of HIV prevention strategies that can be 
combined. A latent class analysis in a study from Canada, where PrEP has been formally avail-
able for some time, showed that PrEP is often combined with other HIV prevention strategies 




In addition to PrEP and condoms, there are other strategies that are part of the comprehensive 
framework of HIV prevention that can be combined. The combination of PrEP and Treat-
ment as Prevention (TasP) probably has the most impact in reducing the incidence of new 
HIV infections (Doyle et al., 2020; Jones et al., 2019; Rozhnova et al., 2018). In practice, TasP 
facilitates so-called viral load sorting: the selection of sex partner based on whether the per-
son living with HIV is virally suppressed (Grov et al., 2018). This strategy is more than merely 
selecting a partner on the basis of HIV status, as is the case with serosorting (Eaton et al., 
2009). Besides viral load sorting and serosorting, PrEP sorting also occurs, whereby sex part-
ners are selected based on their PrEP use (Martinez & Jonas, 2019). In the qualitative study 
in chapter 3, PrEP users indicated that they were sometimes seen as favorable sex partners, 
because others preferred to have sex with them without a condom (and assumed that PrEP 
users would have condomless sex): This shows that non-PrEP users relied on the protection 
of PrEP (of the PrEP user) against HIV and the transmission of HIV. PrEP is hence not an 
isolated phenomenon: It can be used in combination with other HIV prevention strategies, 
and it also has an impact on MSM who do not use PrEP.
This thesis also contributes to our understanding of disparities in PrEP uptake. Particularly in 
the United States, it is often found that certain demographic groups, such as Black, Hispanic, 
and younger individuals are less likely to use PrEP (Bush et al., 2016; Kamitani et al., 2020; 
Kelley et al., 2015; Marcus et al., 2016; Rolle et al., 2017; Snowden et al., 2017), while they 
are at increased risk of HIV (Hess et al., 2017). Likewise, in the Netherlands non-Western 
migrants have an increased risk of HIV (Visser et al., 2017), but often have less access to HIV 
prevention services such as PrEP (Bil et al., 2019). The increased risk of HIV and the lower 
likelihood of PrEP use among certain demographic groups are not isolated events, and can 
jointly be understood from a syndemic perspective. The syndemic perspective is a framework 
for understanding health conditions as resulting from the interplay of the co-occurrence of 
multiple diseases with social, economic, and environmental factors (Singer et al., 2017; The 
Lancet, 2017; Tsai et al., 2017). In our studies, we found that economic and environmental 
factors play a role in PrEP access and PrEP uptake. In the study in chapter 4 we found that 
MSM in a less favorable financial situation were less likely to use PrEP, despite high interest in 
PrEP. Due to decreases in the price of PrEP, PrEP will become more available for less finan-
cially privileged people, but even with a low price of PrEP it remains important to ensure the 
availability of PrEP for them. Regarding environmental factors, we found in the qualitative 
study in chapter 3 that PrEP use in rural areas was lower and much less accepted. Also in rural 
areas in the United States, it was found that MSM have to travel far to obtain PrEP (Weiss et 
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al., 2018) and that access to information and PrEP-related healthcare is limited (C. Owens et 
al., 2020). In France, it was also found that gay men who live in villages, or in areas with few 
PrEP access points, are less likely to use PrEP (Annequin et al., 2020).
Lastly, the studies in this thesis underline the importance of the role of PrEP in sexual health. 
Sexual health not only refers to the prevention of STIs, but it is “a state of physical, emotional, 
mental and social well-being in relation to sexuality” (WHO 2015 sexual health). Both the 
qualitative study in chapter 3 and the quantitative studies in chapters 5 and 6 showed that 
PrEP users have less fear of HIV since they started using PrEP and therefore are more likely 
to enjoy sex. PrEP is not only beneficial for the prevention of HIV infections, but also for im-
proving the quality of sex life. PrEP uptake may increase if the psychosocial benefits of PrEP 
are promoted. Moreover, the psychosocial benefits of PrEP can contribute to bridging the 
serodivide: PrEP users may feel more comfortable having sex with men living with HIV and 
may be more willing to have sex with men living with HIV. 
Strengths and limitations
A strength of this thesis is that it is the first in the Netherlands to study PrEP use outside a 
clinical setting, such as in the demonstration trial AMPrEP (Public Health Service Amster-
dam, 2015). There is a need to study PrEP in a real-world setting, to investigate the social im-
plications of PrEP beyond its clinical efficacy (Auerbach & Hoppe, 2015). Moreover, clinical 
trials may give a biased view of changes in sexual behavior, because of the selection of par-
ticipants (i.e. selected participants are MSM with (extreme) high risk behavior) or because of 
the included PrEP-related healthcare, such as behavioral counseling and regular HIV and STI 
testing, that may be absent in a real-world situation (Buttram, 2018; Kurtz & Buttram, 2016). 
Therefore, the qualitative study in chapter 3 explored the experiences of PrEP users on a wide 
range of topics. In addition, some behavioral changes may not be present immediately after 
PrEP initiation, as a meta-analysis of open-label studies showed that more recent studies and 
studies with a longer follow-up time did show an increase in STIs among PrEP users (Traeger 
et al., 2018). Therefore, we included multiple points of assessment in the studies in chapter 4, 
5, and 6.
Another strength of this thesis is the in-depth analysis of recruitment strategies in the study 
in chapter 2. We found that MSM participants recruited through the research panel Am-
sterdamPinkPanel were less interested in PrEP and had a lower intention to use PrEP than 




age, and their lower interest in PrEP may be explained by their personal history of HIV pre-
vention. Notably, they may be more likely to rely on established HIV prevention strategies 
that have worked for them for many years, and they may not feel a need to change their HIV 
prevention strategy to PrEP use. The findings of this study indicate that recruitment strategies 
have a substantial impact on findings regarding interest in PrEP and intention to use PrEP. 
We recommended that researchers tailor their recruitment strategies to their research aims 
and inclusion criteria. For the other studies in this thesis, we used convenience sampling and 
recruited participants via the website of the Dutch PrEP advocacy group PrEPnu.nl. This al-
lowed us to target potential PrEP users in particular, in a context and time (2017) when PrEP 
use was limited. As a result, we mainly recruited PrEP users and MSM with a high interest in 
PrEP. This was useful for the research aims, but it limits the representativeness of the studies 
to the whole MSM population.
There are several further limitations to the studies in this thesis. Regarding the representative-
ness of the findings; it is unclear to what extent the findings of our studies are generalizable 
to future PrEP users. The PrEP users in the studies in this thesis can be seen as early adopters 
who had to make an increased effort to obtain (informal) PrEP, and who often had high PrEP 
knowledge because of high community engagement. These early adopters may differ from 
later PrEP adopters. According to the Diffusion of Innovation theory (Rogers, 2010), the ac-
ceptance and dissemination of new ideas and products progresses through acceptance by a 
sequence of groups within social systems or societies. This theory has also been applied to the 
uptake of HIV prevention strategies (Bertrand, 2004). The innovators and early adopters, who 
are the first to embrace a prevention strategy, differ in their characteristics from the early and 
late majority; they are more open to change and take more risks (Rogers, 2010). In the con-
text of PrEP, a study in Australia found that early PrEP adopters reported higher risk sexual 
practices (compared to non-users) and were more likely to know other PrEP users (Holt et 
al., 2019). The authors suggested that, according to the Diffusion of Innovation theory, future 
PrEP users may require greater reassurance about the efficacy of PrEP to increase PrEP up-
take among the early and late majority.
Another limitation of this thesis is that we only studied PrEP interest and use among MSM 
and not among other populations. While it is relevant to study PrEP use among MSM, MSM 
are the main risk population for HIV in the Netherlands (Van Sighem et al., 2019), there are 
other populations that may benefit from PrEP as well. A priority group for PrEP is transgen-
der individuals. A recent meta-analysis found that transgender women are 66 times more 
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likely to have HIV compared to adults in the general population worldwide (Stutterheim et 
al., 2020). Transgender women are often recognized in national PrEP guidelines as a risk 
group for PrEP eligibility, but are often underrepresented in PrEP studies (Hoornenborg, 
Krakower, et al., 2017). Studies in the United States show that PrEP awareness is low among 
transgender women (Poteat et al., 2019), and consequently, their PrEP use is also low (Reisner 
et al., 2019). Transgender men have a lower HIV risk than transgender women, but are still at 
increased risk of HIV compared to the general population (Stutterheim et al., 2020). A study 
in the United States found that 24.3% of transgender men would meet eligibility criteria for 
PrEP, but only 3% had been prescribed PrEP (Golub, Fikslin, Starbuck, et al., 2019). Future 
research should address the HIV prevention needs of transgender individuals to improve 
PrEP awareness and PrEP use among them. 
A final limitation of this research is that not all research aims that were formulated in the orig-
inal research proposal were investigated, due to the rapidly changing context of PrEP in the 
Netherlands. One of the aims in the research proposal was targeted at the effect of PrEP use 
on the behavior of non-users. We expected that PrEP use would be limited in the Netherlands, 
because PrEP was not approved in the Netherlands at the time of writing the research propos-
al. Therefore, we expected to have few PrEP users in our study, and we planned to investigate 
the effect of PrEP on non-users. However, PrEP uptake increased in 2017 and 2018 after 
generic (and cheaper) PrEP became available, and we decided to focus on the experiences of 
PrEP users themselves. Moreover, the research proposal focused on MSM attending circuit 
parties, as we expected that PrEP use would be higher among these MSM. However, as PrEP 
use became normalized thanks to the formal approval and increased availability, we did not 
limit our recruitment to MSM attending circuit parties, but we aimed to include a broader 
group of PrEP using MSM. 
Directions for future research
In the section above, we already mentioned a few directions for future research following 
the limitations, namely to investigate differences between early PrEP adopters and late PrEP 
adopters, and to investigate PrEP use among other risk groups such as transgender individ-
uals. In addition, there are a number of other topics that we recommend for future research.
Firstly, there is a need for research with people who stop or have to stop using PrEP. This was 
not addressed in this thesis because we focused on MSM who started using PrEP as PrEP 




people who stop using PrEP, and in particular what their HIV prevention strategies are when 
they stop using PrEP. There are several reasons to stop using PrEP: Someone can voluntarily 
stop with PrEP because they perceive their risk of HIV as lower (e.g. they get into a monog-
amous relationship). It could also happen that someone has to stop involuntarily because of 
side effects or reduced access to PrEP due to a move or changes in insurance policies (Jonas & 
Yaemim, 2018). People who stop using PrEP can remain at risk of HIV (Spinelli et al., 2020). 
Tailored HIV prevention strategies are needed for MSM who stop using PrEP, as going back 
to condoms may not be a viable strategy in all cases (Jonas & Yaemim, 2018).
Secondly, there is a need for research on how to reach young MSM in the Netherlands. The 
Dutch PrEP guideline advises PrEP use for MSM who have had condomless anal intercourse, 
had an STI, or have been prescribed a PEP treatment in the past six months (Hoornenborg 
& Rijnders, 2019). This excludes young people who are not yet sexually active, but want to 
become so, from the eligibility criteria, because the criteria are based on sexual behaviors 
that inexperienced young people did not yet engage in. Nevertheless, PrEP can be prescribed 
to them, as the guideline also encourages PrEP to be prescribed to those who ask for it. A 
number of studies have already been done in the United States regarding PrEP and adoles-
cents. A study among 1541 adolescent sexual minority males aged 13 - 18 years found that 
only 28% were aware of PrEP (Dunville et al., 2020). Other studies found a higher awareness 
of PrEP among adolescents and investigated barriers for PrEP uptake, such as the role of 
parents (Macapagal et al., 2020; Moskowitz et al., 2020). Some young MSM were afraid that 
their parents would be unsupportive of their PrEP use, which limited their interest in PrEP 
(Moskowitz et al., 2020).
Lastly, it is important that future research continues to investigate informal PrEP use. Infor-
mal PrEP use exists in many countries, and may emerge as long as formal PrEP access is not 
implemented. In addition, informal PrEP can re-emerge in countries where PrEP is already 
formally available when new forms of PrEP are introduced. Currently tenofovir disoproxil 
fumarate with emtricitabine (TDF-FTC, Truvada) is used for PrEP in most countries, but in 
the United States, tenofovir alafenamide with emtricitabine (TAF-FTC, Descovy) has been 
approved for PrEP by the Food and Drug Administration (FDA) since October 2019 (U.S. 
Food and Drug Administration, 2019). TAF-FTC may have fewer side effects than TDF-FTC, 
but it is more expensive (Krakower et al., 2020). The higher price of TAF-FTC may motivate 
MSM to obtain this form of PrEP outside formal channels for a lower price. Furthermore, 
long-acting injectable PrEP may become available in the coming years, as initial studies show 
Chapter 7
116
that cabotegravir is a highly effective form of long-acting injectable PrEP (Cohen, 2020). The 
introduction of long-acting injectable PrEP may lead to a new wave of informal PrEP use if 
this form of injectable PrEP is first only available in a limited number of countries, triggering 
interested MSM to travel to these countries for PrEP. It is likely that only a small amount of 
people will opt for informal PrEP use, yet it is important to monitor whether they have addi-
tional risks due to possible limited medical supervision.
Conclusion
The studies in this thesis examined the interest and attitudes of MSM towards PrEP and the 
experiences of PrEP users during the early years of PrEP in the Netherlands. Informal PrEP 
users had a high level of PrEP knowledge through community engagement. Most informal 
PrEP users switched to formal PrEP procurement, as soon as generic PrEP became available 
in the Netherlands for a more affordable price. PrEP-related healthcare should remain acces-
sible for informal PrEP users, as informal PrEP use may continue to exist when new forms 
of PrEP appear on the market. MSM with high-risk sexual behaviors were interested in PrEP, 
but PrEP use mostly happened among MSM who could afford it. The studies in this thesis 
also demonstrate that the benefits of PrEP go beyond just HIV prevention: PrEP has a positive 
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Pre-exposure prophylaxis (PrEP) is a novel biomedical intervention that is highly effective 
in reducing HIV infections. The World Health Organization (WHO) recommends the use of 
PrEP for people at high risk of HIV, such as men who have sex with men (MSM). However, 
PrEP uptake has been slow, because of limited accessibility and affordability. In the Nether-
lands, PrEP became available for € 500 per 30 pills in 2016, which was unaffordable for most 
people who are at risk of HIV. Consequently, some MSM obtained PrEP via informal channels 
such as (online) pharmacies and clinics abroad, and through pill sharing of people living with 
HIV who take antiretroviral therapy. Because informal PrEP users are usually not medically 
supervised, concerns were raised about misinformation and incorrect use of PrEP. This thesis 
aims to assess whether informal PrEP use occurs in the Netherlands, and what risks are relat-
ed to informal PrEP use. Therefore, we investigated the interest in PrEP and the experiences 
of PrEP users in the years prior to formal PrEP implementation in the Netherlands. 
We examined the attitudes towards PrEP and interest in PrEP in the study reported in chapter 
2. We conducted this study in the summer of 2016, before PrEP was available in the Neth-
erlands. At the time, many MSM were already aware of PrEP and had correct knowledge of 
PrEP. About half of the participants were interested in PrEP and had the intention to start 
using PrEP when it would become available. We found that MSM who may benefit from PrEP 
(i.e. those with high-risk behavior) were indeed those who were more interested in PrEP. In 
addition, we found that the recruitment strategy was also significantly related to interest in 
PrEP: Participants of the research panel AmsterdamPinkPanel were less interested in PrEP 
compared to participants recruited via convenience sampling. This indicates that it is impor-
tant to take recruitment strategies and sample characteristics into account in explaining study 
findings.
In the study reported in chapter 3 we qualitatively explored the ways in which PrEP users 
obtained PrEP and what their experiences were regarding accessing PrEP. Participants who 
first bought PrEP informally abroad or online, had mostly switched to buying PrEP formally 
at the pharmacy in the Netherlands as soon as PrEP became more affordable in 2018. Some 
participants indicated that they had to switch general practitioners (GP) because their previ-
ous GP had moralistic ideas about sex and PrEP and therefore did not want to prescribe PrEP. 
Overall, informal PrEP users were quite capable of arranging PrEP and the care associated 
with PrEP for themselves, although renal function testing was not always done regularly, as 
some PrEP users did not find this necessary. In addition to accessing PrEP, we also explored 




responses to their PrEP usage. However, stigmatizing reactions also emerged. For example, 
PrEP users were rejected for sex because other MSM thought that PrEP users would have 
more sexually transmitted infections (STIs) due to irresponsible sexual behavior. PrEP users 
described that their condom use had generally decreased since they started using PrEP.  How-
ever, they still used condoms in certain situations, depending on the perceived risk and their 
familiarity with the sex partner. An important benefit of PrEP use was a reduced fear of HIV. 
PrEP users felt more in control of their sex life and experienced more sexual freedom, which 
made them more willing to experiment with sex practices they did not dare before.
In the study reported in chapter 4 we examined correlates, and potential barriers, of PrEP 
uptake. We found that PrEP uptake was higher after the price drop of PrEP in 2018, among 
MSM who were in a favorable financial situation, and among MSM who had previously had a 
post-exposure prophylaxis (PEP) treatment. Our study showed that the price of PrEP mainly 
played a role in the PrEP uptake among MSM in an average financial situation. MSM with a 
low financial status still could not afford to pay PrEP despite the price drop, while MSM with 
a high financial status could afford PrEP regardless of the price.
In the study reported in chapter 5 we quantitatively investigated the psychosocial benefits 
of PrEP. PrEP users reported consistent improvements in quality of sex life after PrEP ini-
tiation. Reduced fear for HIV was related to improved quality of sex life. In contrast to our 
expectations, this association was not mediated by condom use. Drug use in a sexual context 
(chemsex) was high in this group, but PrEP users reported no increase in experimentation 
with novel drugs since PrEP initiation.
In the study reported in chapter 6 we investigated in more detail the attitudes of PrEP users 
when having sex with men living with HIV. The majority of PrEP users indicated to have sex 
with men living with HIV. They reported high levels of reduced fear for HIV and increased 
comfort when having sex with men living with HIV. They also indicated that since they start-
ed using PrEP, they felt safer to have condomless sex with men living with HIV. These feelings 
increased over time and showed that PrEP users may have been more confident relying on 
PrEP over time. The findings suggest that PrEP can play a role in overcoming the serodivide, 
and that this manifests quite soon at the onset of PrEP use.
In the general discussion in chapter 7 the main findings are summarized, contextualized and 
critically appraised. The implications of the findings are also discussed, with a focus on set-
tings in the Netherlands, in other countries with a similar PrEP situation, as well as more 
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broadly from an international perspective. A strength of this thesis is that it reports on the 
first research program in the Netherlands to study PrEP use outside a standard healthcare set-
ting, such as in the demonstration trial AMPrEP. Informal PrEP use exists and may continue 
to exist, as MSM may find it more convenient or more affordable. The studies in this thesis 
show that this informal use of PrEP can work quite well, but it may mainly reach MSM who 
have a high community engagement, and who are consequently well informed about PrEP. 
For them, the transition to formal PrEP likely proceeds smoothly as soon as formal PrEP is 
accessible and affordable. There is a gap between interest in PrEP and actual uptake of PrEP 
among MSM in the Netherlands. PrEP mainly reaches MSM who can afford it, even though 
there is high interest from other MSM with high-risk behaviors. PrEP should be seen as part 
of a range of HIV prevention strategies that can be combined. The combination of PrEP and 
Treatment as Prevention (TasP) probably has the most impact in reducing the incidence of 
new HIV infections. The studies in this thesis demonstrate that the benefits of PrEP go be-
yond just HIV prevention: PrEP has a positive impact on the quality of sex life by reducing 
fear for HIV. PrEP uptake may increase if the psychosocial benefits of PrEP are promoted. 
Future research should focus on people who stop using PrEP, as they remain at risk for HIV 
and condoms are not always a viable strategy for them. Research is also needed on PrEP use 







Pre-exposure prophylaxis (PrEP) is een nieuwe biomedische interventie die zeer effectief is 
in het voorkomen van hiv-infecties. De Wereldgezondheidsorganisatie (WHO) beveelt het 
gebruik van PrEP aan voor mensen met een verhoogd risico op hiv, zoals mannen die seks 
hebben met mannen (MSM). De ingebruikname van PrEP verloopt echter traag, vanwege de 
beperkte toegankelijkheid en betaalbaarheid. In Nederland kwam PrEP in 2016 beschikbaar 
voor € 500 per 30 pillen, wat onbetaalbaar was voor de meeste mensen met een verhoogd 
risico op hiv. Daarom hebben sommige MSM PrEP verkregen via informele kanalen zoals 
(online) apotheken en klinieken in het buitenland, en door het delen van pillen door mensen 
met hiv die antiretrovirale medicatie gebruiken. Omdat informele PrEP-gebruikers meestal 
niet medisch begeleid worden, zijn er zorgen geuit over onjuiste informatie en onjuist gebruik 
van PrEP. Dit proefschrift beoogt te onderzoeken of informeel PrEP-gebruik in Nederland 
voorkomt en welke risico’s verbonden zijn aan informeel PrEP-gebruik. Daarom hebben we 
de interesse in PrEP en de ervaringen van PrEP-gebruikers in de jaren voorafgaand aan de 
formele invoering van PrEP in Nederland onderzocht. 
We onderzochten de attitudes ten opzichte van PrEP en de interesse in PrEP in het onderzoek 
dat in hoofdstuk 2 wordt beschreven. We hebben dit onderzoek uitgevoerd in de zomer van 
2016, voordat PrEP in Nederland beschikbaar was. Op dat moment waren veel MSM al op de 
hoogte van PrEP en hadden ze correcte kennis over PrEP. Ongeveer de helft van de deelne-
mers was geïnteresseerd in PrEP en had de intentie om PrEP te gaan gebruiken wanneer het 
beschikbaar zou komen. We vonden dat MSM die mogelijk baat hebben bij PrEP (zoals dege-
nen met hoog risicogedrag) inderdaad degenen waren die meer geïnteresseerd waren in PrEP. 
Daarnaast vonden we dat de wervingsstrategie voor de steekproeftrekking ook significant 
gerelateerd was aan de interesse in PrEP: Deelnemers van het onderzoekspanel AmsterdamP-
inkPanel waren minder geïnteresseerd in PrEP in vergelijking met deelnemers die werden 
geworven via gemakssteekproeven (‘convenience sampling’). Dit geeft aan dat het belangrijk 
is om bij de interpretatie van onderzoeksresultaten rekening te houden met de wervingsstrat-
egieën en de steekproefkenmerken.
In het onderzoek dat in hoofdstuk 3 wordt beschreven, hebben we op kwalitatieve wijze onder-
zocht hoe PrEP-gebruikers PrEP bemachtigen en wat hun ervaringen zijn met de toegang tot 
PrEP. Deelnemers die PrEP voor het eerst informeel in het buitenland of online kochten, 
waren meestal overgestapt op het formeel aanschaffen van PrEP bij de apotheek in Nederland 
zodra PrEP in 2018 betaalbaarder werd. Sommige deelnemers gaven aan dat ze moesten wis-




daarom PrEP niet wilde voorschrijven. Over het algemeen waren informele PrEP-gebruikers 
goed in staat om PrEP en de zorg die bij PrEP hoort voor zichzelf te regelen, hoewel nier-
functietests niet altijd regelmatig werden uitgevoerd, omdat sommige PrEP-gebruikers dit 
niet nodig vonden. Naast de toegang tot PrEP hebben we ook de reacties van de community 
en het seksueel gedrag van PrEP-gebruikers onderzocht. De meeste PrEP-gebruikers ontvin-
gen positieve reacties op hun PrEP-gebruik. Er kwamen echter ook stigmatiserende reacties 
naar voren. Zo werden PrEP-gebruikers afgewezen voor seks omdat andere MSM dachten 
dat PrEP-gebruikers meer seksueel overdraagbare aandoeningen (soa’s) zouden hebben als 
gevolg van onverantwoordelijk seksueel gedrag. PrEP-gebruikers beschreven dat hun con-
doomgebruik over het algemeen was afgenomen sinds ze PrEP gebruikten.  Ze gebruikten 
nog steeds condooms in bepaalde situaties, afhankelijk van het veronderstelde risico en hun 
vertrouwdheid met de sekspartner. Een belangrijk voordeel van PrEP-gebruik was een ver-
minderde angst voor hiv. PrEP-gebruikers voelden zich meer in controle over hun seksleven 
en ervaarden meer seksuele vrijheid, waardoor ze meer geneigd waren te experimenteren met 
seksuele activiteiten die ze voorheen niet durfden.
In het onderzoek dat in hoofdstuk 4 wordt beschreven, hebben we gekeken naar correlat-
ies, en potentiële barrières, van PrEP-gebruik. We vonden dat PrEP-gebruik hoger was na de 
prijsdaling van PrEP in 2018, bij MSM die zich in een gunstige financiële situatie bevonden, 
en bij MSM die eerder een post-exposure profylaxe (PEP) behandeling hadden gehad. Ons 
onderzoek toonde aan dat de prijs van PrEP vooral een rol speelde bij PrEP-gebruik bij MSM 
in een gemiddelde financiële situatie. MSM met een lage financiële status konden zich on-
danks de prijsdaling nog steeds geen PrEP veroorloven, terwijl MSM met een hoge financiële 
status zich wel PrEP konden veroorloven, ongeacht de prijs.
In het onderzoek dat in hoofdstuk 5 wordt beschreven, hebben we de psychosociale voordelen 
van PrEP kwantitatief onderzocht. PrEP-gebruikers rapporteerden consistente verbeteringen 
in de kwaliteit van het seksleven sinds zij PrEP gebruikten. Verminderde angst voor hiv was 
gerelateerd aan een verbeterde kwaliteit van het seksleven. In tegenstelling tot onze verwa-
chtingen werd deze associatie niet gemedieerd door condoomgebruik. Drugsgebruik in een 
seksuele context (chemsex) was hoog in deze groep, maar PrEP-gebruikers rapporteerden 
geen toename in experimenteren met nieuwe drugs sinds zij PrEP gebruikten.
In het onderzoek dat in hoofdstuk 6 wordt beschreven, hebben we de attitudes van PrEP-ge-
bruikers bij het hebben van seks met mannen die leven met hiv onderzocht. De meerder-
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heid van de PrEP-gebruikers gaf aan seks te hebben met mannen die leven met hiv. Zij rap-
porteerden een hoge mate van verminderde angst voor hiv en een verhoogd comfort bij het 
hebben van seks met mannen die leven met hiv. Ze gaven ook aan dat ze zich sinds ze PrEP 
gebruikten veiliger voelden om condoomloze seks te hebben met mannen die leven met hiv. 
Deze gevoelens namen in de loop van de tijd toe en lieten zien dat gebruikers van PrEP in de 
loop van de tijd misschien meer vertrouwen kregen in PrEP. De bevindingen suggereren dat 
PrEP een rol kan spelen bij het overkomen van de ‘serodivide’, en dat dit zich vrij snel mani-
festeert bij het begin van het gebruik van PrEP.
In de algemene discussie in hoofdstuk 7 worden de belangrijkste bevindingen samengevat, 
gecontextualiseerd en kritisch beoordeeld. De implicaties van de bevindingen worden ook 
besproken, met aandacht voor situaties in Nederland, in andere landen met een vergelijk-
bare PrEP-situatie, maar ook meer in het algemeen vanuit een internationaal perspectief. Een 
sterk punt van dit proefschrift is dat het verslag doet van de eerste onderzoeken in Nederland 
naar informeel PrEP-gebruik buiten de reguliere gezondheidszorg om, zoals in de demon-
stratieproef AMPrEP. Informeel PrEP-gebruik bestaat en blijft mogelijk bestaan, omdat MSM 
het handiger of betaalbaarder vinden. De onderzoeken in dit proefschrift laten zien dat dit 
informele gebruik van PrEP redelijk goed gaat, maar het bereikt vooral MSM die een hoge 
betrokkenheid bij de community hebben en die daardoor goed op de hoogte zijn van PrEP. 
Voor hen verloopt de overgang naar formeel PrEP waarschijnlijk soepel zodra formeel PrEP 
toegankelijk en betaalbaar is. Er is een discrepantie tussen de interesse in PrEP en het daad-
werkelijke gebruik van PrEP bij MSM in Nederland. PrEP bereikt vooral MSM die het zich 
kunnen veroorloven, ook al is er grote belangstelling van andere MSM met risicovol gedrag. 
PrEP moet worden gezien als onderdeel van een reeks van hiv-preventiestrategieën die kun-
nen worden gecombineerd. De combinatie van PrEP en Treatment as Prevention (TasP) heeft 
waarschijnlijk het meeste effect op het verminderen van nieuwe hiv-infecties. De onderzoek-
en in dit proefschrift tonen aan dat de voordelen van PrEP verder gaan dan alleen hiv-preven-
tie: PrEP heeft een positief effect op de kwaliteit van het seksleven door het verminderen van 
angst voor hiv. Het gebruik van PrEP kan toenemen als de psychosociale voordelen van PrEP 
worden benadrukt. Toekomstig onderzoek kan zich richten op mensen die stoppen met het 
gebruik van PrEP, aangezien zij risico blijven lopen op hiv en condooms voor hen niet altijd 
een haalbare preventiestrategie zijn. Er is ook onderzoek nodig naar het gebruik van PrEP 







Men who have sex with men (MSM) are at increased risk of HIV. Pre-exposure prophylaxis 
(PrEP) is an established form of biomedical prevention strategy that greatly reduces the risk 
of HIV transmission. The main goal of this dissertation was to investigate the attitudes of 
MSM towards PrEP and the experiences of PrEP users during the early years of the introduc-
tion of PrEP in the Netherlands.
The studies in this thesis are among the first studies in the Netherlands on the informal use 
of PrEP outside a standard healthcare setting. We focused on MSM who obtain PrEP through 
informal channels, such as in clinics and pharmacies abroad. Previous concerns about incor-
rect PrEP use (and subsequent potential HIV resistance) seem unjustified, as most informal 
PrEP users in our studies used PrEP correctly and engaged in regular testing. Most informal 
PrEP users have made a smooth transition to formal PrEP use as soon as PrEP became more 
affordable in the Netherlands in 2018. Now that the price of PrEP has dropped, and PrEP has 
also become available through the public health centers, PrEP will be accessible to a broader 
audience. It is important that these MSM are well informed about PrEP, which is why the 
information on the website mantotman.nl has been extended with information about PrEP. 
This information was created in the project We Are PrEPared in collaboration with GGD 
Amsterdam, GGD Gelderland-Zuid and SoaAids Nederland. The findings of the studies in 
this thesis on PrEP interest and PrEP knowledge among MSM provided insights for the needs 
assessment and the development of this information.
In the Netherlands, PrEP services have been implemented in the public health centers in a 
project with room for 6,500 people. However, it can still be possible that MSM go to the 
general practitioner for PrEP care, for example when there is no place in the local GGD, or 
when it is more convenient for them (e.g. due to travel distance). It is therefore important 
that healthcare professionals outside the public health centers, such as general practitioners, 
are also well informed about PrEP. This PrEP-related healthcare should also be accessible to 
informal PrEP users. The PrEP users in our research indicated that general practitioners were 
often not well informed about PrEP, or even refused to prescribe PrEP, highlighting a need 
for improving PrEP knowledge among general practitioners. Improving the knowledge of 
healthcare professionals was also part of the goals of the working group We Are PrEPared.
The findings of our studies are also relevant for PrEP use in other countries. In most coun-
tries in Europe and Central Asia PrEP is not yet available or formally implemented, so MSM 




is not widely discussed in the scientific literature. In the studies in this thesis we found that 
informal PrEP users are highly self-reliant. This does not imply that formal implementation 
of PrEP should be discontinued. The formal implementation of PrEP is important, because it 
makes PrEP accessible to more people. Our research showed that the price of PrEP is a sig-
nificant barrier to PrEP uptake, and this barrier can be removed when PrEP is included in the 
national healthcare system and reimbursed by health insurance. This will ensure that people 
in vulnerable financial situations also have access to PrEP. In addition, when implementing 
PrEP, the accessibility of PrEP for other vulnerable groups such as migrants and transgender 
people should also be taken into account, by increasing PrEP awareness among these groups.
The studies in this thesis fit into the scientific debate on PrEP in which there is an increasing 
demand for sociobehavioral studies on PrEP. Initially, research focused on the effectiveness 
and safety of PrEP. However, PrEP use has implications that go beyond just HIV prevention. 
In the studies in this thesis we found that PrEP has psychosocial benefits in addition to its 
preventive effect. PrEP users reported an increase in quality of sex life, and this was mainly 
related to a decrease in fear of HIV. Decreased fear of HIV and increased comfort were also 
reported in the context of having sex with men living with HIV. This shows that PrEP can 
play a role in reducing HIV stigma: PrEP users are more open to having sex with men living 
with HIV. HIV community organizations could promote and emphasize the role of PrEP in 
stigma reduction campaigns.
PrEP should be seen as part of a range of HIV prevention strategies that can be combined. 
Promoting the psychosocial benefits in addition to its preventive effect may help to increase 
PrEP uptake and to reach the full potential of PrEP in preventing new HIV infections. Com-
bining multiple HIV prevention strategies is essential to reach the Aidsfonds goal of zero new 
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